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It has been suggested that conducting clinical trials in palliative care is unethical and
may be burdensome for patients. Despite these suggestions, there is evidence that
the opinions of patients with advanced cancer are favourable towards clinical trials.
However this evidence is based on hypothetical studies; no studies have been done
which explore the opinions or experiences of patients who have actually participated
in symptom control trials. This thesis is the first study to examine the experiences of
advanced cancer patients who have participated in symptom control trials.
Methods
A qualitative study was conducted using a constructivist grounded theory approach.
Patients known to be in the palliative phase of their illness were purposively selected
from two double-blind placebo-controlled clinical trials of novel analgesic agents
that took place across two clinical centres in Scotland. Semi-structured interviews
were conducted until a suitable degree of data saturation was reached. In keeping
with a grounded theory approach, analysis of the generated data developed core
categories and a central theory that described the studied phenomenon.
Results
Experiences of taking part in a clinical trial were initially divided into three parts:
pre-trial experiences, experiences during the trial and patients' reflections on the trial
after they had finished. Pre-trial experiences of the patients included the reasons for
taking part, their initial contact with the trial staff and their prior knowledge of
clinical trials. Experiences during the trial involved the manner in which they went
through the trial, the impact on their pain and the interaction with the trial staff.
Patients reflected on their overall opinion of the trial that they had taken part in and
clinical trials in general.
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One of the most significant categories was the impact of the interaction with the
research staff. For some patients this relationship was beneficial, independent of the
pain response during the trial.
The central theory of the study related to a patient's wellbeing. All the different
aspects of participating in a clinical trial made an impact on a patient's sense of
wellbeing. Many different components of the trial, such as the relationship with the
trial staff, could have a positive impact on a patient's wellbeing. A positive impact
on wellbeing could be found even in the presence of something which may have a
negative impact on a patient's wellbeing, such as a lack of pain reduction.
Conclusions
This is the first study that explores the experiences of advanced cancer patients in
symptom control trials. I have described the factors that motivate patients to take
part in clinical trials, their experiences of being in the trials and how they view the
experience of the trial after it is finished. The results provide examples of
experiences that are very positive from a patient's perspective.
I have developed a concept ofwellbeing that the clinical trial impacts upon. While a
patient's overall wellbeing is not exclusively linked to the clinical trial, the clinical
trial has the potential to have a large impact on the overall wellbeing of the patient.
Interventions such as the relationship with the trial staff can have a positive effect on
a patient's wellbeing, independent of the outcome of the trial from a pain
management point of view. The results of this study contribute to the debate on the
ethics and benefits of research in palliative care.
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The experiences of patients matter. They matter because as researchers, physicians,
health care providers and humans we need to learn from the experiences of one
group of patients to better inform the care of future groups of patients. The best way
to learn about patients' experiences is to ask them. This thesis studied the
experiences of advanced cancer patients with incurable disease who took part in
symptom control clinical trials.
The context of this thesis merits some discussion. The majority of symptom control
care of advanced cancer patients comes under the responsibility of a palliative care
team. The past 20 years have seen a marked increase in research across all aspects of
palliative care (Flemming et al., 2008). Despite this, conducting research in the
palliative care population is not straightforward. One of the reasons is the existing
debate about the palliative care population being a vulnerable one; vulnerable,
amongst other things, of taking part in research that is too much of a burden for
them.
' When time is running out on life, can we ask people to give time to
research? When such a paucity of information exists on how to help those
who are dying, how much individual distress is too much when weighed
against the potential future benefit such information will provide to
society?'(Hawryluck, 2004)
There are also ethical concerns of researching patients with life limiting illness.
'
...to research at all into the needs and experiences ofthis client group could
be said to be an affront to the dignity of those people who are terminally ill
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and an expression ofprofound disrespectfor the emotional andphysical state
ofsuch patients, '(de Raeve, 1994)
These views are not shared by all palliative care providers however. Some palliative
care providers believe that while some patients may be vulnerable, the palliative care
population is too diverse in areas such as prognosis, clinical status, and capacity to
make decisions to be able to be generalized as a vulnerable population (Berry, 2004).
A wide range of viewpoints remain but the unique nature of the palliative care
population is beyond doubt. This population has the potential for vulnerability but it
also has the potential for poor symptom control and a low evidence base for the
treatments available. It would seem that the challenge in palliative care is to
undertake the research whilst remaining vigilant, informed and sympathetic to the
nuances of the population.
Amongst researchers, the debate may continue regarding research in the palliative
care population, but what do the patients themselves think? Opinions are formed by
experiences and a question remains as to the opinions and experiences of those
palliative care patients who have taken part in research.
1.2. Developing a research question
I developed the following research question that my thesis would address:
What are the experiences of advanced cancer patients who have taken part in a
symptom control clinical trial?
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While the choice of studying only advanced cancer patients is discussed in chapter
1.5, one other point is worth stressing. I did not intend to research patients who were
trialling chemotherapy agents. Trials that involve chemotherapy are inextricably
linked to the topic of life prolonging treatment. As palliative care aims neither to
prolong nor shorten life, I did not want to include chemotherapy trials in my study. I
wanted to understand the experiences of patients taking part in clinical trials that did
not affect their survival prognosis.
1.3. Aims
In order to address my research question, I developed the following aims:
• To explore the experiences of advanced cancer patients who have taken part in a
symptom control clinical trial involving novel analgesic agents
• To find out the impact that this trial had on their lives
• To propose a model of these experiences that can be used to inform current and
future practice of clinical trials in advanced cancer patients
• To review critically the study and identify further areas of research that may
provide more information on this topic
1.4. Layout of thesis
The thesis is divided into four sections. Section one contains the introduction and a
literature review. Section two contains the methodology and methods chapters with
explanation and justification for the chosen approaches. Section three contains the
results of the study. Section four describes the uniting theory of the study, discusses
the findings of the study, appraises the study critically and offers suggestions for
future research in the area.
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1.5. Definition of the population
For the purpose of this thesis, it is necessary to define a 'palliative care population.'
This is recognized to be a difficult challenge (Borgsteede et ah, 2006). Although
patients with metastatic cancer make up the majority of a palliative case load,
chronic conditions such as obstructive airway disease, heart failure and neurological
conditions are playing an increasingly large part. To study such a heterogeneous
population taking part in clinical trials would pose greater logistical challenges than
could be surmounted in one thesis. Therefore the decision was made only to study
patients with an advanced cancer diagnosis. Throughout this thesis, any discussion
of the palliative population refers to patients with a diagnosis of advanced,
metastatic, incurable cancer.
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Chapter 2. LITERATURE REVIEW
2.1. Introduction
The purpose of this literature review was to examine previous research into the
experiences of advanced cancer patients who have taken part in clinical trials.
Before starting this literature review I was aware of two recent systematic reviews
that had looked at palliative patients' and their care givers' attitudes towards research
(White and Hardy, Todd et ah, 2009). The aim of White and Hardy's systematic
review was to ' identify the views of palliative care patients and their families
towards research, the factors that are important when considering participation and
the types ofresearch trial they would support or reject.' Similarly, the aim of Todd
et al was 'to examine the attitudes of patients with advanced cancer towards
research and establish common themes.' The positive themes that emerged from
these two systematic reviews were altruism, self benefit and hope.
The primary limitation when drawing conclusions from these systematic reviews,
however, was that the majority of papers studied were asking patients to voice their
opinion on a topic which they had not experienced. Ross and Cornbleet, for
example, asked patients in a specialist palliative care unit about their attitudes
towards taking part in theoretical clinical research of increasing invasiveness (Ross
and Cornbleet, 2003). In addition, in the systematic reviews, only two papers
referred to trials that had taken place (Dobratz, 2003, Ling et al., 2000). In both
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instances, the focus was on reasons for patient withdrawal or declining participation
in the first case, rather than experiences of the trial itself.
2.2. Methods
Ethical approval was not required for this systematic review. The databases Medline
(1988-2010) and Embase (1988-2010) were searched electronically through the Ovid
gateway. In addition, the contents of editions of 'Journal of Pain and Symptom
Management \ 'Palliative Medicine', 'European Journal of Palliative Care' and
'Supportive Care in Cancer' were searched separately from September 2010 back to
the start of 2005. The date of the last literature search was the 23rd of September
2010. The reference list of the reviews mentioned above and other significant papers
were included.
In an exploratory literature search the terms 'palliative' and 'advanced cancer' were
used along with 'research'attitudes', 'opinions' and 'experiences'. This failed to
identify several significant papers in the general field of interest that had been
previously cited by both Todd and White. The recent systematic review by White
and Hardy used the MeSH terms of 'attitudes'motivation', 'willingness
'preparedness'clinical trial' and 'randomized controlled trial'. The results of this
were then manually checked, either in title, abstract or full article form for their
relevance to the palliative care population. This method has the advantage of not
requiring the variable terminology for palliative patients that features in the
literature. Terms for the palliative population can include 'advanced cancer',
'limited prognosis', 'palliative', and 'terminal'. Checking papers manually for
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patients who met the inclusion criteria reduced the chance of missing relevant papers
pertinent to this systematic review.
The electronic search was made up of three arms. These arms were 'cancer' AND
'trial'cancer' AND 'researchand 'cancer' AND 'studyWithin each arm, the
combination of the two search terms was then subsequently searched individually
with 'palliative'supportive'opinions'experiences', and 'attitudes.Where
possible, for search results of fewer than 6000 papers, any duplicates were removed.
Results were assessed firstly by the title. If further information was required, the
abstracts and full articles were assessed.
2.2.1. Inclusion criteria
• Studies where the population was patients with a diagnosis of metastatic cancer
• Studies that examined patients' experiences of taking part in clinical trials for
symptom management
2.2.2. Exclusion criteria
• Clinical trials of medication whose primary or secondary aim was to prolong life
• Clinical trials that did not involve medication
• Studies exploring patients' attitudes to research of any nature that they had not
explicitly taken part in
• Any studies involving a population less than 18 years old
20
2.3. Results
The literature search produced a total of 46,735 papers. These were broken down
further by search criteria as shown in Table 1.
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Table 1 - Papers generated from search













13875 2669 566 2666 3997 23773
Totals 25268 6231 1164 5467 8605 46735
Note: Due to duplicates, some papers featured in more than one search
The results of the searches produced a large number of papers to be reviewed. The
search process and assessment process is shown in Figure 1.
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Figure 1 - The search process and exclusion of papers from literature review
Forty-three full papers were examined to assess for eligibility. No papers met the
eligibility criteria for inclusion in this literature review. The most common reasons
were either that the drug being trialled was chemotherapeutic or that the study
involved theoretical research. An example as described above is Ross's exploration
of patients' attitudes to research (Ross and Cornbleet, 2003). This was excluded
because the patients were asked about escalating levels of theoretical research rather
than experiences of taking part in their own trials. Other papers excluded looked at
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caregivers' opinions, discussed methods relating to research or described research
that was conducted rather than patients' opinions on the research.
2.4. Discussion
The fact that there were no papers exploring advanced cancer patients' experiences
of clinical trials was not altogether surprising. The recent reviews described above
have covered individually the area of patients' views on palliative care research
systematically in recent years. It was important to search the literature for actual
patient experiences of research rather than their opinions on theoretical research, and
to make this distinction clear.
Despite the different approach taken by Todd et al and White and Hardy, it is still
worthwhile noting the salient findings of their papers. The review by Todd et al,
published in 2009, describes the positive and negative aspects of research in
palliative care. The three positive themes were that of altruism, self-benefit and
hope. The negative themes were of being too unwell to participate, anxiety
surrounding the issue of a placebo, concern regarding increased hospital admissions
and limited self benefit or deterioration in symptoms. Of the 11 studies included,
seven showed altruism as a motivating factor for taking part in clinical trials. Six
trials showed that the possible improvement of the patients' own symptoms was a
motivating factor. Maintaining individual hope was discussed in three studies
examined. These studies were looking at patients with regards to phase I clinical
trials.
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White and Hardy published another systematic review into patients' and carers'
views on research in palliative care (White and Hardy, 2010). The themes of
altruism and personal gain were similar to those found by Todd et al. The theme of
the importance of patients maintaining their own autonomy was also identified here.
Similar concerns regarding randomization, placebo studies and double-blind trial
designs were discussed by White and Hardy.
Three papers from the systematic review were of particular relevance to this thesis
and therefore merit further discussion.
2.4.1. Hospice patients' views on research in palliative care, (Terry et
al., 2006)
Terry et al interviewed 22 hospice in-patients in Australia. The aim was to find out
the opinions of these patients regarding palliative care research. The questions
included:
• 7/ we were doing research into hospice or palliative care, what do you
think we should do?'
• 'Who wouldyou prefer to ask you about being in research?'
• 'How much information do you thinkyou would need to be in research?'
Although patients were not asked specifically about all research designs, they were
asked specifically about randomized controlled trials:
'Ifwe had two treatments and we did not know which was better, would it be
OK to give halfthe patients one and halfthe other?'
The results from the interviews were predominantly positive towards research.
• Patients spoke of a continuing utility in their 'unique position' by participating in
research and of having a sense of validation
• Although patients spoke in general terms of research towards the ultimate cure of
their cancer, when pressed for specific topics to be researched, their answers
focused more on symptom control issues
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• Patients were clear in their desire that the research should not prolong their life
• Patients were firm in their views that the trial information given to them should
focus more on discussion rather than written information
• Patients were opposed to the concept of randomized controlled trials although the
authors found that this was in the context of a poor understanding of what a
randomized controlled trial entailed
This qualitative piece of work interviewed patients admitted to a hospice. The
majority of patients (n=14) died within 48 hours of taking part in the interview. The
authors concluded that their study went some way to refute the practical and ethical
difficulties cited in palliative care.
2.4.2. Participating in a cancer trial
2.4.2.1. Madsen's' work (2007a and b)
These two papers were published from the same set of interviews conducted on
female patients with either breast or ovarian cancers in Denmark. Although the
population was not a palliative one, a lot of the issues raised were similar and the
grounded theory approach matched that of this thesis. The study explored the
experiences of patients who had actually taken part in randomized controlled trials.
Madsen comments on this fact within the papers:
'The majority ofstudies investigating attitudes towards clinical research have
been based on hypothetical scenarios.... Consequently, it is almost unknown
how it actually feels like to be the subject ofclinical research. '(Madsen et ah,
2007b)
The difficulty in deciding to take part in the trial was a large part of the results of the
study. Thirty patients were interviewed of whom half agreed to take part in the trial
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and half declined. Both groups of patients discussed their reasons for their decision.
Weighing up the 'pros and cons' of taking part in the research trial was the central
phenomenon of the generated theory. ' The goal was to maximize personal benefits,
minimize the risks and at the same time find confidence and trust.' Interestingly, even
those patients who declined to take part in the trial still had a positive attitude
towards clinical trials. The theme of participating in research being a moral
obligation was both suggested to patients and offered spontaneously.
'Two thirds ofpatients stated that trial participation possessed elements ofa
moral imperative...' (Madsen et al., 2007a)
The interaction with health staff and the implication for the patients differed between
the two trials from which the patients were selected. Breast cancer patients largely
felt a lack of personal confidence and trust in their doctors which was put down to
the fact that they interacted with a large and variable number of doctors who often
gave the impression of incompetence and being rushed for time. Ovarian cancer trial
patients only interacted with two doctors and reported a strong feeling of trust and
confidence in the 'empathetic and knowledgeable' team. Being treated 'as whole
human beings' was, one of the most important expectations from patients.
The concern regarding the randomization of patients was a strong theme. Patients
did not feel confident in the stated clinical equipoise (where clinicians are uncertain
of the benefits of one arm of a trial over another, required for a trial to be deemed
ethical).
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Although the patient group was involved in life prolonging treatment, the fact that
patients interviewed had taken part in the research makes the discussion of this paper
valid for my thesis.
2.4.2.2. Randomized controlled trials of palliative care (White et al.,
2008)
White et al produced this paper in 2008 before White and Hardy's systematic review
paper of 2010. With the use of a questionnaire, the opinions of 101 palliative
patients towards research were generated. The specific aim was to enquire about
trials that concentrated on symptom control rather than prolonging life, particularly
in the context of randomized controlled trials.
Patients were asked about the design of trials, what they would find acceptable in a
trial depending on the level of invasiveness and issues regarding potential side
effects of trial medication.
Altruism was a strong reason for wanting to take part. As trials became more
invasive, fewer patients were willing to participate. The potential for side effects
was also a strong consideration for patients prior to deciding to take part in the
theoretical trials.
2.4.3. Limitations of literature review
There are several limitations of this literature review which may have yielded salient
papers. Not every database available online was searched. Major authors in this
field, such as Janet Hardy, were not contacted directly to highlight any papers that
28
they were aware of that had not been considered. The abstracts of conferences such
as the European Association ofPalliative Care were not studied as this was felt to be
too time consuming for the yield that it may produce. Although several key journals
were hand searched, not every journal which may have published a significant paper,
such as the 'Journal ofClinical Oncology' or 'Journal ofPalliative Medicine \ was
hand searched. Despite the limitations identified, I am confident that no key papers
have been missed.
2.5. Conclusion
To our knowledge there has yet to be a study that explores the experiences of
palliative patients who have taken part in a clinical trial for symptom control. There
are two good quality systematic review articles regarding the area of palliative
patients' views towards research which have been discussed above (White and
Hardy, Todd et al., 2009).
The individual studies by Terry and White give a useful insight into the views of
palliative patients towards research; however, the theoretical opinion of patients has
limited value. It is only through the lived experience of patients that firm data can be
generated.
Several of the papers discussed by both Todd et al and White and Hardy in their
systematic reviews used questionnaires to interview patients. An argument against
the use of questionnaires is that the questions being asked are related to the pre¬
existing knowledge and opinions of the research team (a priori) rather than allowing
the patients to take the project in a direction that may not have been expected or
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predicted. In contrast, by using the broader tool of grounded theory, Madsen et al's
research into patients' experiences of phase I oncology trials offers an interesting
insight into a similar phenomena to the one that is explored in this thesis (Madsen et
al., 2007a and b). The one significant difference is the use of potentially life
prolonging treatment. Madsen et al's work can be viewed with interest as a close
relative rather than for direct comparison, due to the fundamental difference that the
issue of life prolonging treatment provides.
With no studies to compare with directly, this thesis was the first to explore the
experiences of palliative care patients who take part in clinical trials for symptomatic
benefit.
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SECTION 2 - METHODOLOGY AND METHODS
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Chapter 3. METHODOLOGY:
'Not everything that matters can be counted. Not everything that can be
countedmatters.' Albert Einstein
3.1. Introduction
Every individual's experiences are unique. In the same situation, another person
would have a different experience and would subsequently describe the experience
differently.
It is the personal, unique experience of each individual's participation in a symptom
control trial that forms the basis of this thesis. The patients have a common
condition - advanced cancer, and a common exposure to a trial - a double-blind
randomized controlled trial (RCT) of symptom control analgesics, but they have
hugely diverse experiences. This diversity is driven both by the variable nature of
conditions in a RCT (e.g. the possibility of receiving a placebo) and by inter-person
differences in the perception of experiences.
The challenge of this thesis was to capture the diversity of these experiences in as
vivid detail as possible. This chapter outlines and justifies the methodology of the
thesis which allowed me to capture the diversity of these experiences.
3.2. Qualitative vs. quantitative research
Before starting this thesis I thought that the main distinction in research was between
qualitative and quantitative research. However, I am now aware that there are
significant differences underpinning these contrasting approaches. These differences
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are both in the abstract principles guiding the very paradigm (belief system) of that
research, and in the emphasis and expected outcomes of the research.
'These principles combine beliefs about ontology (What is the nature of
reality?), epistemology (What is the relationship between the inquirer and the
known?), and methodology (How do we know the world, or gain knowledge
of it?). These beliefs shape how the qualitative researcher sees the world and
acts in it.' (Denzin and Lincoln, 1994)
Complex issues indeed but ones that required careful consideration if I was to fully
understand the studied phenomenon and my reasons for studying it in the way that I
chose.
Broadly speaking, quantitative research adopts a positivist paradigm of research.
This belief system is based on one truth that is 'out there' awaiting discovery,
independent of the consciousness or awareness of this truth. Although qualitative
research can adopt many paradigmatic styles, including positivism, a constructivist
paradigm is a more common approach. This constructivist paradigm is a belief in
multiple truths, cognizant of the mind that is creating the meaning; in other words, an
interaction between the subject and the object to 'construct' an interpretation of
reality.
Crotty illustrates the difference through the example of the existence of a tree. A
positivist view of the tree is that it is a tree regardless of an awareness of its presence.
Its 'treeness' is waiting to be discovered. (Crotty, 1998). The positivist stance deals
in absolute fact. In a constructivist paradigm, 'there is no meaning without a mind.
Meaning is not discovered, but constructed...different people may construct meaning
in different ways, even in relation to the same phenomenon?(Crotty, 1998). In
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relation to the tree, although the tree may exist without a conscious mind, the tree¬
like properties that we ascribe to it would not. In relation to a clinical trial, different
people may construct different meanings to the same phenomenon.
When different meanings are being constructed from the same phenomenon, how
might a researcher approach this situation?
'Qualitative researchers stress the socially constructed nature of reality, the
intimate relationship between the researcher and what is studied, and the
situational constraints that shape inquiry. Such researchers emphasize the
value-laden nature of inquiry. They seek answers to questions that stress how
social experience is created and given meaning. In contrast, quantitative
studies emphasize the measurement and analysis of causal relationships
between variables, not processes. Proponents ofsuch studies claim that their
work is done from within a value-free framework.' (Denzin and Lincoln,
1994)
While not always as clear cut as Denzin and Lincoln describe, the 'value-laden
nature of inquiry' involved in qualitative research was an important consideration for
this thesis. As a widely held belief, 'The goal ofqualitative research is enriching the
understanding of an experience.'' (Polkinghorne, 2005). I wanted to take in the
various constructions of reality along with my own interpretation of them to enrich
the understanding of advanced cancer patients' experiences of clinical trials. I chose
the qualitative approach as the best way of exploring this phenomenon.
3.3. Framework for principles of quality in research
'Quality is elusive, hard to pre-specify, but we often feel we know it when we
see it. In this respect research is like art rather than science.' (Seale, 2002)
All research has the aim of reaching a wider readership than those who were
involved in the research. However, the reader has to decide whether the presented
material is of sufficiently high quality to contribute to previous knowledge; whether
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they can trust what has been presented. But how is the quality to be measured and
how can a reader trust what they are reading?
In the methodological literature, there is debate regarding the measurement tools of
quality in qualitative research. Lincoln and Guba lay out their criteria of principles
to apply to a piece of research in order to provide evidence of the trustworthiness of
that research. These principles are credibility, transferability, dependability,
confirmability and latterly authenticity (Lincoln and Guba, 1985, Guba and Lincoln,
1989). However this approach is potentially flawed:
'But it became evident ....that their criteria depended on a contradictory
philosophical position since their belief in 'multiple constructed realities'
(Lincoln and Guba, 1985: 294) rather than a 'single tangible reality'
(Lincoln and Guba, 1985: 295), which lies at the heart of the constructivist
paradigm, is not consistent with the idea that criteria for judging the
trustworthiness ofan account are possible.' (Seale, 2002)
To be truly relativist, and in so doing accept the belief of multiple realities, would be
to reject all form of validation, citing that each piece of research is individual and
valid in its own form. This creates a difficulty in relating the relevance of any work
to another situation. Alternatively, a traditional realist quantitative researcher
presents work with a definitive answer. Within this process they look to eliminate all
researcher bias from a study. By doing this, they are suggesting that there is a true
reality that the researchers' perspectives, something key to a constructivist approach,
are hindering them from seeing (Kuper et ah, 2008). Mays and Pope adopt the
stance of a subtle realist (Mays and Pope, 2000). Although rejecting the notion of
one definitive 'truth' they accept that there is an underlying reality which can be
studied. This allows general criteria of quality such as validity and relevance to be
applied (Mays and Pope, 2000).
35
Within qualitative research, practices exist to show evidence of rigor. The criteria
outlined by Lincoln and Guba above are examples. Rather than adhere to a fixed
checklist of rigor and the difficulties that this come with (Barbour, 2001), in the
methods chapter, I will describe the processes used to adhere to the principles of
validity and relevance. These processes, described in more detail in chapter 4.3,
were theoretical sampling, member checking, negative case analysis, use of thick
description of the methods used, reflexivity, peer debriefing and audit of analysis
process. (Guba and Lincoln, 1989, Lincoln and Guba, 1985, Seale, 2002, Barbour,
2001, Mays and Pope, 2000, Kuper et ah, 2008). Mays and Pope also outline a list of
questions that can be asked of a study by reader and researcher that can assist in the
assessment of quality (Table 2).
Table 2 - Assessing qualitative research
• Worth or relevance—Was this piece of work worth doing at all? Has it
contributed usefully to knowledge?
• Clarity of research question—Ifnot at the outset of the study, by the end of the
research process was the research question clear? Was the researcher able to
set aside his or her research preconceptions?
• Appropriateness of the design to the question—Would a different method have
been more appropriate? For example, if a causal hypothesis was being tested,
was a qualitative approach really appropriate?
• Context—Is the context or setting adequately described so that the reader could
relate the findings to other settings?
• Sampling—Did the sample include the full range ofpossible cases or settings so
that conceptual rather than statistical generalisations could be made (that is,
more than convenience sampling)? If appropriate, were efforts made to obtain
data that might contradict or modify the analysis by extending the sample (for
example, to a different type ofarea)?
• Data collection and analysis—Were the data collection and analysis procedures
systematic? Was an "audit trail" provided such that someone else could repeat
each stage, including the analysis? How well did the analysis succeed in
incorporating all the observations? To what extent did the analysis develop
concepts and categories capable of explaining key processes or respondents'
accounts or observations? Was it possible to follow the iteration betM'een data
and the explanations for the data (theory)? Did the researcher search for
disconfirming cases?
• Reflexivity of the account—Did the researcher self consciously assess the likely
impact of the methods used on the data obtained? Were sufficient data included
in the reports of the study to provide sufficient evidence for readers to assess
whether analytical criteria had been met?
I tried throughout this thesis to be mindful of these questions and apply them to my
work.
3.4. The use of grounded theory
There are many qualitative methodological approaches available to researchers.
These include phenomenology, ethnography, case studies, content analysis and
grounded theory. I will briefly discuss the approaches that I considered for this study
before describing in detail the reason for choosing a grounded theory approach.
A phenomenological approach seeks to understand the phenomenon of a lived
experience. However, phenomenology is concerned with the study of experience
from the perspective of the individual, seeking to describe rather than explain
(Punch, 1998). An example is a study that used a phenomenological approach to
examine and describe the barriers experienced by health care providers to timely
palliative care referral (Melvin, 2009). As I was interested in interpreting the
patients' experiences, I rejected the use of a phenomenological approach.
The basic premise of ethnography is to explore the culture of a group of people.
Ethnographic methods rely 'substantially or partly on 'participant
observation"(Denzin and Lincoln, 1994). To a variable degree, the researcher
involves themselves with the activities that the studied population take part in. I had
two concerns regarding an ethnographic approach to this study. Firstly, I felt that
although patients had much in common with each other, they had almost no
interaction with each other. Subsequently, there was very little scope for them to
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influence or be influenced by each other and develop a culture amongst themselves.
Secondly, being a participant in the clinical trials in any form was not an option for
me. It was for these reasons that I rejected ethnography as an unsuitable approach.
Case study analyses have been used in palliative care research. The value of case
study analysis lies in the examination of complex cases where context is important
and a deep understanding of each case, from multiple perspectives, can be achieved
(Walshe et al., 2004). Williams et al used a case study analysis to track the evolution
of hospice palliative care Canada (Williams et al.). Although a deep understanding is
important in this thesis, the lack of previous knowledge on the topic, and so the lack
of information on the best cases to select led me to reject case study analysis as the
most beneficial methodological approach.
Qualitative content analysis has been defined as a 'research method for the
subjective interpretation of the content of text data through the systematic
classification process of coding and identifying themes or patterns.' (Hsieh and
Shannon, 2005). One of the strengths of the approach is the ability to work through a
large volume of data collating similar or related pieces. However, the approach is
suitable when testing prior hypotheses rather than exploring a new area of which
little is known (Miles, 1994). For this reason, content analysis was rejected.
While there were aspects of each methodological approach described above there
made them unsuitable, other aspects were appealing. For example, a description of
patient experience was relevant to this study, as used in the phenomenological
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approach, but it was important also to interpret these findings. Similarly a case study
approach was appealing but it unclear which cases to study. I felt that a grounded
theory approach would draw on the strengths of several of the methodological
approaches described above. The detailed reasons for this decision are discussed
below:
Summary ofgrounded theory
The methodology of grounded theory is known in qualitative research to be
appropriate when there is a 'lack of knowledge or theory of a topic.' (Bluff, 2005).
Theory is generated from the collected data rather than testing a pre-existing theory.
The literature search described in chapter two revealed the lack of research into the
experiences of advanced cancer patients who had taken part in symptom control
trials. With this lack of research, and no pre-existing theory to test, I chose grounded
theory as an appropriate methodology to develop further knowledge of this topic.
A 'grounded theory' comes from a large collection of data and will have taken its
influences only from that collection of data. The theory is grounded within the data.
Other work that may have taken place before should only be considered towards the
end of the process. The data studied are usually a collection of information gathered
from the studied population, typically in the form of transcribed interviews. These
data are studied carefully for similarities, differences, patterns and comparisons
between different contributing participants. Throughout the process, the data are
broken down, analysed and refigured to direct the course of the research. By the end
of the research, as the last pieces of data are being collected, the overall grounded
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theory will have emerged from the data as a way of explaining succinctly the studied
phenomenon and will be able to link all other aspects of the phenomenon to it.
This short summary of grounded theory does not cover all of its subtleties. These
subtleties and the important points that make up the process of using a grounded
theory approach are described and discussed throughout chapter 3.4. I have found
grounded theory a difficult concept to understand fully. It is for this reason that I go
into grounded theory in detail to put across what I understand to be the important
factors of this methodological approach.
3.4.1. The history of grounded theory
The creation of grounded theory was a defining moment for social science research.
However its use as a research tool has evolved in the four decades since its inception.
These two facts merit some discussion of the background to grounded theory.
The Discovery of Grounded Theory was written and published by sociologists
Barney Glaser and Anselm Strauss (Glaser and Strauss, 1967). This seminal work
was published as a description of their methodology while studying dying patients in
hospitals. At the time of publication, qualitative research was not viewed as
scientifically credible by the research community. The aim of Glaser and Strauss
was to redress this opinion.
Before grounded theory, qualitative theory development of a phenomenon was
conceived from a priori, or previously known, knowledge. The novel difference in
grounded theory was that this was ' the discovery of theory from data'' (Glaser and
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Strauss, 1967). As Kelle describes, 'One ofthe main purposes ofGlaser and Strauss'
"Discovery book" was to challenge the hypothetico-deductive approach which
demands the development ofprecise and clear cut theories or hypotheses before the
data collection takes place.' (Kelle, 2005)
Fundamental to grounded theory is the belief that knowledge may be increased by
generating new theories rather than analysing data with existing ones (Heath and
Cowley, 2004). Generating new theories is an inductive process, contrasting with the
deductive approach of testing theories or hypotheses to be true or false.
According to Strauss and Corbin, grounded theory must include four essential
principles: fit, understanding, generality and control (Strauss and Corbin, 1990).
• Fit entails that the theory fits the substantive data
• Understanding entails that the theory be comprehensible to all involved in the
area of study
• Generality entails that the theory is applicable in a variety of contexts. It may be
that this aspect of the theory is undertaken in further studies in another setting
• Control implies that the theory should provide control with regard to action
toward the phenomenon. The researcher should control the conditions of the
study positively toward the theory generated
The completed theory '...provides the best comprehensive, coherent and simplest
model for linking diverse and unrelated facts in a useful and pragmatic way.
Theorizing is the process of constructing alternative explanations until a "best fit"
that explains the data simply is obtained. ' (Morse, 1994)
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3.4.2. Differences in grounded theory
After the original work on grounded theory, Glaser and Strauss' views altered
towards the theoretical paradigm underpinning their work. Glaser remained true to
the original concept while Strauss, with his subsequent research partner Juliet
Corbin, published work which challenged and modified the original concept. Glaser
felt that these deviations were not in keeping with the original concept of grounded
theory (Glaser, 1992).
The commentary on the differences in their work is prolific with several theoretical
issues still unresolved. Annells claims that the methodological differences between
Glaser's and Strauss & Corbin's work are created by an ontological and
epistemological divergence. (Annells, 1996). Heath and Cowley describe a shared
ontology with epistemological differences (Heath and Cowley, 2004).
The main differences between Glaser and Strauss & Corbin's work lie in previous
knowledge of the studied phenomenon, subsequent data analysis and verification of
the generated theory.
3.4.2.1. Previous knowledge of the studied phenomenon
Emergence is one of the key components of grounded theory. It is the phenomenon
of allowing the theory to develop from within the data. Glaser maintains that this is
done most effectively when all preconceptions on the studied topic are put to one
side. With respect to the topic, the researcher's mind is a tabula rasa, or blank slate,
so that generated data are not contaminated by preconceptions. He or she has to put
aside all preconceived notions so that they can "remain sensitive to the data by being
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able to record events and detect happenings without first having them filtered
through and squared with pre-existing hypotheses and biases" (Glaser, 1978).
Strauss and Corbin felt that what was more important was to be aware of your
previous knowledge so that you were able to discern what was relevant in the data
and what was not. Dey comments that 'there is a difference between an open mind
and an empty head.' (Dey, 1999).
3.4.2.2. Data analysis
Data are generated by interaction with participants, usually in the form of an
interview. Coding is the term that is used for the process of organising sections of
data from different interviews into comparable collections. The complex differences
between the coding approaches of Glaser and Strauss have been well described
(Kelle, 2005). Strauss and Corbin, through the use of axial coding, offered a much
more directive approach to the elaboration of categories. This was particularly aimed
at novice researchers. Glaser offers theoretical codes that can be adapted to
categories to aid their elaboration. His criticism of Strauss and Corbin was that axial
coding forces' the data into a preconceived framework that it may not have naturally
developed into, thus being a consequence of the researcher's previous influences,
rather than 'emerging' from the data (Glaser, 1992). Once the process of axial
coding has taken place, Strauss and Corbin outline the process of 'selective coding'.
This is the process of selecting the core category and systematically relating other
categories to this. The core category is the central phenomenon around which all
other categories are based. A more detailed description of the coding process is
found in chapter 3.4.5.
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3.4.2.3. Verification of the generated theory
The ontological and epistemological incongruence that developed between Glaser
and Strauss created a further difference on the issue of verification. Glaser thought
that if the findings of the grounded theory were felt to be significant, "a
verification^ study (an experiment or survey) can be made to verify its true
import"(Glaser, 1992). Strauss and Corbin would maintain that the findings would
be verified "throughout the course of the research project, " by the multiple realities
being offered and assimilated (Strauss and Corbin, 1994).
3.4.3. Constructivist Grounded Theory
The original grounded theory has been described as positivist or at least post-
positivist in its theoretical stance (Kelle, 2005) (Annells, 1996). Strauss and
Corbin's later work is more complex.
'Undoubtedly however, their work demonstrates a mixture of language that
vacillates between post-positivism and constructivism, with a reliance on
terms such as recognising bias and maintaining objectivity when describing
the position the researcher should assume in relation to the participants and
the data. Nevertheless, they mix these ideas with observations such as "we
emphasize that it is not possible to be completely free of bias. " This has led
some researchers to remark that 'people can find support in it for any
ontology that they wish (Macdonald & Schreiber, 2001) ' (Mills et al., 2006c).
An emerging form of grounded theory, with sociologist Kathy Charmaz being
largely credited as its pioneer, is that of a constructivist approach. She lays out her
manifesto towards constructivist grounded theory thus:
'In the classic grounded theory works, Glaser and Strauss talk about
discovering theory as emerging from data separate from the scientific
observer. Unlike their position, I assume that neither data nor theories are
discovered. Rather, we are part of the world we study and the data we
collect. We construct our grounded theories through our past and present
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involvements and interactions with people, perspectives, and research
practices.' (Charmaz, 2006)
Rather than the theory waiting to be discovered, Charmaz argues that the generated
theory is an interpretation of the studied phenomenon with the influence of
participant and researcher being central to the construction. My belief system puts
this interaction between participant and observer at the centre of the grounded theory.
I therefore adopted a constructivist approach to this study.
The differences between Glaser and Strauss and now Charmaz in their approach to
grounded theory is complex and at times more philosophical than practical. A lot of
criticism of grounded theory has been aimed at the initial work rather than at the later
and modified approaches. Glaser and Strauss maintained at the time of their first
publication that this was an evolving process and so it has proved. Mills puts the
differences of Glaser, Strauss and Charmaz most eloquently:
'...all variations of grounded theory exist on a methodological spiral and
reflect their epistemological underpinnings. The form of grounded theory
followed depends on a clarification of the nature of the relationship between
researcher andparticipant(Mills et al., 2006b)
3.4.4. Summary of the constructivist grounded theory approach
adopted
A grounded theory approach has several key stages to be followed: data collection,
data analysis, patient sampling and data saturation. This section will describe these
elements in theoretical terms before discussing them in relation to this study, in
chapter four (Methods) and appendix A (Data Analysis).
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3.4.4.1. Data collection
Glaser stated that'all is data' (Glaser, 2002). Data can be in the form of observation
studies, written documents, interviews or focus groups. The form of data collection
that will generate the richest data to be analysed should be chosen. Focus groups or
semi-structured interviews are commonly chosen as the primary means of data
collection. The strength of a grounded theory depends on the quality and depth of
the data generated. Superficial data will only provide a superficial insight into a
phenomenon.
As an example of generating rich data, Kvale describes the art of the second
question; following up a patient response with another pertinent question (Kvale,
2009). It is the second answer that may shed more light on a topic than has been
already offered. The intention of the second question is to start the data analysis
during the data collection phase, or at least to make the data analysis easier.
3.4.4.2. Data analysis
The components of grounded theory analysis are shown in Figure 2.









The move from transcribed interviews to a generated theory is one that seems to be
the hardest conceptual leap to make. Kvale asks the question 'How shall I find a
method to analyse the 1,000 pages of interview transcription I have collected?'
(Kvale, 2009). The answer lies in avoiding getting to the stage where this question
may be asked. Data analysis occurs concurrently with data collection. The ongoing
analysis shapes the data collection and the direction in which it proceeds.
The next two sections look at the two main components of data analysis: coding and
memo-writing. Coding is further divided into initial coding, focused coding and
theoretical coding.
3.4.5. Coding
As previously mentioned in chapter 3.4.2.2, the process of coding organizes data into
comparable collections. The first process, initial coding, aims to break down the
transcriptions into small sections of data such as a sentence or phrase from an
interview. During focused coding, these smaller sections can be built up again, not
around the person who generated the data but around collected concepts and
categories into which the section of data fits. As the process develops into
theoretical coding, the codes and categories become increasingly abstract from the
original source and move towards the final theory. Each of these three processes,
initial, focused and theoretical coding and their ramifications are now discussed
separately.
The description of the data analysis for this thesis is in appendix A - Data Analysis.
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3.4.5.1. Initial coding
Charmaz outlines the aim of initial coding as one which 'sticks closely to the data''
while 'remaining open to exploring whatever theoretical possibilities we can discern
in the data' (Charmaz, 2006). Every line of a transcript, potentially every word, is
studied and described. She suggests the use of words that describe actions rather
than topics. The use of gerunds (words ending with -ing, e.g. avoiding, feeling,
anticipating) helps with this process (Charmaz, 2006, Glaser, 1978).
' This method ofcoding curbs our tendencies to make conceptual leaps and to
adopt extant theories before we have done the necessary analytic work.'
(Charmaz, 2006)
Codes are flexible and one should expect to have to re-organize codes as they emerge
from data. Codes should be modified to accommodate new data rather than forcing
data into codes that do not fit. Codes should be precise and descriptive to offer a
flavour ofwhat they are describing.
Most codes are developed constructs of the researcher. Some codes, in vivo codes,
are a direct quote from a patient. In vivo codes can have specific and descriptive
meaning beyond the scope of the words used and create a strong connection with the
generated data; more so than the substantive codes developed by the researcher.
3.4.5.2. Focused Coding
Focused coding is the next stage after the initial coding. Focused coding uses the
most significant and/or frequent earlier codes to sift through large amounts of data.
'Focused coding requires decisions about which initial codes make the most analytic
sense to categorize your data incisively and completely' (Charmaz, 2006). The aim
is to develop the initial coding to give a clearer structure of preliminary directions of
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interest. It is a dynamic process whereby you return to the data to explore a new
concept or clarify or modify an existing one. The researcher looks for new concepts
to emerge. 'You act upon your data rather than passively read them.' (Charmaz,
2006) As the interviews progress, they do not have to be analyzed in as much detail
as the initial interviews. Coding a similar response to an already well outlined topic
generates data that will add to complexity without adding further descriptive weight.
Although initial coding may be more common at the start of data analysis and
focused coding more common as analysis progresses, data are continually coded in
both ways throughout the process as ideas and categories vary in their development
through the study.
The type of coding that may be best known in relation to grounded theory is axial
coding. This was developed by Strauss and Corbin in an attempt to give specific
instructions into the process of coding for novice researchers. Axial coding puts the
codes back together around an 'axis'. Categories and sub-categories are linked and
described. Axial coding has its critics as well as its champions (Charmaz, 2006,
Kelle, 2005, Strauss and Corbin, 1990, Strauss and Corbin, 1998). Charmaz does not
feel that it is an essential step in the process:
'Axial coding provides a frame for researchers to apply. The frame may
extend or limit your vision, depending on your subject matter and ability to
tolerate ambiguity ....Those who prefer simple flexible guidelines ...do not
need to do axial coding. They can follow the leads that they define in their
empirical models At best axial coding helps to clarify and to extend the
analytic power ofyour emerging ideas. At worst, it casts a technological
overlay on the data - andperhaps on your final analysis.'(Charmaz, 2006)
I chose to not to adopt axial coding in the data analysis.
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3.4.5.3. Theoretical coding
Once the data are organized into more manageable sections, these sections, or
categories can be analysed between themselves. Relationships between categories
can be explored and described. In this manner the analysis moves away from the
direct data towards a more theoretical level. Glaser has developed over 18
theoretical codes that can 'hone your work with a sharp analytic er/ge'(Charmaz,
2006). However Charmaz also warns that they have to earn the right to be in the
final grounded theory. Otherwise the researcher runs the risk of forcing context and
a framework onto a situation which is not present within the data. In relation to
previous concepts of grounded theory, theoretical coding is similar to selective
coding. Within this stage of coding, the central category is sought for comparison
with all other categories.
Constant comparison is a key aspect of data analysis. This is the process of
comparing actively data to the category to which they are assigned. Constant
comparison allows the growth of the theory by finding areas in categories that need
to be expanded and going back to the data to address these gaps.
3.4.6. Memo writing
Memo writing is the corner-stone of conceptual writing in grounded theory. It is the
process where the organized codes and concepts move into a narrative description of
the theory.
Early memo writing can be colloquial and informal. Getting ideas, observations and
thoughts onto paper about initial codes and extracts from the data begins to collect
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and refine the study of the data as a whole. Memos allow you to explore categories
to see conceptual gaps or weaknesses. The data can then be re-examined or more
data can be collected to fill these gaps.
As the analysis continues, the memos become increasingly abstract to move towards
the completed theory. Memos are collected into similar topics and are compared
with other groups ofmemos. Further memos are written on these comparisons.
'As in Glaser's approach, the sorting of memos keeps the researcher in
contact with the data while descriptive concepts are gradually replaced by
abstract categories as the analysis progresses.' (Heath and Cowley, 2004)
The abstraction is vital to avoid the result of a 'grounded description more than
theory', a criticism of some attempts at grounded theory (Charmaz, 2006). Despite
the move away from direct handling of the data, Charmaz advocates continuing to
use quotes from the data so that the theory remains grounded in the data and
participants' voices still resonate through the text.
3.4.7. Patient sampling
Qualitative research in general and grounded theory in particular does not look for a
representative sample of a population. Instead, sampling of a population is
performed to give the fullest description of the population being studied.
'The selections are based on the likelihood that they will confirm or elaborate
on the emerging descriptions or provide opportunities for disconfirmotion of
the emergingpattern. ' (Polkinghorne, 2005)
Authors have described many different types of sampling (Strauss and Corbin, 1990,
Sandelowski, 1995, Coyne, 1997). At the start of the project, patients may be
selected where the phenomenon is known to exist. This can be termed selective
sampling or purposive sampling. Once the initial data have been examined and
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tentative topics are identified, subsequent patients are selected on the basis of these
topics. This step is known as theoretical sampling.
In keeping with the principles of grounded theory, theoretical sampling is emergent.
'Initial sampling in grounded theory is where you start, whereas theoretical
sampling directs you where to go' (Charmaz, 2006). Theoretical sampling is central
to the inductive-deductive components of constant comparison in grounded theory.
Data are generated and studied. From these data, preliminary concepts may be
considered cautiously. Specific patients are selected theoretically to test or elaborate
on these concepts. Depending on their responses, further theoretical sampling takes
place for further data generation and analysis. At the same time, the interview
schedule changes to address issues that are emergent and to remove issues that are
less prevalent. It is in this manner that sampling, coding and analysis take place
concurrently and are all influenced by each other (see Figure 2: The components of
grounded theory data analysis).
3.4.8. Data saturation
The number of cases studied in qualitative research tends to be smaller than in
quantitative research. In quantitative research, a larger number of recruited patients
allows a greater chance of being able to claim statistically significant findings, one of
the key aims of quantitative research.
As outlined already, the aim of data collection in qualitative research is to explore all
dimensions of a topic, rather than interview a representative sample. But when do
you stop interviewing? When have all aspects of a phenomenon been fully explored?
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The term used in qualitative research is "data saturation".
'Categories are 'saturated' when gathering fresh data no longer sparks new
theoretical insights, nor reveals new properties of your core theoretical
categories.' (Charmaz, 2006)
However, there is a risk of claiming saturation too early. Charmaz describes the
incorrect perception of saturation when researchers 'keep finding the same patterns'
The real goal should be to achieve 'theoretical saturation' (Charmaz, 2006). On this
point she is happy to agree with Glaser:
'Saturation is not seeing the same pattern over and over again. It is the
conceptualization of comparisons of these incidents which yield different
properties of the pattern, until no new properties of the pattern emerge. This
yields the conceptual density that when integrated into hypotheses make up
the body of the generated grounded theory with theoretical completeness.'
(Glaser, 2001)
By probing a topic superficially, conceptually thin categories which are quickly
saturated may emerge. Charmaz offers the following questions when considering
saturation:
• Which comparisons do you make between data within and between
categories?
• What sense do you make ofthese comparisons?
• Where do they lead you?
• How do your comparisons illuminate your theoretical categories
• In what other directions ifany do they take you?
• What new conceptual relationships, ifany, might you see?
(Charmaz, 2006)
When considering saturation of certain categories, I tried to apply these questions to
that area.
Strauss and Corbin maintain that saturation is a 'matter of degree' (Strauss and
Corbin, 1998). While there will always be the potential for the 'new to emerge',
beyond this point, the data generated do not add to the overall theory or framework.
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3.5. Conclusion
This chapter has outlined the theoretical discussions and justifications for the
approach that I chose for this study. The next chapter will discuss the specific
methods used during the study.
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Chapter 4. METHODS
This chapter describes the methods used to explore the phenomenon of advanced
cancer patients' experiences of taking part in symptom control clinical trials. It
details ethical approval for the study, patient selection, the interview process and an
assessment of quality of the research process that took place.
4.1. Ethical Approval Process
It is appropriate that ethics committees want to be reassured that the use of patients in
research is done in the correct manner. This is particularly true in patients with
advanced cancer. When their life expectancy is limited, it is critically imperative that
the central tenants of ethics i.e. that patients' time is used considerately and with
their best interests in mind, is upheld. To this end, ethical approval was sought and
gained for this study (See Appendix H for ethical approval letter).
At the time of submission to the ethics committee, there was the possibility that a
third trial would be used for patient recruitment. This was the Menthol in
Neuropathic Type Pain trial (MiNT-P). The ethics application included this trial as
one from which patients would be recruited. However, this trial did not begin at the
time that was expected and patients were not recruited from it.
It was also intended that part of the data collection would be in the form of focus
groups. This was included in the ethics application. However, as the trial
progressed, the decision was made not to recruit patients into focus groups. During
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recruitment, some patients had indicated a reluctance to take part in a focus group.
In addition to this, the relatively small number of patients who were eligible to take
part in this study posed problems. The intention of focus groups is to compare
groups rather than individual opinion within each group (Barbour, 2005). Patients
with similar characteristics who might be recruited into one focus group could be
either separated by 50 miles in distance or several months in time. It was felt that if a
suitable number and quality of focus groups could not be arranged, it would be better
not to use them at all.
Recommendations of the Ethics Committee
The ethics committee felt that the study was a meaningful piece of research that was
worth doing. However they had some concerns that were highlighted. They were
very keen that patients did not feel that they were put under undue pressure to take
part in the study. Therefore they stressed that patients should only be contacted once
by telephone after they had been given the information leaflet. If they did not
verbally consent they were not to be contacted again. As discussed in chapter
10.4.2.1 this posed difficulties if patients did not answer their telephone or there was
an answer machine. In these instances I exercised tact and judgement whether to
contact a patient again. With this comment taken into consideration, the ethics
committee approved the study.
4.2. Patient selection
At the time of this study, the Edinburgh Palliative and Supportive Care Group
(EPaS) were conducting two randomized controlled trials. These were the Ketamine
Pain Study (KPS) and the Pregabalin Bone Trial (PBT). The trials were double
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blind, randomized controlled trials studying the use of ketamine and pregabalin as
novel analgesics against a placebo control. These trials were being conducted in
multiple centres in the United Kingdom. Patients taking part from the Edinburgh and
Glasgow centres provided a suitable patient cohort for this thesis. Descriptions of
these trials can be found in Appendices B and C.
Although I was a member of the EPaS group, I had no involvement in any aspects of
the PBT or KPS and had no contact with patients in these trials prior to contacting
them for this study.
A set of inclusion and exclusion criteria was devised for patients in this study.
4.2.1. Inclusion criteria:
• A cancer diagnosis of an incurable nature i.e. metastatic spread
• Age >18 years
• Ability to complete the necessary interview
• Participation in either the PBT or the KPS (patients who had completed the study
and those who withdrew before completing the study were both eligible for
inclusion)
• Written informed consent
• Undergoing or had completed palliative treatment (this can include tumoricidal
therapy or supportive care) for cancer
4.2.2. Exclusion Criteria:
• Age < 18 years
• A cancer diagnosis with a potential curable outcome
• Patients in the dying phase of their illness
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'The dying phase of their illness' is deliberately ambiguous. Rather than require a
rigid guide for such an intangible state, it was felt better to allow this decision to be
made in conjunction with those health care professionals who were looking after the
patient. Such a decision is potentially controversial. One of the key arguments
against palliative care research that I hope to consider is the supposition that
palliative care patients are too unwell to take part in clinical research. However it
was felt that it would not be appropriate to approach patients who were actively
dying for this study.
4.2.3. Suitability of patients
The KPS included patients with terminal and curative cancer. As this thesis was
looking at patients with a diagnosis of a terminal nature, this was the first distinction
to be made when reviewing patients for suitability. All patients in the PBT were
being treated for metastatic bone disease with radiotherapy, making them all eligible
for inclusion.
The trial nurses in Edinburgh and Glasgow referred patients who were eligible to
take part. The initial patients recruited were purposively sampled to cover both trial
centres. Patients were contacted either by myself or by a member of the trial staff
and informed of this study. If interested in the study, patients were given the
information sheet and allowed at least 24 hours before being contacted again. This
time delay was in adherence of the ethics committee guidelines on patient
recruitment. Patients were given the opportunity to raise any questions they might
have. If patients were happy to take part in the study, a date and venue were
arranged at the patient's choosing. Most often patients were happy to be interviewed
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at home but occasionally patients were interviewed on hospital grounds. This was
either because the patient was visiting the hospital already or they preferred to be
seen in the hospital. Also in compliance with the ethics committee's guidance,
patients were only contacted once after they had been given the information sheet
unless they gave consent to be contacted again. An example of this might be if they
were not feeling well at the time of the telephone call but were happy to speak at a
later date.
The details of all patients who had taken part in both the KPS and PBT were
collected to keep record of who had and had not been recruited to the study. Of
those who were not recruited, the reasons for this were documented. Common
reasons might be that they were not eligible for the study, they declined to
participate, they were deemed too similar to previous patients interviewed or I was
interviewing other patients at the time that they had finished the trial. I made an
effort to try and recruit patients who had recently completed the trial so that their
memories could be fresher in their mind. On occasion, I interviewed patients some
months after being on the trial. Some patients struggled to recall details of the trial
which may have been clearer in their mind the interview taken place sooner after the
completion of their trial.
4.2.4. Theoretical sampling of patients
The principles behind theoretical sampling have been discussed in chapter 3.4.7. As
the study progressed, patients were chosen more selectively. Initially, 1 intended to
interview similar patients from Edinburgh and Glasgow. Once the initial data were
analyzed, a group of patients with similar experiences were those who felt their pain
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had reduced during the trial. These patients were very positive towards the trial and
found few flaws in it. Because patients with a perceived pain reduction were positive
about the trial, I became interested in the responses of those patients who had not had
a reduction in pain from the trial. I began to look at the pain scores of the patients
before and after the trial. The scoring systems used were the Brief Pain Inventory
(BPI) for the PBT and the McGill Pain Questionnaire (MPQ) for the KPS. By
looking for a pain reduction of >30% in the BPI or a drop of 5 points in the MPQ,
patients were deemed to have a significant pain reduction. I began to contact patients
who had not had a significant pain reduction. I also interviewed patients who had
withdrawn from the trials for any reason. It was felt by the trial staff that some
patients had not been happy with them when they withdrew from the trial. I wanted
to try and find out why this was and tried to target these patients specifically.
However these patients were reluctant to be recruited to the study and I did not
manage to recruit any. Finally, I became interested in those patients who had
contacted trial staff members after the trial had finished. I was interested in patients
who might have felt a great significance in the relationship they had developed with
the trial staff. I wanted to find out how they felt after the trial had stopped and the
impact this had on their relationship with the researchers.
4.3. Interviewing
4.3.1. Interviewing Theory
Patients were interviewed using a semi-structured format.
'Semi-structured interviews are conducted on the basis of a loose structure
consisting of open ended questions that define the area to be explored, at
least initially, and from which the interviewer or interviewee may diverge in
order to pursue an idea in more detail. \Britten, 1995).
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This fits well with the principles of grounded theory and semi-structured interviews
are the most commonly adopted format for data collection. Interviews are also
thought to be appropriate in the palliative care setting (Gysels et ah, 2008). When
this study was submitted to the ethics committee, it was also with the intention of
conducting several focus groups. The primary aim of focus groups is to stimulate
discussion and to compare groups (Barbour, 2005). As the study progressed
however, it was felt that patients' opinions would be better heard individually rather
than in a group.
In preparation for the interviews, I studied several texts, in particular Interviews:
Learning the Craft ofQualitative Research Interviewing (Kvale, 2009). In line with
the constructivist approach that I have taken in this thesis, I was aware of the shared
construction of the data; the data being 'co-authored' (Kvale, 2009). In the same
manner, the power dynamic should be as equal as possible, rather than the traditional
objectivist, hierarchal structure with the participant being subordinate to the
researcher (Mills et al., 2006c, Fontana and Frey, 1994). Seymour writes of two
dimensions of the power differential: 'that between 'well' person and 'unwell'
person; and that between 'professional' and 'patient'.' Rather than resolving these
tensions completely, the imbalance can only be 'more or less' equal. (Seymour and
Clark, 1998). I was guided by Mills regarding the power imbalance:
'In order to move the researcher andparticipant to a more equal position of
power within the relationship, the researcher needs to assume a more
reflexive stance and proactively plan for the time they and the participants
spend together. ' (Mills et al., 2006c)
During the study my age was 30-32 years. I was a doctor specializing in palliative
care with concurrent clinical commitments in a Scottish hospice. I am a white,
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middle class, unmarried male with an English non-regional accent; a 'posh' accent
for want of a better word. I think that my accent is pertinent as a lot of the patients I
interviewed were from a low socio-economic background which might put my
immediate persona at odds to theirs. I felt that I might appear as a stereotypical
doctor and wanted to attempt to reduce any barrier that this may represent from
patients' previous experiences. Rather than try to alter any of the facts of my
background, I acknowledged these and their impact on the power dynamic as part of
the construction of data that would be generated.
Prior to the interviews, patients were made aware in the information sheet that my
background was a doctor in palliative care. If I was posed a question regarding their
medication for example, I answered this as I was able to do rather than shy away
from my position and the knowledge that I held.
I used several questions to consider the power relationship and the bearing that it had
on the constructed data:
'How is this [person] like me?
How [are they] not like me?
How are these similarities and differences being played out in our
interaction?
How is that interaction affecting the course of the research?
How is it illuminating or obscuring the research problem ' (Seibold, 1992)
I actively undertook several measures to try and reduce any power imbalance:
• Invited patients to call me Tom
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• Arranged interview at time and date (where possible) and venue of patient's
choice
• Accepted any offer of food or drink
• Established rapport at beginning and end of interview with social discussion
• Offered my opinion at times and gave my professional experience in appropriate
context of the discussion
• Assured patients of the confidential nature of the study and that anything they
said would be anonymized
• Sent copies of the transcript back to patients to read and comment on if desired
The impact ofmy personal and professional background is explored in the discussion
in chapter 10.
4.3.2. The process of the interview
Before recording started
At the start of the interview, I would discuss with the patient what was planned. I
would also check that they did not have any questions that had arisen since we had
arranged the interview. I accepted any offer of food or drink in order to develop an
early rapport. After this introduction, I would invite patients to read and sign the
consent form. Some patients had difficulty holding a pen or filling in their full
names and I would assist as possible. I was happy to accept a patient's initials rather
than their full signature in order to keep the process as undemanding for patients as
possible.
During this initial period before recording started, I would also assess a patient's
capacity to take part in the study. As has been discussed in the literature, as the study
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posed minimal risks to the patient, this was conducted 'with an informal assessment
ofunderstanding' (Casarett, 2003). The assessment of capacity was also for my own
benefit to assess whether I felt that the patients would be sufficiently lucid and
eloquent to put across their recollections of the trial.
The presence of a partner during the interview
Often I would be met at the door by a partner or they would be present during the
introduction. My intention had always been to interview patients alone. I felt that
this would make interpretations of the data more straightforward as it was only the
views of patients that the study was investigating rather than the views of relatives
and care-givers as well. Sometimes partners were present during interviews. I felt
that this had a negative impact on the quality of data generated. Depending on the
relationship, patients might defer to their partner for their opinion rather than have to
explain their own mind. Also, when I tried to employ a pause in an interview, to
allow a patient to consider the topic or elaborate further, this silence was filled on
occasion by the partner. As the interviews progressed, I requested that I saw patients
on their own. Clearly, if patients and partners felt strongly about them being present,
despite only the gentlest request that the partner was not present, I relented to this,
albeit reluctantly. I was subsequently to discover other reflections on this topic; it
was reassuring to read a shared experience on the matter (Gysels et al., 2008).
During the interview
When all the preliminary work had been done, I would start the recording. At the
start, I would explain to patients the format of the interview. I also explained that
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although I worked with the research staff, I did not work on the trials that they had
taken part in. I stressed that what they said would be anonymized and would not
have any impact on their care. I wanted patients to feel that they were able to discuss
positive and negative features of the trial without reservation or concern of
repercussion.
An interview schedule was designed initially to explore four main topics. These
were:
• How the patients found out about the trial
• Patients' thoughts before entering the trial and their previous experiences or
knowledge of clinical trials
• Patients' experiences of being on the trial
• How the patients would improve or change the trial
As the interviews progressed, this interview schedule altered as topics emerged, grew
or receded in importance. Copies of the first and final interview schedules can be
found at appendix F and G.
At the start of an interview these topics were covered with open questions to allow
patients to raise areas that were important to them. I explored these areas with
patients, using a range of initially open and latterly closed questions during each
interview to fully understand their opinion or experience. I tried to allow patients to
put across their views as much as possible while keeping them on the topic of
interest. I was mindful of the art of the second question, as discussed by Kvale, and
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tried to consider future data analysis during the course of an interview (Kvale, 2009).
As I was unlikely to be able to contact patients again after the interview, it was
important to consider and ask any further questions that I might have during the
interview rather than be left speculating about a topic at a later date.
Interviews ranged in time from 20 minutes to over an hour. Once I had completed
my questions, patients were given the opportunity to mention anything else that had
not been covered. Patients usually did not have anything else to add at this point and
the recording would be stopped.
After the interview
After I stopped the recording I conducted a debriefing session with the patient. This
involved asking the patient how they had found the interview and what we had
discussed. I was aware through previous reading that patients may have wanted to
say something after the recording had finished (Kvale, 2009). My aim was to give
them this opportunity. However patients did not feel the need to say anything 'off
the record' which they had been unwilling to say during the interview. Again I
accepted any offer of food or drink before leaving. Once in my car, I recorded my
own views on how the interview had gone and on the surroundings of the house and
the condition of the patient. This helped in future analysis to remind myself of the
patient interviewed and as part of the reflective process. I described areas of the
interview that were new or had prompted new thoughts in my mind.
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4.3.3. Transcription
Patients were allocated a patient number in sequential order. For the transcription,
their initials were used, however for any published material and throughout this
thesis their sequential patient numbers are used. Similarly any mention of any
professional staff members by name has been anonymized. Every new statement by
the patient was numbered for ease of reference during data analysis.
The transcription of your own interviews allows a researcher to gain great depth of
intimacy with the data. Flowever, it is also time consuming with every hour of
recording taking approximately eight hours of transcribing. As this project was
conducted two days a week over a two year period, I did not feel that the full
transcription of every interview was a justifiable use of my time. Some of the
interviews were transcribed by a medical secretary. However, I transcribed over half
of the interviews. Of the interviews that were not transcribed by me, I went over the
transcripts with the recording to check for the validity of the transcript. I often found
that I was able to fill in gaps in the transcription that the transcriber had not been able
to decipher as I could remember the conversation as it had happened.
Once the interview was transcribed, patients were given the opportunity to be sent a
copy. They were invited to read over the transcript and contact me if there was
anything that they were not happy with or that they wished to discuss further.
4.3.4. After the interview
Once a patient had taken part in an interview, I entered their anonymous details onto
a database. This included their demographic details, cancer diagnosis and in which
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trial they had taken part. A list of the participants can be found at appendix H. I
informed their GP that they had taken part in the study with a letter.
As previously mentioned, a copy of the transcript was sent to patients. However, I
found that no patients contacted me to discuss their interview. I did see one patient
some time later at the hospice during my clinical work. Although he had not
contacted me at the time, he told me that he and his wife had enjoyed reading the
transcript and remembered the interview very well. I was pleased to receive this
information as although patients may not have contacted me, I felt that they or indeed
relatives after a patient had died may have taken some pleasure in having a document
of their views and nuances in speaking to look over in the future. This could be
along similar lines to Prof Harvey Chochinov's work into dignity therapy
(Chochinov, 2009).
4.4. Assessment of quality
In the methodology chapter, I outlined the steps taken to ensure the quality of
research. These are now discussed in more detail.
4.4.1. The interview process, the accuracy of interview data and
member checking
Throughout the interviews, I remained flexible with the interview schedule and
allowed patients to discuss issues that were important to them. The intention was to
allow patients to feel that their views were important and also to increase the
potential of patients bringing a new insight into a particular topic. As the interviews
progressed and the schedule changed, I altered the direction of interviews into areas
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that I felt were underdeveloped rather than going over similar points to previous
patients.
The interviews were transcribed verbatim either by me or by the medical secretary. I
reviewed all transcripts while listening again to the interviews to aim for the most
accurate transcript possible. Some comments were inaudible despite best efforts and
these were annotated on the transcripts. The transcripts were also sent to the patients
to give them the opportunity to read the transcripts to either correct a statement or
expand on a topic. No patient took up this opportunity to contact me.
4.4.2. Peer debriefing
The interviews were read by one ofmy supervisors, Dr Laird. We would discuss my
questioning and the data that were being generated. This also happened on two
occasions with an independent person, Prof Mari Lloyd-Williams over May and June
2010.
4.4.3. Presentation of data
A poster of the main findings was presented at the European Association of
Palliative Care Annual Meeting in Lisbon in 2011. I also gave an oral presentation
of the study in St Andrews Hospice, Airdrie to a group of multidisciplinary
professionals.
4.4.4. Theoretical sampling and negative case analysis
The sampling of patients had the intention of examining the widest range of
experiences of advanced cancer patients taking part in clinical trials. Attempts were
made to conduct a negative case analysis of patients who it was felt had not had a
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good experience of the trial. However, it was not possible to recruit these patients to
take part in the study.
4.4.5. Audit of analysis process
Appendix A gives an in-depth description of the data analysis process from initial
coding up to the generation of the central theory. The intention is that the reader is
able to see the steps that were taken to build up the concepts of the generated theory.
4.4.6. Use of thick description
Thick description is considered appropriate for demonstrating the potential for the
transferability of a study (Seale, 1999). My findings have been presented with thick
description of the responses of patients, both in summary and direct quotes. I have
also described the methods used in detail.
4.5. Conclusion
This chapter has outlined the processes that took place during the running of the
study. I have described how patients were selected to be approached, the process of
patient recruitment and the interview situation. I have also described the processes
that attempted to ensure the study was conducted to a high level of quality.
Data analysis has been discussed in a theoretical manner in the methodology chapter.
Appendix A outlines the process of the data analysis in this study with examples
used to illustrate the description. The next section looks at the results of data that
were generated during the interviews.
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SECTION 3 - RESULTS
The results section is made up of chapters five to nine. The results are divided along
a linear time frame. Chapter five looks at patient experiences before starting the trial.
Chapters six, seven and eight look at patient experiences during the trial. Chapter
nine looks at patient reflections of being on a trial.
I have chosen to present the data in this way as a reflection of the initial interview
schedule. The interviews naturally flowed along a linear manner which I think
myself and the patients intuitively expected. As the interviews developed, I did not
adhere to this pattern in the interviews but still kept this in my mind for the analysis.
Before I developed the overriding theory of the study, I conceptualized the study
over a linear time frame to aid the data analysis.
The majority of the data related to the time when patients were taking part in the
trial. This may have been expected at the start of the study. Rather than collect these
findings into one large chapter, I have divided the findings into three chapters.
Chapter six, Experiences ofbeing on a trial, relates largely to the practical aspects of
patients' experiences of being on a trial. Within the experiences when patients were
on the trial, there were two categories of particular significance. These were Pain
and The interaction with the trial staff. These have been given their own
consideration in chapters seven and eight.
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The conclusions and overriding theory of the study are examined in Section four,
Discussion.
Sampled Patients
Figure 3 is a CONSORT diagram detailing the patients who were eligible to take part
in this study.
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Figure 3 - CONSORT diagram of patient recruitment
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Table 4 shows a comparison of those patients who were recruited into the study with
those who were eligible to take part in the study but were not recruited.
Table 4 - Comparison of recruited and eligible patients' demographics
Interviewed Patients Eligible Patients
n=21 n=66
Gender
Male 15 (71%) 38 (58%)
Female 6 (29%) 28 (42%)
Age mean = 62.1 years mean = 62.1 years
(range 48-24) (range 32-84)
Diagnosis
Breast 6 (29%) 20 (30%)
Colorectal 0 (0%) 4 (6%)
Haematological 1 (5%) 6 (9%)
Lung 2 (10%) 9 (14%)
Prostate 7 (32%) 15 (23%)
Other 5 (24%) 12 (18%)
Trial
KPS 7 (33%) 21 (32%)
PBT 14 (67%) 45 (68%)
Trial Site
Edinburgh 9 (43%) 30 (45%)
Glasgow 12 (57%) 36 (55%)
Although when recruiting, achieving a proportionally representational sample was
not the aim, what the table does show is that an appropriate number of patients with
differing variables such as age, sex, diagnosis, trial and trial site were interviewed.
Chapters. PRE-TRIAL EXPERIENCES
This chapter examines the experiences of patients before the start of the trial. There
were three main topics that arose from the interviews regarding the period of time
between when the patients had their first contact with the trial staff and when they
started the trial. These three topics were:
• Personal prior experience in a trial or prior knowledge about clinical trials
• The reasons why patients took part in this trial
• Patients' views on placebo medication and taking part in a placebo controlled
trial
They are discussed consecutively in this chapter.
5.1. Prior experiences of clinical trials and deciding to take
part
5.1.1. How aware of clinical trials were patients before they are
approached?
The awareness of the concept of clinical trials varied amongst the patients studied.
Some patients had never heard of clinical trials. Other patients had spoken to friends
who had heard of clinical trials. Some patients had been on other clinical trials in the
past or had known friends or relatives who had taken part in clinical trials. Those
patients interviewed who had been aware of clinical trials before taking part in this
one had various views towards them. Many patients believed in clinical trials and
the benefits that they can have, both to current and future patients. As these opinions
and others were linked to their views of the clinical trial they had just taken part in,
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this is discussed in more detail in chapter 9.2.
Within the group of patients who had been aware of the concept of clinical trials, the
extent of their knowledge varied. Some patients had a good understanding of clinical
trials while others had only a broad overview. PtlO gave a good example of how her
knowledge changed before and after the trial. Before starting the PBT, she thought
that it was only novel agents that were used in clinical trials.
'Tom: Are you, were you aware of the concept of clinical trials
before they'd spoken to you?
PtlO: ...yes, 1 always thought they were a brand new, eh, well obviously there
are some brand new drugs, and, and you don't know what the side effects are
going to be however, this , eh, was something that had already been in use... '
To me this showed that she had processed both her initial knowledge of clinical trials
and her new knowledge about this particular clinical trial to realize that her initial
knowledge was only limited to novel drugs.
5.1.2. How did the patients first hear about their trial?
My first thought on patients in these trials was 'Where do they come from?' From a
patient's perspective the question may be turned round; 'How do patients first
encounter trial staff?' Patients described being approached by trial staff after
oncology out-patient appointments. Sometimes patients had been told by their
oncologist that they might be contacted by the trial staff; at other times patients met
the trial staff for the first time without being aware that they were eligible for
participation in the trial.
'She made contact. Um, it wasn 't something that was a consideration, I mean
it's not something I went lookingfor, um, but she made contact' (Ptl6)
Some patients however did actively offer their services for suitable trials.
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'Tom: Had, hadyou heard about clinical trials before they approachedyou?
Ptll: Yes, yes, I heard about them, know what I mean, I heard about clinical
trials and I told [Clinical doctor 1] that I was prepared to do any clinical
trials that he wanted me to do.'
Although a lot of patients had not considered taking part in a trial before they were
first contacted, the association of the trial staff with the oncology department made
patients at least consider taking part more carefully. The ways in which the trial staff
seemed to be associated with the oncology department were by meeting patients in
oncology out-patient clinics or by mentioning that the patient details had been given
to them by an oncologist. Patients described other clinical trials that they had
rejected when they had been contacted without warning by post or telephone, feeling
that these trials were not connected with their current care. This opinion was
strengthened after speaking to one particular patient. He told me that because I was
first introduced to him by one of the trial nurses that he knew, he was happy to be
interviewed for my study because of the faith he had in the trial nurse.
'Pt9: the other thing, last Monday, you turned up with [Trial Nurse 1]....
Tom: yeah...
Pt9: Now, because I trust [Trial Nurse 1], it was easy when you said 'I want
to do this,' it was easy to say 'Oh right fine we 're in the same team here'...
Tom: yeah...
Pt9: Let's go, you know, you said 'Would you like to read this?' and I said
'No no, just make an appointment'. So because of the trust issue with [Trial
Nurse 1] and [Trial Nurse 1] introduced me to you, it was quite easy for me.
Now ifyou hadphoned me up and said, 'I'm Tom Middlemiss, and I'm doing
a survey...' I'd have probably said 'Yes' but because of how it was done, it
was easier for me to say yes.'
At the first meeting, patients could be approached by one or more members of the
trial staff. This was usually described as a straightforward event for patients. For
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some patients though, this first encounter came as quite a surprise:
'the first day they spoke to me they actually hijacked me as I was getting,
clothes back on and getting sorted, one of the girls said 'Oh, there's two
research people waiting for you.' And I came out and they were sitting and
said, they both came up and said 'Hello' and Ifelt 'Wow! Wow!' you know
'Boom' you know, I've just walked out of there and I'm here. Well, then we
went off to a room and we did what we had to do,' (Pt9)
Pt9 subsequently chooses to re-phrase his choice of words, but the term 'hijacked' is
an evocative one. Other patients used 'confronted' and 'persuaded' when talking
about their initial contact and entry into the trials. The impression I received from
these patients was that it was a slightly unsettling experience. This may have been
due to the number of people waiting to see the patient or the way in which they were
approached in a sudden manner. A combination of both may have created their
feelings. Although the episode was clearly not enough to put these patients off
taking part in the trial, it made me aware that the first meeting with trial staff had the
potential to be stressful for the patients.
5.1.3. Patient understanding of the trial they were taking part in
Trial staff spent time with patients to explain what was required when taking part in a
trial. Patients were also given an information sheet that explained their prospective
trial, and any potential side effects that could occur, in plain English. Patients were
then given time to consider taking part in the trial with the opportunity of contacting
the trial staff with further questions if necessary.
In the group of patients that I studied, my overall impression was that patients had a
good understanding of what the trial consisted of and what was required of them.
'...it was all pretty plain sailing... I don't, I can't remember anything out the
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ordinary... that happened or I expected, or didn 't happen or that, you know.
It was just all, get the tablets, take the tablets, jinish them or hand them back
or whatever and speak to the, speak to the girls. No there was nothing out of
the ordinary.' (Ptl2)
However some patients did have misunderstandings about parts of the trial. Pt5
thought that in the randomization part of the trial, he would receive a combination of
real and placebo medications with the daily pain scores indicating to the researchers
which one of the two he was on each day.
'Pt5: Probably, I think there were a hundred drugs in it, the chance is fifty-
fifty- (laughs)
Tom: That's right
Pt5: You know, so....
Tom: You were happy with that?
Pt5: I was happy with that, taking, you know, if I can get three good ones,
three nights in a row, or you could get five good ones, and then, you know.'
This same misunderstanding was reiterated by Ptl 8 later in the interview process. It
may be expected in clinical trials that a proportion of patients will show
misunderstandings when questioned at a later date.
Patients did remember receiving the information sheet but their recollection of its
content could be poor. They may have only read it once, confused it with many
other information sheets they have been given or not read it at all.
'Tom: I think you were given an information sheet?
Ptl2: Probably, I've been given so many ...during that...
Tom: Do you particularly remember it?
Ptl2: Not particularly no, being honest, no.
Tom: Are they the sort ofthing that you do read?
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Ptl2: Oh yes, I read them, I read them, oh don't get me wrong. Although I
can't, I can vaguely remember getting it, actually, but oh no I would read
these things.
Tom: You do read them.
Ptl2:1 do read them. Yes.
Tom: And do you remember the content of it, or, or... ?
Ptl2: No. (chuckles)'
A view held by some responders was that the researchers had explained everything
to them, negating the need to read the sheet. Anything serious regarding the trial
would have been explained to patients. Others, such as Pt20 want or expect
everything to be explained to them:
'Pt20: Oh, don't put it down on pieces, pieces ofpaper because I don't, I
won't understand halfofwhat you put down on pieces ofpaper.
Tom: Really.
Pt20: ....well I, you need to tell me, face to face what's going on, and I will
ask you face to face, tell me what I'm doing, I prefer you to tell me what's
going on, then I can take it in better, then I know what's going on, yeah, if
you explain to me, then I'm quite happy, if somebody explains to me what's
going on, I'm quite happier.'
Pt20 was expressing the desire for more discussion rather than the information being
transferred by a written document. However, she did go on to say that she would
give the information sheet to her husband or son to consider before agreeing to take
part in a trial.
Knowing the trial as intimately as trial staff do, it may be hard to imagine that a
patient would want anything other than a desire for a complete understanding of the
intricacies of the trial. However some patients seem happy to have a vague
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understanding of what they are taking part in and to place their trust in the trial staff
to guide them through the process.1
5.1.4. How patients decided to take part in the trial
How did patients decide to take part in the trial? Clearly, there were many reasons
for taking part and these are discussed in chapter 5.3. Before deciding however,
some patients discussed the trial with other people. Some patients talked over the
decision with their GP while others spoke to family members.
'Tom: did you um think about it, or discuss about it, discuss it with anyone else
before agreeing?
PtlO: Ah, yes, I spoke to my husband, my son, uh, my Dad (laughs), ahm, but
eh, really it was a no brainer, it was eh, it was the idea ofpain relief is always
a brilliant thing and eh, um, I do agree with the principle of why they're
looking at it.'
The people that patients discussed taking part in the trial with had the potential to act
as a significant influencing power. Patients described GPs looking over the
information sheet and allaying any concerns they might have. For example, patients
reported that their GPs reassured them that the medication being trialled was one that
was already in common usage with a good safety record behind it. Conversely,
patients described times when their GP had advised them not to take part in other
trials that they had been contacted about.
Other patients needed no time to consider their options and had no need to discuss
their decision with anyone. To them, the severity of the pain merited taking part in
the trial.
'Tom: What were things like at the start?
' The issue of trust in relation to researchers is discussed in detail in chapter 8.4.3 Trust ofthe staff.
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Ptl7: Oh, it was awfy sore you know ....Especially from my bottom. I don 7 know
what that wee bone is called at the bottom ofyour....
Tom: Coccyx...
Ptl7: ....spine. Coccyk, yeah, that' it coccyk, I mean I was having terrible, terrible
pain in it. It's alright ifI lie down....but as soon as I get up, sit in a chair, oh, it's
murder...
Tom: mmm
Ptl 7: Ken what I mean, I could sit in the chair for about five or ten minutes, then
I've got tae get up and use my walker [..], then come back to my bed..
Tom: mmm
Ptl 7: Just can 7 take the pain.
Tom: mmm
Ptl 7: But I thought that maybe the pill, that the pill, be able to shift, something to do
without. It would maybe take the pain away, you know.'
Other patients were very relaxed about taking part, '...what the heck, I'll do it' (Ptl6).
5.2. Conclusion - taking part in a trial
The patients were approached by the research team, given information about the trial,
allowed time to think about the trial and then recruited onto the trial if they were
willing to take part. Patients had a wide range of previous experiences of clinical
trials prior to taking part and varied in who they discussed the trial with before
consenting.
5.3. Reasons for taking part in the trial
A summary of patients' reasons for trial participation is shown in Figure 3.
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Figure 3 - Reasons for trial participation
Pt20 stated 7 would never say no to a trial. ' Such an absolute statement was rare but
what were the other reasons for patients wanting to take part in this or in any trial?
As can be seen in Figure 3, the reasons that patients stated for taking part in the trial
were numerous. Some reasons were common and were predicted before interviews
began. Other reasons were individual and surprising.
The all-inclusive reason for a patient taking part in a trial was for someone to benefit.
The person to benefit could have been the patient themselves, someone else, or both
at the same time. The relative importance of who benefits varied between patients.
A patient could be happy knowing that they and others benefited at the same time.
This part of chapter five looks at the patients' reasons for taking part in a clinical trial
and who benefits from them taking part. When patients discussed others benefiting,
they were referring to both other patients and the researchers themselves. This
section also looks at elements of the trial that were not present which acted as
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motivating factors for patients to take part.
5.3.1. Self benefit
5.3.1.1. Pain
Patients recruited into the trials had not had satisfactory pain control up until that
point. If they had, they would not be eligible for the trial. Patients had to have a
consistent level of pain to enter either trial and in addition to this, also had to
maintain a significant level of pain after a period of optimal pain management with
2 • *conventional treatment medications . So when the option arose to control the pain
by entering the trial, some patients were willing to take it. As to be expected from
such a subjective topic, the degree of pain that patients felt varied. Some patients did
not recall having any pain at the start of the trial while others described pain so
severe that it made them question whether their life could be tolerated.
7 was waking up during the night anjust wanting somebody to do away
with me...that how much pain I was in.' (Pt5)
Pt6 also remembered his pain in similar terms:
'I'd 'a given anything a go at that point because the pain was ridiculous.'
The origins of pain and what pain meant to patients, was beyond the scope of this
study and was not explored in detail. However patients were encouraged to describe
the impact of pain on their lifestyle. Patients reported that family dynamics altered,
relationships with partners were strained and social activities were curtailed.
'Tom: How do you, how do you find it when your family see you in this
situation, when you 're being affected by the pain...
Pt6: I don't like it. I don't like them seeing me. I don't mind being in, I don't
say I don't mind being in the pain, but I can live with being in the pain
2 More in depth details of both trials can be found in appendices B and C
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(cough) when they 're at school because they don't see me struggling, they
don't see me. But it's when they come home at night, you try and reverse
everything, you try not to be in pain, you try not to show them that you 're in
real agony andyou 're struggling.'
Patients struggled to leave their houses when racked with pain. One patient's guitar
playing fluctuated with the degree of pain he was in. The increased number of hours
spent playing the guitar indicated that his pain medication was working.
5.3.1.2. A desire to reduce their strong opioid
Patients talked about the strong opioids that they were taking in addition to the trial
drug. A fear of opioids and its connotations existed in this patient population. It is
something which I have also encountered anecdotally in my clinical work and is
recognized in the literature (Sun et ah, 2007, Davis and Walsh, 2004). As in my
clinical experience, this fear of opioids was countered by the acknowledgment of
their effectiveness. Patients were concerned that they may become immune to
opioids in the future or that their effect would run out.
'Pt7:1 don't like taking them, I try not to take them.
Tom: Why is that?
Pt7: I dunno...I think in case I maybe need them later on, you know. If the
pain is really
Tom: Do you think they will run out, or, or ... ?
Pt7:1 thinkyou'd get sort o' immune to it, you know.'
The addictiveness preconception that is well recognized in the literature was also
present in the patients I studied (Sun et al., 2007, Davis and Walsh, 2004).
'Tom: So, so am 1 right in saying that morphine's a drug that you don't
really enjoy taking?
Ptl 1: No I don't, no. It's just not doing any harm at all, it's just the name, I
think it's just the name.
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Tom: Do yon think, what, what d'you, can you elaborate on that, on that a
bit?
Ptll: Because it's morphine. Because it's a heavy, heavy doses and different
things, you know what I mean? Because of its addictiveness.'
Patients described their experiences of common opioid side effects, such as over-
sedation and constipation.
There was a hope expressed by patients that being on the trial medication would
allow them to reduce the quantity of opioid that they took. Trial drugs could be seen
as the lesser of two evils.
'Tom: What are you going to get out ofthe pregabalin trial?
Ptl4: Well, I mean to say, it did the, could stop the, the, the pain.., the...
Friend: Morphine.
Ptl4:...morphine. Eh, that'd be quite a good thing because I mean to say,
it's, they 're powerful drugs.
Tom: Mm, mm.
Ptl4: The pre model., whatever they call it...
Tom: Pregabalin.
Ptl4: Pregabalin, I mean to say, it's quite a powerful drug an' all, but it's
not nearly as powerful as the, as the ...
Friend: Morphine.
Ptl4: morphine.'
Patients described feeling happier on the trial medication rather than on an opioid.
Pt7 was 'more fun' according to his wife on ketamine rather than on his opioid as he
was able to have an evening drink. PtlO and Ptl 1 had fewer concerns about driving
while taking pregabalin than when taking opioids.
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5.3.1.3. Other reasons for self benefit
Some patients felt that their care lacked a coordinated effort by healthcare staff. Ptl 1
took part in the trial with the desire of creating a better 'structure' of care. He gave
the example of feeling uncertain about his medication regimen. He felt that taking
the correct medications was his responsibility and this created an anxiety in him:
7 felt that I was self-medicating....So this gave me the chance, [Research
doctor 1] gave me a chance to structure the drugs.' (Ptl 1)
Some patients showed a lack of insight into the aim of the trial by wanting to control
symptoms of nausea as the primary reason for taking part in the trial. Other patients
saw the trial as something else to add on to their treatment:
'It might be goodfor me, it might not, so let's go for it.' (Pt9)
The experience of taking part in other clinical trials was also a motivating factor for
some patients. They felt that they received additional input from trial staff during a
clinical trial and this motivated them to take part in this trial. A good experience
from a previous trial was either related to the outcome of the trial, or simply from
getting more attention, which was reported as a welcome experience in itself.
Pt9: ...So, then to be told that you're just being monitored, you think, 'Wow!'
However, I'm happy because, I'm getting the attention...
Tom: yeah
Pt9: ...that a lot ofpeople aren't getting because I'm being monitored every 6
weeks. So, it's a bonus.'
It did not necessarily follow, however, that bad experiences of previous trials put off
patients from taking part in this trial. Ptl 7 described a bad experience that he had
had in the past with a different trial and yet he was still willing to take part in this
trial.
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'Tom: So ....you'd been on that trial, of that ....pill, that 'nearly killed you,'
like you say...
Ptl7: Uh-huh.
Tom: ....and it was after that, that you were approached, by the research
team to on to this pregabalin trial, is that right?
Ptl7: Uh-huh.
Tom: ....after having had such a... bad experience with the first trial....
Ptl 7: mmm-hmmm
Tom: ....were you anxious what might happen to you on that trial?
Ptl7: No I wasn't anxious ....no, not at all...I was still of the mind, that I
mightfind something you know, to help... '
5.3.2. Benefit to others
Apart from patients' desire for self benefit, a strong motivating factor to take part in
a clinical trial was for the benefit of others. An action that benefits others can be
described as altruistic. For some patients this was the only stated motivation for
taking part, particularly if they felt that there was no personal pain to relieve, but this
viewpoint was unusual. If a patient did feel that their actions were for the benefit of
others, it was usually in association with benefit to themselves. The mutual benefit
sat easily with patients and the fact that others were benefiting at the same time
seemed to be comforting.
5.3.2.1. The Dynamics of Altruism
The dynamics of altruism are summarized in Figure 4.
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Figure 4 - Dynamics of Alturism
When some patients were reflecting on their care and treatment, they realized that
they had benefited from similar altruistic actions of patients in the past.
'Pt6: At the end of the day, ifyou didn 7 have people to try trials, you didn 7
get this guy who had cancer, I wouldn 7 he at this stage with my pain, so
you've gottae, there've gottae he guinea pigs along the line somewhere.
Tom: So you 're happy to be one?
Pt6: I'm quite, I was quite happy to he one on that case study, yeah.'
At any time, there was a dynamic process of altruism. Firstly, patients were
benefiting from previous patients' efforts. At the same moment, patients were
offering a benefit to other patients, both in the same process as them and other
patients, including themselves, in the future. I will explain this in more detail.
All patients have benefited from patients before them, whether through structured
clinical trials or by anecdotal evidence and the experience of their doctors. A drug
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that a patient takes has been used with good effect by someone before them. Pt6
realized this fact as shown in the quote above. His insight allowed him to see those
who had gone before him and gave him the desire to act as a 'guinea pig' for the
benefit of others in the future. He acknowledged that his desire was to help himself
but at the same time he showed his desire to help others. Patients commonly cited
their own children or grandchildren as the people who might benefit in the future.
'Tom: did you um...did you have any um... did you take part in the trial for
any reason apart from yourself?
Ptl9: Um, well you never know if it might do some good somewhere along
the line, you know what Imean?
Tom: Yeah
Ptl9: And um, I mean, this is the secondary breast cancer and I've got five
daughters so (laughs), so I've got an interest in how the...um, ....everything
goes for that you know. So yeah..
Tom: Was that a sort ofmotivating factor as well?
Ptl9: Mmm'
I think that 'helping others' is quite vague and so for some patients, putting their own
family in the category of people who may need help in the future allowed them to
personalize the altruistic act.
Pt4 stated that part of the reason for taking part in the study was for the benefit of
others. While the benefit of future patients was a common, and expected motivating
factor, she stated that she felt she was helping other patients in the same trial as
herself. Her rationale was that if she was to receive the placebo, others in the trial
would be more likely to receive the active drug. This was a new concept that I had
not considered.
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'Tom: Okay. And so who, who were you helping, or who did you feel you
were helping by takingpart...
Pt4: Myself as well. Any maybe other people that were going to do, do a
survey, I mean, if that drug helped me, I would say "Brilliant, that, I had the
proper drug and it's helped me. " ...
Tom: Yeah.
Pt4: ... and things like that, you know.
Tom: But...
Pt4: But that, but that drugjust didn't help me.
Tom: Did you feel that there were other people you were helping as well,
apart from yourself?
Pt4: Yeah, other people that were gonnae do the survey eh as well. Maybe
they got the proper drug.
Tom: Right.
Pt4: You don't know.
Tom: Okay.
Pt4: If they would get the proper drug...'
PtlO wanted her own pain to improve as well as wanting to help others in the future
who had the same pain. She counted herself as one of the people in the future whom
she hoped would benefit from the current trial:
'There was the idea of helping people in the future and hopefully me in the
future, selfish little so-and-so that I am! Because I know my cancer's going to
come back and keep coming back for many, well hopefully, touch wood, many
years...and um, um hopefully I'll be able to get some of this pregabalin as a
proper drug....in the future,' (PtlO)
Again I had not considered that patients would view the benefit to themselves both in
the present and in the future.
Although not asked by myself to quantify specifically the division of where the
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benefit lay, several patients stated spontaneously that the motivation was evenly split,
'fifty-fifty' between the benefit to themselves and to others.
5.3.2.2. Benefit to the researchers
'Tom: ....the potential reason for that (having no benefit from the trial) may
be that you've been on the placebo....
Pt3: ...indeed...
Tom:... how you feel about the fact that there's a possibility ofyou going onto
a trial with no benefit?
Pt3: Well there is a benefit, to the people running the trial....'
Pt3 described another beneficiary of the research apart from the patients themselves.
Although the ultimate gain from researchers benefiting is to benefit future patients,
he also described the current benefit to researchers.
5.3.3. Aspects that were not in the trial
When considering whether to agree to take part in a clinical trial, patients weighed up
what the trial would involve for them. Was it worth it? To be 'worth if a trial had to
have a greater perceived benefit than burden. In the eyes of the patient, and as
discussed above, the benefit from the trial did not have to be solely for the individual
taking part. Conversely, patients only considered the perceived burden that they
themselves would encounter. Patients described three areas of the trial that appeared
favourable when considering what the trials did not contain rather than what they
did. These three factors were an apparent lack of excessive trial demands, a
perceived lack of possible side effects and the lack of a lengthy trial period.
5.3.3.1. Excessive burden of trial demands
Patients spoke of fatigue in their current state. Their mobility was reduced, their day
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could be dominated by pain and their usual activities were curtailed. A clinical trial
which did not create an additional and excessive tier of complication to a patient's
existence was attractive. The clinical trials that the studied patients took part in were
designed specifically for their target patient groups. Each had a deliberately small
number of hospital visits, blood samples and complex assessments. Patients
understood this and were attracted by the lack of these burdensome activities.
Ptl 5 had breast cancer with axillary node clearance from one of her arms, rendering
that arm unusable for blood tests. Her concern about the frequency of blood tests
had made her reject clinical trials in the past despite a desire to take part.
'IfI can do it, I'll do it. Um...the blood test's the, you know, I'd kind ofread
through it and if it says, bloods, or blood tests every two weeks or something,
I'm no' interested.... '(Ptl5)
The two main requirements of the trial from a patient's perspective were to take the
prescribed tablets and to receive telephone calls from the research staff when
arranged.
7 was persuaded a bit more by the fact that it was only going to last for a
short time and it wasn't going to really, cause me any hassle, in the sense of
having to go anywhere, or go to the hospital, get ah...it was all going to be
done locally or on the end ofa telephone.' (Pt3)
5.3.3.2. High risk of side effects3
A topic that I thought I would have to concentrate on at the start of the study was the
risk of medication side effects. With my medical background, the topic of side
effects of any drug is continually pertinent. I would think this to be particularly the
case in clinical trials. The counter argument to this, however, is that ketamine and
3 The occurrence of actual or perceived side effects is discussed in chapter 6.2.2
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pregabalin are already licensed drugs, with a good safety profile, and are used
commonly in the treatment of pain in the palliative care setting. Ethics committees
are stringent regarding the potential harm that could occur to patients who participate
in clinical trials and one of the most common concerns is that of the potential side
effects of medications given. Although the potential side effects were explained in
the information sheet that patients were given at the start of the trial, the recollection
of these potential side effects is variable. PtlO pointed out that the trial medications
were already established drugs in general usage for other purposes. This information
gave her the peace of mind not to be overly concerned by the potential of side
effects. Some patients showed an informed attitude towards the balance of risk and
benefit in clinical trials. They were willing to accept a degree of risk given the
potential benefit. 'Well, having been on so many drugs, ifyou read all the forms, you
wouldn 't go on any drugs andyou wouldjust die!' remarked Pt9.
Other patients showed a lack of awareness of side effects.
'Tom: Ah was that described to you? The potential side effects of the
pregabalin?
Pt8:uhhhh
Tom: Were you made aware ofthat?
Pt8: No. I knew it had something to do with nerves, but eh, the nuts and bolts
of it no.
Tom: No? OK, OK. So that wasn't a concern ofyours that there wasn't any
side effects?
Pt8: I was just assured by the fact that it would have no adversal [sic] effects,
by adverse I include pain, or anything which is of an uncomfortable or
unpleasant nature.'
I was concerned that Pt8 seemed to have such a low concern for the potential side
effects of the medication that he might be taking. However the medications used in
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both trials are ones that I use regularly in clinical practice. Although both drugs have
a recognized and encountered side effect profile, this does not prevent their usage.
Perhaps patients have been told about the risks of side effects with these medications
in the way that I might discuss it with a patient in the clinical setting. I describe the
risks to patients but do not portray these risks in a manner beyond the severity with
which I perceive those risks. In this case, perhaps I should not necessarily expect the
trial patients to be overly concerned in the trial setting either.
5.3.3.3. Long trial duration
Patients were attracted to the trials by the short nature of their duration (four to five
weeks). Despite entering into a randomized controlled trial (RCT) with the
possibility of receiving a placebo, patients were also aware that a poor response to
the trial medication might result in a trial of the active drug after the trial had
finished. Ptl6 described his initial encounter with one of the research staff:
'...my questions obviously were 'Is it liable to have any kind of effect on my
quality oflife?' and the answer was negative. Regardless ofanything else we
knew this particular drug trial wouldn 't really necessarily affect my quality of
life, however, were it to do such a thing I would, they would stop it
immediately and that would be it, finished and done with.' (Ptl6)
5.4. The placebo arm
Placebo drugs are common in double blind RCTs examining pain medication. RCTs
are considered the form of clinical trial that generates the most robust evidence. The
presence of a placebo is one of the key components to this. Placebo is a word that is
familiar outside the medical world and the 'placebo effect' is also a well known
concept.
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All patients who go into an RCT are told that they may not get any treatment at all,
yet they are still willing to take part in the study. The general reasons for this group
of patients taking part in a study have been discussed above. This section looks at
patients' attitudes towards placebos before they started on the trial.
5.4.1. Patient awareness of the concept of placebo
During interviews, patients would often say the word 'placebo' unprompted before I
had raised it. If patients were aware of the concept of placebo before starting the
trial, this was for a variety of reasons. This may have been through general
knowledge, such as doing crosswords, as one patient remarked. Patients or their
relatives may have taken part in clinical trials in the past which had used placebos.
Pt6 stated that he was aware of the concept of placebos having worked in a hospital
environment, albeit as an electrician. I asked Pt8 if he was aware of the concept of
placebo to which he replied 'Of course.' This demonstrates that along the spectrum
of patients' awareness of placebos, there is a group who would consider awareness to
be almost "a given" within the realms of normal life.
Some patients had never been aware of clinical trials or placebo medication before
starting their trial. Whilst some went on to demonstrate their newly informed
understanding of clinical trials and placebo medication, other patients showed a
potential misunderstanding of the concept of placebo medication. I have already
discussed the misunderstanding of Pt5 regarding placebo medication in chapter 5.1.3.
The conversation with Ptl 8 further illustrates the point.
'Tom: ...but did you, did you go down one route or the other, or didyou get a
different sorts on different days? What was your understanding of the, of the
way the dummy drugs were given to you?
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Ptl8: ...so much o' them was dummy, and so much o' them, I don't know
what ones
Tom: so a proportion ofthe ones you were getting....
Ptl8: Aye
Tom: ...some were real and some ofthem were dummy....
Ptl8: Aye, some were, some must have been real and some o' them were
dummy, as far as, 'cos the pain wasnae, I wasnae getting great pain, know
what I mean, some time.
Tom: So on the days that yourpain was, better...
Ptl8: Aye.
Tom: ...do you think that was the days you got a real drug rather....
Ptl8: ...aye must have been a real one, you know what I mean, I must have
got (laughing).'
Despite the interaction with research staff and information sheets, there is still the
possibility of misunderstanding regarding how the placebo is administered to
patients.
5.4.2.1 did not mind being on a placebo
A preconception of mine that I wanted to explore was the patients' attitudes to being
on a placebo; how they viewed this possibility. Several times I asked patients if they
thought that it was 'unfair' to be on a placebo. Patients were quick to deny that they
thought this might be unfair.
'Tom:.. What didyou think about the fact that you might be on a placebo?
Ptl5: Well, no' much, you know, somebody's got to be. It's the only way they
can find out.'
Patients showed a relaxed attitude to being on placebo. At the very least they
understood that the drug they took may not have any effect on them. Yet there were
still benefits to the trial from the patients' point of view. As discussed earlier, some
98
patients felt a benefit would be for researchers or other patients. They reiterated their
belief in clinical trials for the future and as a way in which medicine had progressed
to this point.
Although some patients did not mind being on a placebo, some patients, and their
family members, were curious to find out which arm of the trial they had been on.
Ptl6's wife came into the room where we were talking halfway through the
interview. When she found out that I was not there to discuss the result of the trial,
she was a little exasperated that the uncertainty remained. Ptl 9 was withdrawn from
the trial because extreme fatigue was having too large an impact on her daily life. As
no other medication had changed, she was sure that the culprit was the trial
medication. However, this assertion was complicated when the fatigue continued for
several weeks after the trial medication had been withdrawn. She was left with no
clear idea which medication she had been on.
'Ptl9: I'd be interested to find out which one I was on, ken, I think [Research
Nurse 1] said something about the summer, before I get to find out but yeah,
it'd be interesting to, see which one I was on....'
5.4.3. Conclusion of the placebo arm
The awareness of the placebo being the central point of the trial seems to be well
understood. I was surprised that patients could take a relaxed attitude to being on a
placebo. Some patients showed a poor understanding of the concept of placebo by
thinking that the drugs they received throughout their own trial could vary.
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5.5. Conclusion of pre-trial experiences
I have discussed patients' attitudes and experiences of trials, the reasons why patients
wanted to take part in the trial and patient opinions of placebo medication before
they went onto their trials. Some patients were aware of benefits from taking part in
a trial, including some benefits which were independent of which drug they would
receive. Patients with previous experiences of trials felt that they would still get a
higher degree of attention and input than if they were not on a trial. Another patient
knew he would still get the organization of his medications which had prompted him
to participate in the first place. Some patients were aware that they may be given the
active drug after the trial period if they were still reporting significant pain.
The next chapter looks at the patients' experiences of being on a trial.
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Chapter 6. EXPERIENCES OF BEING ON A TRIAL
This chapter examines the descriptions patients gave of taking part in a clinical trial.
It looks more at the physical process rather than their thoughts on either taking part
or on the benefits they received from the trial. Patients described both positive and
negative aspects of being in a trial. As well as this, they described features of a trial
that had no great impact on their life in a positive or negative manner. The two most
significant features of taking part in a clinical trial, pain and interaction with research
staff are discussed in greater detail as separate entities in chapters seven and eight.
6.1. Positive features
When patients spoke positively about being on the trial, it was frequently with
warmth and affection.
'Ptl: ...it's just been, perfect, it's, I've no negative thoughts at all, about
anything.
Tom: Nothing at all?
Ptl: No.'
I found it was easy for me to get caught up in the emotion of the positive feelings
they had for the trial. Although I was not involved in the trial, I have worked with
the staff who have been and know them individually. Along with an affiliation to
your profession, these positive responses made me feel proud of the impact that the
trial had had on patients. Everyone likes to hear positive responses and I was no
different.
Patients described receiving clear instructions of what to do during the trial. The
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patient who had entered the trial looking for structure in his medication regimen felt
he had received that. Another patient enjoyed the occasional interaction with other
patients who were on the same trial as her. These chance meetings in waiting rooms
helped her decide to go onto the trial in the first place and also gave her confidence
in the trial while she was on it. She enjoyed sharing a connection with others in a
similar situation to herself.
Patients felt secure within the process of the trial. They did not feel pressurized into
remaining on the trial and knew that they could withdraw at any time.
'Pt2: Easy to talk to, they've explained every situation, every part of the trial
and they've always made sure that I've known that ifI wanted to withdraw at
any time, that's myprerogative.
Tom: Is that, is that an importantpiece ofknowledge for you to have?
Pt2: Well it's good to know that you 're not being pushed into something.
Tom: Yeah. And they were clear about that, were they?
Pt2: Oh yeah.'
Patients felt the security of being able to contact a member of the trial staff if needed.
On the information sheet were several numbers to call in an emergency. Although
this brought some anxiety as to what may take place that required the calling of the
numbers, having the numbers available was comforting. Patients responded to the
security that this provided. Security of the trial is discussed in greater detail in
chapter 8.4.2 in the context of the research staff.
Some patients found the participation in the trial to be an educational event.
'Fascinating' as Ptl 5 put it when describing the neurological equipment used for
assessing peripheral nerve function.
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Another aspect that patients described on one site was the environment of the
hospital.
'It's like a different world..... They were just so friendly and, they spoke about
things andjust, made you feel dead comfortable It's so relaxing (Ptl)
Another patient continued on the same theme,
'..the [Hospital 1J's even got this little car park for patients now which is
fantastic, eh cos that was always a worry, you know, 'Where am I going to
park the car?' (PtlO)
The atmosphere was compared favourably to other hospitals that patients had been
to. Advanced cancer patients are experienced health care consumers and have spent
enough time in waiting rooms and hospitals to be able to appraise the atmosphere of
a health care facility. It should be noted however that as the regional cancer centre,
this particular area that PtlO describes was not specific to the clinical trials. It is
small details that meant a lot to patients like Ptl6:
'Tom: Can you tell me why that's so important to you?
Ptl 6: Och it is important to people who are feeling sorry for themselves and
don 't know what direction they 're going in. You 're looking for, you 're no '
looking necessarily for reassurance, but you 're looking for (sighs) a bit o '
light-heartedness, I dunno. I've not really considered that aspect of it but
that's what it's about, it's just the general demeanour of the chap who's
always...always seems to be there in the, the arrival lounge area at the
[Hospital 1], so nice and chatty "Can I help you get a coffee, or can you
manage to get one yourself? " and it makes a difference.'
I think that the clinical environments that the trials took place in is relevant, even if
the environment was not exclusively used by the trial staff or that the trial staff were
not able to influence the environment significantly. It is important because the
patients described it as a positive feature of being on the trial and something that
should be taken into account when considering the experiences of the patients.
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6.2. Negative features
Why is it important to know the features of a trial that patients thought could be
improved? My view is that the answer lies in anxiety. Negative aspects that patients
describe cause an underlying anxiety which researchers should be trying to avoid.
Minimum anxiety may reduce patient attrition within a trial and also provide patients
with an opportunity to enjoy taking part in a trial.
Advanced cancer patients have a limited life expectancy. The intention of palliative
care is to address any symptoms that may cause distress, whether they are physical,
emotional or spiritual. Anything that was to cause distress, or anxiety, would be
against the principle tenets of palliative care. Anything that causes anxiety should be
discovered and considered in an effort to reduce this if possible.
No patient interviewed stated clearly that they did not like being on the trials. As is
discussed in chapter 10.4.2.1, there may be reasons for not interviewing these
patients, if there is a group who had this experience. However, patients did describe
aspects of the trial that they found difficult. I enquired about these difficult aspects
of the trial, without the intention of highlighting negative features of the trials, but
instead to look for balance in the study and therefore a full description of all
experiences.
6.2.1. Difficult questions
Throughout the trial period, patients were frequently contacted by the research team
to describe their pain on that day. This might have been daily or several times per
week. There were two main types of questioning: a numerical scoring of zero to ten
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regarding the severity of their pain and a positive or negative reply to descriptive
adjectives describing their pain (for example, 'burning' or 'aching'). Some patients
described these questions as challenging to answer. However it would appear that if
a patient did have difficulty in answering the questions, it was with only one type of
question. They found the other type much more straightforward.
Being asked to describe his pain numerically was difficult for Pt3 to do. This was
something that he felt he 'was not very good at.'
'Pt3: I find that a very difficult thing to do, I mean, I don't know whether I
have typical severe pain, or, mmmm, so how, how, how, whether it's between
zero and ten, whether it's five or, seven, I really don't know. And I have to,
(inhales) try and give really a calculated guess of that.... and hopefully, could
do that, but eh, I wouldn't know for sure whether I was being accurate or not
on that.'
Although retired, Pt3 was an accountant by trade and I speculated that numbers in his
life were very rigid things with fixed meaning. The subjective scoring of pain along
a scale that was specific to him only, may have been a difficult concept to accept.
PtlO showed another thoughtful attitude on the same difficulty:
'Tom: How, how didyou find that concept ofscoringpains?
PtlO: Umm, it's, it's a good idea, cos it is one of those things, although
different people have different pain tolerances, ahm, so it's a, it's a difficult
science to work that one out, what is a, what is a 'three' really? (laughs) and
eh, urn....yeah, it's, it's quite hard to work out, you know whether it's a three or
a four or a
Tom: So yourselfyou find it difficult?
PtlO: Yeah, uh-huh, but then I think everybody will, it's not an exact science,
it's not like um, you know, it's not something you can put on a measuring
scale...'
The tone and style of her words suggested that this was not as much a source of
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difficulty for PtlO as it was for Pt3.
With regard to patients having to describe their pain, this too caused difficulty. It is
unclear whether this was a source of anxiety to patients but Pt9 put across clearly the
difficulty he had with this concept.
'Pt9: Because, the statements that were written, you know, that you had to
choose from, you know, the words etc etc, that was something that, you know,
you had to think about and the pain is extreme and I've never felt pain like this
before. You know, you've had a pain in your leg, or a pain in your back and all
the rest of it, but this was something else, you know And it was just an
annoying pain and, you know, you can 7 say it's like toothache because it's not
like toothache, it's just extreme pain and some of the expressions I did say,
'Yes' it was like, but Ifound it difficult to relate what the pain was....
Tom: ...did you feel that your pain didn't fit in with the descriptions that were
being given to you?
Pt9: Some of them it did, but, you know, because it was just something that
was, something because you'd never felt this before... you had sort of various
words in front ofyou and, yes it was like some of them but it was more extreme
than a lot of them....
Tom: ...right....
Pt9: ....so....that was difficult....
Tom: ....mmmm
Pt9: You know, you picked something that you think 'Well'. When you were
scoring it was easy, when you had to pick something, Ifound that difficult when
you had to put something in the boxes.'
The difficulties were there for patients. Should you be able to, or want to, predict the
type of patient that might have difficulty with this? From this study it may seem that
patients who are more thoughtful and reflective have a greater difficulty in answering
the questions about their pain. Patients can develop an anxiety about the answers
that they are giving. My speculative thoughts that would go through a patient's mind
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would be questions such as: 'Is it the right score that I am giving?', 'How does this
compare to others?', 'Should I he scoring this pain as high as this?'
6.2.2. Side effects
The experience of side effects encountered in the studied population ranged from
none at all to having to withdraw from the trial. For many patients, their relaxed
attitude to the prospect of side effects was matched by the lack of side effects during
the trial. It may have been that their retrospective attitude towards the prospect of
side effects was because they had not experienced any side effects while they were
on the trial.
Some patients reported mild side effects of hallucinations or somnolence. However,
this was not met with anxiety or irritation because their pain improved at the same
time, balancing the impact of the side effects.
Two interviewed patients had to stop the trial early because they experienced side
effects of hallucinations and excessive somnolence. Even when Ptl 9 described the
fact that 7 could have fallen asleep on a knife edge' she did not remember being
overly concerned about the side effect.
'Tom: ...when you were on the trial, andyou foundyourselfbecoming more
sleepy, what didyou think then, having thought at the start it wasn 7 going to,
do any harm, you know?
Ptl9: Um. Oh, I wasn't um, I wasn't worried about it, um, I told [Research
nurse 1 ] everything, you know so um, I left it in her hands as to what to do,
ken so um, yeah, when, when she said 'I think the best thing is that you
come off it,' Ifigured, 'Yeah', I agreed with her on that because we did seem
to have tried.
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Tom: And, andyou said it was a relief, when she said that.
Ptl9: Yes it was, because I thought 'Oh, this tiredness will go now.' You
know. Of course it didn 't straight away, urn, and I think now it's probably
um, fatigue to do with the chemo and everything as well, you know.'
The situation regarding Ptl9's side effects was complicated by the fact that her
sleepiness did not resolve once she had come off the trial. This made it unclear for
her, as she states above, whether it was the medication or other factors that was
making her so tired.
In the case of Pt20, on the KPS, the visual and tactile hallucinations which she
described were in keeping with sensitivity to an escalating ketamine dose. This is
supported by the fact that the symptoms resolved when she reduced the dose of the
trial medication. Despite the side effects, Pt20 reported that she would have
continued to take the drug, despite the side effects, if the trial staff had asked her to.
'Tom: But. Was it you, did you wait until they rung you for you to decide to
stop taking it or what happened there?
Pt20: Probably. Ifthey hadn 't said to me 'Stop taking it' I'd a taken it.
Tom: But, ifthey'd said that earlier, you would have then said to them....
Pt20: [...] I was gonnae stop taking it. I thought I should stop taking it, but
if they had said to me, would you, would I have done another night for them,
I would, I would have saidyes. I'd a given it a go.'
Her disappointment seemed to be more with having to come off the trial and not
being able to get to the maximum dose of ketamine than experiencing the side
effects.
6.2.3. Pills
By the time a patient reached the fourth week of a study, they could be taking up to
108
eight trial tablets in a day. This fact was raised in different manners but I think with
the same intention of bringing this up as a comment about the trial.
'PtlO: ...and then it went up to four in the morning andfour at night....
Tom: mmm, mmm
PtlO: so I didn Y need much supper! (laughs)
Tom: ....ah, so how, so so, what happened, what happened when you started
taking the tablets?
PtlO: umm, well 1 didn't actually notice much difference, well actually no
difference at all really, other than just needing less breakfast.. .(laughs)
Tom: mmhmm, mmhmm....because there's so many tablets?
PtlO: Well 1 already have plenty other tablets to take as well....
Tom; yeah yeah
PtlO: umm, so it was lining them up on the work top and making sure I counted
out the right number ofeverything...yep, mmmhmm'
As corroborated by Ptl 6:
'Tom: You said maybe it was the commitment?
Ptl 6: Well it's just the thing of when you see the amount oftablets I've gotta
take every bloody day, and you think you've gotta stick an extra four onto
that in the morning and four onto it at night, you go through a tumbler o'
water just trying to swallow all this bloody stuff so that's the sort o', that's a
kind o' commitment. And that's the sort o' thing, I mean if they can get you
these, these tablets, instead ofhaving these great big bombs, if they could get
them down to something the size o ' halfyourpinkie, then ...in one tablet, then
I'm sure it would be more acceptable to everybody...'
It is interesting that patients can downplay the issue of the size and quantity of
tablets. This could have been in the form of a joke or as something that did not
concern the patient personally as Pt3 described:
'Pt3:... 1 did get instructions beforehand but I don't remember to be honest,
getting the fact that build it up to as many as four tablets at a time but eh, that
wasn Y a problem.
109
Tom: Was it difficult to take the four tablets?
Pt3: No, I'm quite easy, I can swallow tablets
Tom: ....take afew tablets....
Pt3: No I mean I'm quite happy to do that. '
Although Pt3 did pass this off as something that was not a problem for him, it was
still a deliberate point to make when asked about what he thought the trial would
involve. My speculation is that patients did not like having to take so many tablets,
particularly when they may have been taking a large number of tablets already.
However they did not feel legitimate in complaining about this, either because they
knew that the tablets might have been doing them some good, it was a requirement of
the trial, or they did not feel that they should find taking tablets a difficult task.
Therefore they dressed up the criticism as a joke or as something that may have
affected others rather than themselves.
6.2.4. Creating your own aids
Pt4 described the anxiety of taking the right tablets. She said that if it was a genuine
drug rather than a placebo for pain control 'you want to get it right, you don't want to
be taking too much'(Pt4). Her drug regimen was explained to her over the telephone
and she subsequently described writing these instructions down as she had been
uncertain in the past about her drug requirements. After a discussion, although she
raised the point that she felt that dosette boxes were stigmatized for the elderly, she
would have found one useful to avoid drug errors.
'Pt4: Yeah. It would be better if likes o ' when you're on that drug, say, like
there's a box, for older people, mind you saying that I'm getting old myself,
but putting them, when you were going to collect them at the Western from
Dorothy, say, "Right, there's a box. I've put they tablets in, that's you're
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tablets for Monday to, till you come back Monday to Thursday " or something
like that, so they know.
Tom: That wouldn't, you wouldn't have found that um offensive or anything
suggesting that you were old? []
Pt4: No, no, no. If somebody had handed one o' the boxes I would have
probably said "Oh, that's me getting old now, you know, with a box"
Tom: Yeah well ...
Pt4: But the further I was getting into it Ifelt "Oh, mindyou, I could've done
with one o ' they boxes". Cos I, I still say now, in fact I'll probably buy one
because my drugs are getting increased quite a lot and I, I do say to myself
"oh, have I took that tablet the day ".
Tom: S'if they had given you a box from the outset do you think that would
have taken out ofyour hand a little bit of the "Have I taken this, have I taken
that?"
Pt4: Yeah. Yeah and I needn't o' had to've written it down, I dinnae think. [
] didn't bother writing it down, I done itfor my own good. For myself.
Tom: But that might have made that an easier...
Pt4: Yeah.
Tom: sort ofexperience for you?. Okay, okay. That's very interesting.'
The tone of her description suggested an anxiety that she would get something
wrong. She was motivated enough by this anxiety to create an organizational system
for herself to prevent any errors. She had considered this and other systems that
could be incorporated into the trial to prevent herself or others from making similar
mistakes.
6.2.5. Talking with someone new
When patients have built a rapport with members of staff, be it in the trial or not, it
can be difficult for them when they have to speak to someone else. Ptl 2 liked to feel
that he was well known by the staff that he interacted with. When his regular phone
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call came in from one of the trial staff that he had not spoken to before he was a little
less relaxed than normal:
'Ptl2: As with all organisations, when you get to know people that you 're
talking to and they're not there, talking to someone else is difficult ....There
was one ofthe nurses that I hadn 't spoken to the first time I spoke to her and I
just answered the questions and that, I didn't say anything... But eh, it was a
bit strange, someone come on that I didn't know...it takes one or two phone
calls or meetings with people before I do that, Ijust stick strictly to the rules
shall we say. So that the, the nurse that I spoke to on one occasion that I
didn't know, eh I just answered her questions ....You know, there was no
problem at all.
Tom: So, you 'd've, you 'd've rather you just dealt with the same person every
time, is that, is that right?
Ptl2: It's helpful, it's helpful. Or even you know the people, there's maybe
one or two that you deal with and, you know, you 're fine, you 're comfortable,
you know, you know you can talk to them.'
His concern at speaking with someone new also extended to the emergency numbers
that are given on the information sheet.
7 often thought, they give emergency numbers to phone, one of them was
Edinburgh, right, and I thought T hope I don't have to phone Edinburgh,
because I don't know anybody there.' And although they've got it in front o'
them, or I assume they would anyway, I just hoped I wouldn 't have to phone
Edinburgh' (Ptl2).
Although it may not always be possible to have absolute continuity of care, being
mindful that some patients can find uncertainty in dealing with a new face or voice is
important.
6.3. A straightforward experience of the trial
Some patients seem to take being on a trial in their stride. They looked at it as just
another part of the treatment' (Pt2), rather than a significant individual event.
Questions asked about pain were easily answered; the tablets taken were 'like
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drinking a glass of water' (Pt8); patients explained their understanding of the trial
and their commitments within it in a clear manner. These patients remembered the
trial being well explained and events happening as they expected.
For some patients being on the trial fitted into their current lifestyle with no impact
or bearing at all.
'Pt6: So during the trial it didn't alter, Ijust took my, it was another tab, tab
or drink that I took during ma, ma, I dunno, ma daily routine. But Ijust, all I
done was took the tablet, got up in the morning, get dressed, put the telly on
and lie on the couch and watch TV and that's what I done all day, everyday.
Tom: And that was normal for you regardless ofthe trial?
Pt6: Whether I was on the trial or not that was just my daily life and still was
up until last Wednesday. '
It struck me that some patients were approaching their participation in the trial 'like
an obedient puppy'. To me this node, which I named rather than the phrase coming
from the data, represents the unquestioning trial participant who holds the view that
'it was just do as you were told, when you were told' (Pt3). When writing about this
in an early memo, I wrote the sentence 'This may be an acceptable approach to
taking part in a trial? It occurred to me later on that to deem this 'acceptable' was
suggesting that this was a substandard approach to a clinical trial. If this was
substandard but acceptable, what would have been better? In my mind, as a medical
physician, I would expect my understanding and subsequently patients'
understanding of a trial to be comprehensive. Some patients did not seem to see this
as a priority in their participation in a trial. Reflecting on my own interpretation, I
viewed these patients' position of compliance without full understanding as sub-
optimal. Even the node 'Obeying like an obedient puppy' is somewhat derogatory. I
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actually changed the node to 'Followed the instructions' because I was unhappy with
the negative tone of the original title. If I were a lay person conducting this study, I
may not hold this viewpoint of the patients, expecting them to have a good
understanding of the trial. I would be in a similar position to them, lacking a
previous grounding in medicine and clinical trials.
6.4. Experiencing something you did not expect
Pt3 described the difficult task of having to score his pain every day as 'landed upon
me rather than knowing in advance.' My interpretation is that he found this a
difficult chore or a burden within the trial. I wondered if other patients had found
that things were 'landed upon them'. It suggests that things had not been explained to
them or that they had not taken in what was explained. In my mind, a surprising
event during a clinical trial would not be a pleasant one, such as that which Pt3
described. I asked subsequent patients if they had 'experienced anything you didn't
expect' during the trial. Some patients, as described already, had not expected the
tactile stimulation to test for peripheral nerve function. However, rather than being
an unpleasant surprise, this turned out to be an enjoyable one. I was surprised to
occasionally encounter a positive response to the question when I was expecting
patients to describe something negative.
'Tom: Ah, was there anything during the trial that happened that you hadn't
expected?
PtlO: Umm, well I think the whole extra help from [Research nurse 1] and
[Research nurse 2] ehm, I hadn't expected that and that was just really nice,
having somebody ...because when you do all these things, ehm, you get a bit
scatter-brained, and um, and so you think ofsomething and you think, T must
ask the doctor the next time I see them.' And eh, I know I can send emails to
[Clinical doctor 2] anytime but I don't like to pester her, because she's such a
busy lady and I certainly can't just ahm, phone up my GP, unless it's an
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important thing as well, cos they 're all so busy, so um, I have to sort of try and
write down my questions and then the next time I'm seeing somebody, then I
can ask my silly little question, but it may be that something Ijust want to know
now, so, having all these daily phone calls was fantastic, uhm, for the extra
silly little questions, it was very nice. Quite enjoyed it actually.'
6.5. Conclusion to being on a trial
Patients that I interviewed found the trial to be either a positive experience or one
that they found straightforward. I have discussed aspects of the trial that patients
found difficult. The sections that generated the most discussion were the analgesic
effects of the trial on patients' pain and the interaction with the research staff. These
are discussed separately in the following chapters, seven and eight, because of their
central significance to patients' experiences of the clinical trial.
115
Chapter 7. PAIN
Pain is central to everything in the studied trials in which the patients participated.
The primary aim of the trials was to reduce pain; patients were referred to the trial
staff because of the pain that they had; the trial staffs' primary research interest was
what happens to the pain during the trial. For the most part, patients discussed their
pain with me more than any other topic.
Pain is a subjective entity and clinicians can only base their opinions on what the
patients tell them. The International Association for the Study of Pain defines pain
as 'An unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms ofsuch damage' (www.iasp-pain.org).
Scoring tools have been devised to give clinicians a quantitative insight into this
pain. The tools can screen for a particular type of pain or measure the severity of
pain. The scoring tools assessing severity allow clinicians to follow the fluctuation
of a patient's pain, but only within the context of the individual.
This chapter looks at pain as patients describe it, how the patients view their pain and
the impact of the trial on that pain.
7.1. Pain at the start
As discussed in chapter 5.3.1.1, patients described pain as one of the major reasons
for taking part in their trial. There was a group of patients who described their pain
as severe at the point of starting the trial, even to the point of wanting to die rather
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than tolerate the pain. Another group of patients described significant pain but
without the same sense of desperation. A third group remembered minor or no pain
at the start of the trial. Pt8 remarked that he had been led to believe that cancer pain
was unbearable. He was quite surprised by the lack of pain that he had suffered and
the tolerability of the little pain which he did have. His views, if shared by others
may suggest that some patients expect a level of pain relating to cancer.
7.2. Cause and impact of the pain
For most patients, the pain that they described was related to their cancer. There was
the occasional patient who felt that the origin of their pain was arthritis. Pain could
be caused by the cancer itself or as a result of cancer treatment, most commonly
chemotherapy-induced neuropathy. Among those patients that were suffering from
cancer related pain, it was often pain from bone involvement that was described to
me. This was not surprising considering that the aim of the PBT was to study cancer
related bone pain. The KPS addressed a wider spectrum of underlying causes of pain
but they were always neuropathic in nature.
Patients would describe the impact that the pain had on their lifestyle and their
relationships: shopping trips, meals out and visits to relatives were restricted;
partners took on increased duties for the patient and for the household; patients
described strained relationships with family members.
7.3. How is the pain viewed?
'Pt8: ...although I knew somewhere around there it would come hack.
Tom: It was, it was, the pain was around?
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Pt 8: It was around, yeah. '
The pain was around. Although not always explicitly described by patients, this was
the underlying tone throughout the study on the topic of pain. Even if something
reduced the pain, it was never far enough away that it might not return. Patients
described the recurrence of the same pain or of another pain in a different site.
For some patients, the pain was part of their disease process and something to
contend with. For others, it signified deterioration in their overall condition, and
even an indication towards the terminal phase of their illness. Ptl 5 had breast cancer
ten years prior to her current breast cancer.
'Ptl5:1 always thought I was quite good with pain but ...I think um, I thinkpart
of it was fear you know ...with... 'Is this the beginning of the end', you know,...
as if it's gonnae spread through my body and you know....
Tom: mmm-hhmm
Ptl5:1 know it is but...it's like I'm no' ready yet... you know, ten years time I'll
probably be more ready yet but... '
The pain can hold different significance for different patients studied but whether the
pain was present and dominating their life or under control, it was always around.
7.4. Response to the trial
7.4.1. Reduction in pain
The most straightforward response described was from those patients who felt that
there was a dramatic reduction in their pain while on the trial medication. 'Relief
beyond relief was the description by Pt5 when his pain diminished. For these
patients, whether they were on a placebo or not seemed to be a separate and less
significant matter. Two patients, one of whom was Pt5, described their
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misunderstanding of the way in which a patient could encounter a placebo. Whether
a patient was on a placebo or not was of less importance than the fact that the pain
had reduced.
Other patients described a pain reduction when the active drug was started after the
blinded part of the trial. This suggests that the patient may have received the placebo
during the blinded period of the trial.
'Pt4: Eh, and then when I did get that ketamine, I knew right away eh it was
working.
Tom: You did.
Pt4: Oh aye, oh I knew right away, aye.
Tom: Yeah. And what were you, what didyou feel then?
Pt4: Ifelt relieved. Well, really relieved, aye that I had something that, that
got, I mean I go out to the shops and that. '
The boundary of where the trial started and finished was blurred for patients.
Although strictly off-trial when the active unblinded drug was given to patients, it
was still the same trial staff who managed them. I think that for some patients this
was still regarded as part of the trial period. Their primary concern was the reduction
in their pain, whatever period of the trial they were on.
7.4.2. Failure to reduce pain
Then there are those patients who had no reduction in their pain. As the trial was still
blinded through the course of this thesis, it was not possible for me to know why
their pain did not reduce. From my perspective, I believe that being as equally
blinded as the patients was beneficial. If I had held a greater amount of knowledge
than the patients experiencing the trials, I think that my levels of induction would
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have been less. I remained able to look upon the trial as the patient looked upon it,
rather than as a trial staff member may look upon it. As an example:
'Tom: ...didyou say that the pain wasn 't diminishing at all?
Ptl2: Not really. Not really.
Tom: So if that was the case, um why would you continue on the trial,
continue taking the drug?
Ptl2: Well it could be the other way, if I stopped taking it the pain might go
up.
Tom: Mm, mm.
Ptl2: Maybe it was keeping us at that level.'
As I was unable to know any more than he, this seemed a plausible point of view for
the patient to hold.
How did patients see the failure to reduce their pain? Some patients viewed this with
disappointment having had their hopes raised. Others did not have this same sense of
disappointment. Instead, these patients felt that the chance of failure was one of the
core components of the trial experience. I think that for the most part, patients went
into trials with their eyes open. It may not have been that they had a comprehensive
understanding of the trial, but they did understand that they may not get a benefit
from it. As discussed in chapter 5.4 on the placebo arm of the trial, patients were
aware that part of the trial may include receiving a placebo tablet. The reflections of
the patients on the failure of their trial to reduce their pain are developed in chapter 9,
where patient reflections of the trial in general are discussed. It would be interesting




Pain could dominate a patient's outlook on life and their interaction with others.
Similarly, the response to the trial could cause a tremendous feeling of relief and joy.
However, the reduction in pain was not the only benefit of the trial. The next chapter
describes the interaction with the trial staff.
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Chapter 8. THE INTERACTION WITH THE TRIAL
STAFF
Few patients had met the trial staff before being contacted regarding the trial, yet the
relationship that developed with the trial staff is one of the core categories of
advanced cancer patients' experiences of clinical trials explained in this thesis.
The majority of patient interactions were with the trial nurses. Although the trial
doctors were discussed, and mentioned here, it was the interaction with the trial
nurses that patients discussed the most.
The interaction could be straightforward, with the duties or requirements of the trial
being fulfilled to a satisfactory level. Within this relationship, however, some
patients found a positive experience beyond the physical outcome of their trial.
8.1. Duties of the trial nurses
The role of the trial nurses was to act as the first point of contact for patients
throughout the duration of the trial. They were usually the first person from the trial
staff that the patient met, the person they had the most contact with during the trial
and the last person the patient dealt with at the end of the trial. The interaction
between trial staff and patients is illustrated in Figure 5.
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Figure 5 - Interaction with the trial staff
Before a patient consented to taking part in the trial, the trial staff made contact with
them and explained what was involved in the trial into which they were being
recruited. Patients were given an information sheet and had the opportunity to
contact the trial staff to discuss any questions they had. Unusually for a trial, in the
PBT, patients often had to be recruited and consented on the same day as the first
meeting with the trial staff. This was because starting the baseline trial assessments,
and ideally the trial medication, on the same day as the first dose of radiotherapy was
central to the trial. In the KPS, patients had time to consider taking part in the trial
before consenting.
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Once a patient consented to take part in the trial, there was an extensive initial
assessment involving a large number of questionnaires and an examination of the
patient's peripheral nervous system. This involved the testing of hot and cold
sensation, vibration and light touch.
During the trial, the nurses assessed the patients' pain response to the trial
medication. This involved formal questioning on a regular basis throughout the trial.
Although less extensive than the initial assessment, the questions asked the patient to
score their pain from zero to ten and to answer descriptive questions about the pain.
Depending on the trial, the contact was daily, including weekends, or several times a
week, for the four to five week duration of the trial. If the patients were having any
difficulty during the trial, they were encouraged to contact the trial nurses. There
was always one member of the trial staff between both sites (Edinburgh and
Glasgow) available 24 hours a day.
8.2. The relationship - casually professional
So what were the patients' experiences of interacting with the trial staff, particularly
the nurses? Firstly I think it is important to highlight the quantity of contact the
studied patients had had with health care professionals both during the course of their
cancer treatment and previous to that. Patients described many clinic appointments,
many hospitals and many different staff members. I was told about friendly porters
who remembered patients from several months previously and evasive consultants
who avoided difficult questions. Patients glowed when talking about appointments
that had gone well and shuddered at hospital admissions that had not. I was left with
the impression of a group of patients who had a lot of experience of dealing with the
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health profession, who had experienced both good and bad care and could
differentiate clearly between the two.
When enquiring about the experiences between patient and trial staff, I asked the
patients a broad question to allow them to recall and discuss what came into their
minds; 'What did you talk about?' Pt9 described first of all the social aspect of the
telephone conversation.
'Tom: What didyou talk about with her?
Pt9: Ehm, basically it was 'How are you? '....we spoke about ehm, her having
a week offand what she was doing and then we talked about the pain levels,
how they were and she monitored mypain levels.'
Both the patient and research nurse knew that the genuine reason for the conversation
was professional, yet the social and often jocular element could hold as much weight
for the patient as the clinical aspect and stay in their mind for longer. My interview
with Pt 12 was limited by his poor recollection of events during the trial. However, I
found it interesting that one of the things he did remember clearly was the interaction
with the research team.
'Tom: So you enjoy your talking with the research staff?
Ptl2: Oh yes. Yeah, I did indeed. Yes.
Tom: What didyou talk about?
Ptl2: First ofall we got rid o' the, the real stuff...
Tom: Yeah.
Ptl2: ... you know? And then just in between times it was wee bit banter
about things like, 'What did you do at the weekend?' and 'Did you have a
nice weekend?' and they asked me, things like that. You know, just general
everyday subjects.'
125
Aside from the friendly nature of the trial nurses, patients commented on the
competency of the trial staff in general. They are described as 'superb', 'dedicated'
and 'brilliant' with 'everything explained thoroughly'. The overall feeling by the
patients was that the trials were run smoothly and efficiently with difficulties being
anticipated. Patients felt the staff had a high profile and were easily accessible
throughout the process of the trial. I came to think of the trial nurses as casually
professional. Patients described the nurses making themselves feel at home in a
patient's house, by making a cup of tea for example, while at the same time
delivering the required drug prescription and instructing the patient on how to use it.
'Pt20: She just fitted in to my house, when she came in and took her coat off
and sat down, she didn't, I didn't have to say to her can I take your coat dear.
[Research Nurse 2] just took her coat off and started to sit down, and to me
that's just...
Tom: For you that's goodfor you.
Pt20: Uh-huh, she just settled in, and she was absolutely, she was just an
absolutely lovely person. She was absolutely lovely.'
It was this approach that seemed to resonate with some patients and allowed the trial
staff to be held in such high esteem.
8.3. Actions and characteristics of the staff
Trial staff became valued for actions which patients may not have come across
within the health care profession before. For example, trial nurses would visit
patients in their home if that was more convenient for the patient. One less mobile
patient cited the staffs willingness to conduct all his trial commitments in his home
as one of the motivating factors for taking part in the trial.
'Tom: So was there any, eh, impact on your life or your lifestyle?
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Ft3: None at all really, no. As I say, it was only just done, conducted by
phone and by one... a visit at the beginning and at the end by Dorothy.
Tom: So, was that important to you that it wasn't going to have an impact on
your life?
Pt3: I think it was, because it would have been more cumbersome and more
difficult for me to go to the hospital.
Tom: mmm
Pt3: Certainly if I had had to go more than once, I mean, I would probably
have resisted it. But the fact that it's conducted in the house and not
interfering with a lot in my life.'
Patients would describe trial nurses acting as their advocates when contacting other
doctors, dropping off medication rather than patients having to go to the chemist and
fielding questions that patients did not want to trouble other people with.
Some characteristics were intangible to patients. Patients knew that the feelings the
interactions induced were positive but may not have been aware what the feelings
were. The feelings were compared to what patients were familiar with. Patients
referred to the trial nurses, and doctors, as 'just like a friend' (Ptl); others suggested a
brother or a sister. Who they referred to was a trusted person in their life.
'Tom:.... can you just describe a bit more the interactions that you had with
the staff?
Pt2: Em, well it was just.. I was going to say it's like normal
appointments but it's no ' because we actually ended up on first name terms
with the doctors and that, that's, I like that, that was good because you feel
you can talk better to doctors and that if it is like that you feel there's a
barrier dropping doon, you know.
Tom: Was that a new thingfor you?
Pt2: It was, eh. As soon as [Research doctor 1] introduced himself to me, he
says 'Call me [first name]' and it was pretty informal, so it's always been like
that and it's, it's, I think it's helped.
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Tom: Would that have made you more, em, keen to discuss problems ifyou
had them?
Pt2:1 think so.
Tom: Because you felt that you knew them better.
Pt2: Yeah, yeah.'
The characteristics that I came to think of when describing the trial staff would be
those of versatility and flexibility. Nurses had to call a patient during the day, but if
he wanted to go swimming, they were happy to call him afterwards. As mentioned
above, if a patient was finding it difficult to get to the hospital or a chemist to pick up
a prescription, often one of the trial nurses was able to deliver it to their house. A
colloquial term would be 'going the extra mile'. Ptl6 described his desire for
professional accompaniment as 'riding shotgun'.
'As, you know, I thought she was very good, I thought she was very diligent,
or whatever's the word, she really (pause) seriously rode shotgun on the
situation, she really did. Very good.' (Ptl6)
A double-barrelled shotgun has both barrels running parallel with each other, facing
in the same direction. I had not considered the phrase before but it was one that
resonated with its accuracy. The other descriptive term that Ptl6 used was being
'aware
'Ptl6: They have a lovely attitude, who have a caring attitude and who
genuinely are there or appear to be genuinely there to help...
Tom: Can you tell me why that's so important to you?
Ptl6: Och it is important to people who are feeling sorry for themselves and
don't know what direction they 're going in. You 're looking for, you 're no
looking necessarily for reassurance, but you 're looking for (sighs) a bit o '
light-heartedness, I dunno. I've not really considered that aspect of it but
that's what it's about...they were very helpful, very understanding, very
obliging um and, and aware I suppose that 's it, aware.
Tom: Aware (pause). It's an interesting word.
128
Ptl6:1would say that's the thing, they were tuned in, they were very aware. '
I think that 'being aware' could sum up everything that you would hope for in the
relationship between patient and care giver. Pt 16 described his vulnerability by
admitting to 'feeling sorry' for himself. The trial staff seemed to be aware of the
situation that patients found themselves in and reacted empathetically.
8.4. Reasons for positive feelings towards the trial staff
For some patients, the trial staff were appreciated for being competent and the
experience was not highlighted as anything greater than a satisfactory interaction.
For some patients, the interaction seemed to be the most significant part of the trial.
I will discuss some of the reasons that I think are behind this positive view.
8.4.1. Being known by the staff
The description of patients suggested that they felt cared about. 'It's no' "next
please'", reported Ptl when describing his visits to the trial staff in the hospital.
Why I like this quote is that it alludes to his previous treatment; the appointment
being a small part of someone else's day rather than being the major part of his day;
all in four words. Patients looked forward to the appointments with the trial staff and
wanted to go to the hospitals for them.
Ptl 2 described his daily interaction with some clinical staff in his local hospital. Fie
described warmly the familiar interaction generated through daily contact.
'They all know me. Everybody knows my name.' (Ptl2)
As with being invited to call doctors by their first name, being known was important
to patients. It nurtured a relationship which could offer more than what appeared
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superficially to be a straightforward interaction.
8.4.2. The security of presence of the trial staff
The description of patient/researcher interaction suggested that the patients felt cared
for. However being cared for did not necessarily have to come only from a health
care professional. Family and friends provided this role also. What the trial staff
could provide, which may not have been available from friends and family, was an
aspect of security in their presence. Patients described the contact details of the trial
staff that were available to them; they had office and mobile numbers of nurses and
doctors and were encouraged to use them. They knew that if they had any questions
or ailments they could contact the number and expect a prompt, if not immediate
reply, which was comforting. Not all patients needed to call the staff outside of
arranged times but the availability to do so was reassuring.
Security has the connotation of someone higher up or more powerful looking after
you. I would argue that there is a feeling of experience that comes from the side
offering the security. Security can deliver something more than just being cared for.
It suggests a protection from the vulnerability that exists when taking part in a
clinical trial or with any illness. This is why family or friends could not necessarily
provide this same emotion. Some of the trial nurses were experienced in delivery of
chemotherapy prior to being involved in trials and were able to use this knowledge
when required to with patients.
8.4.3. Trust of the trial staff
Something that was very important to Pt9 in establishing a rapport with the trial staff
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was the transparency of this team.
'Pt9: Oh the research, the great thing about the research staff is... there is no
hidden agendas with them.... so basically they told me, who they were, what
they were and what they were doing.
Tom: What...you say that's the great thing about them. Why is that a good
thing?
Pt9: Because they were up front.... and you felt that they're not trying to hide
anything so, for me that was a bonus.'
This importance of knowing the background of the trial staff speaks about the desire
for integrity in the staff you are working with and for. The relationship between
patient and researcher is symbiotic as each relies on the other for some benefit.
Amongst other things, patients were looking for a reduction in their pain while trial
staff needed patients for their trials to exist at all. Pt9 was expressing his satisfaction
with the credentials of the trial staff that allowed him to trust them. Trust is hard to
win but can last a long time. Actions can also build trust. Pt5 described that he felt
that the research team would deliver on promises that they had made.
Pt5: And that makes a difference, you know, ifyou 're in, distressed or pain
or anything like that she was always there. She was always there, which is a
lot better you know than... some ofthem ones.
Tom: So you've hadprevious experiences that are different to that?
Pt5: Aye
Tom: OK, and so why, why was it, um, so good that you had her number like
that?
Pt5:1 think it makes a big difference. You know, I've got other numbers for
like, the [Hospital 2] and the palliative care nurses and what-have-you. They
promise all these things, and then they don'tfollow them up. Ifound that out,
you know.'
With trust could come confidence as described by Pt20:
'...I had that belief in it, and don't know, where the belief came fae, but the
thing was, [Research doctor 1], I really liked. And if I take a, I don't mean
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'like' like but if I get, I get a I don't know, I kind of get a sorta good
feeling about people, that I sort of trust. And I trusted him. ' (Pt20)
Her trust was so much that she would have been prepared to increase her dose of
ketamine, despite side effects, if asked.
Ptl 7 had no concerns about the trial because he felt that all his treatment up until that
point had been of such a high standard. His trust in the health care profession was
transferrable from one situation to another.
Patients would describe their first contact with the trial staff in different manners.
Pt9 for example, recalled clearly one of the trial nurses going into detail about the
background of the trial staff members. This was important to him to establish his
trust in them. Other patients remembered the friendly approach that the trial staff
projected. I think that it is unlikely that the trial staff varied what they initially
discussed with patients to a significant degree but patients took away what was
important to them.
Those patients who did agree to take part in the clinical trial were satisfied enough
with what they had heard to want to take part in the trial. Establishing trust was one
of the important factors of this first meeting. A sense of trust also contributed to the
security of presence discussed above.
8.5. Conclusion
The interactions with the trial staff prompted patients to refer to them as like a friend
or sibling. A trust and sense of security developed, leading patients to hold the staff
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in high regard for their professional approach. The patients who reported this were
from all areas of the studied population regardless of sex, trial or pain response. Not
all patients were as effusive, with some being positive about the trial staff in a
measured way.
I can only speculate on the attitudes of the trial staff and nurses in particular.
Anything else is beyond the scope of this study. Were the nurses aware of the impact
of their approach on the research patients? Were these conscious actions or
unconscious ones, derived from a combination of their personalities and getting to
know the patients over a period of time? Whatever the background to the staffs
interactions with the patients, it had a large impact on the patient group studied.
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Chapter 9. PATIENT REFLECTIONS ON TRIALS
Previous chapters have examined specific aspects of patients participating in a
clinical trial. This chapter examines the general reflections patients had of the trial
they participated in and also their views on trials in general.
As I have done throughout the results section, rather than relating the complex and
sometimes conflicting reflections of individual patients, reflections about the trial are
discussed in collective sections.
9.1. Patient reflections on their own trial
9.1.1. A positive reflection on their own trial
Positive reflection about their trial came from patients both with and without a
reported reduction in pain. I will discuss these two groups separately.
9.1.1.1. Positive reflection on their trial after a reduction in pain
This group of patients had a clear, positive attitude towards the trial they had taken
part in and its benefits. They felt a strong conviction that everyone should go onto a
trial because of the potential benefit. Pt5 had said 'I'll take my chances here ' before
going on to tell me of the relief that the pain reduction had brought. I began
subsequently to see this group of patients as those who had taken a gamble that had
paid off. Patients were aware of the possibility of having no response but it had not
happened to them; taking part in the trial had been a success.
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These patients were also able to see and discuss the other benefits to being on a trial
but the primary outcome for them was their pain reduction.
9.1.1.2. A Positive reflection on their trial after no clear reduction in pain
Some patients spoke positively about their experiences on their trial despite not
having a reduction in pain. This came as a surprise to me. Before starting to
interview patients I thought that patients would fall into two categories: firstly, the
patients who showed an analgesic effect would be very positive towards their trial;
secondly, those who did not show an analgesic effect would be wistful at best at what
could have been, or even dismissive of the trial as waste of their time. When coding
the patients who still spoke warmly about trials, despite it having no effect on their
pain, I created the node 'stoicism in the face of failure' of the trial.' Failure was in
inverted commas as it was to suggest that the only 'success' was a reduction in pain.
When it became clear that patients were taking other positives from the trial, rather
than just pain reduction, this node became increasingly interesting.
Within these patients who showed 'stoicism in the face of failure' of the trial' there
are two factors that seem to be central to their viewpoint: taking benefits from the
trial other than a reduction in pain, and the manner in which they viewed the failure
of the trial to reduce their pain.
Taking benefitsfrom the trial other than a reduction in pain
In chapters 6 and 8 I have already outlined several benefits that patients felt could be
gathered from taking part in a trial other than pain reduction. In summary, these
benefits included the altruistic reasons for taking part in the trial, an increase in the
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structure of care and an increased contact with health care staff that being in a trial
offered.
The manner in which patients viewed thefailure of the trial to reduce their pain
When it became clear over the period of the trial that a patient's pain was not
reducing, a common response was of acceptance, albeit with a proportion of
disappointment as well.
'Tom: So then when you got a little hit down the line and it wasn't working...
did that not bother you?
Pt6: No. It just, it I mean just, it was just something I've tried and it didn 't
work. And, but it was just unfortunate.
Tom: What didyou think about that, having no relief?
Pt6: It still... didn't matter. You still, you're still on the assumption that
you've still gottae try anything and everything ifyou 're going, no matter what
it is you've still gottae try and beat whatever pain you 're in, whether it's pain
or cancer or whatever, I'm still on the assumption if another trial come up,
I've actually been put forward, I'm on a trial now for the cancer. I'm still
doing a trial. I still would give trials a go, I don't shrug them off because
that one didn't work. '
The acceptance of knowing that the trial might not be successful was also connected
to their awareness of placebo medication.
'Tom: ....it may have been that you were on the placebo.
Pt2: That's right.
Tom: Is that, did that strike you as unfair that you ran the risk of.
Pt2: No, no because that's part andparcel of these trials anyway. You know
that before you go into the trial you know.'
Some people shrugged it off, just my luck', as Pt 19 said. Others did not mind given
the fact that the possibility of a treatment failing was part of the nature of trials.
Despite the stoical approach, an element of disappointment was present, either as a
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spoken emotion or as an undercurrent to the situation. Pt4 stated that she was not
disappointed because she knew she was in a trial but added the caveat that she would
have been 'over the moon' if it had worked. As described above, Pt6 was not
disappointed because 'you've got to try anything and everything that comes along...It
was just unfortunate that it didn't work'. While patients denied that they were
disappointed sometimes their follow-up statements, as shown in these quotations,
suggested there may still have been some lingering disappointment underneath.
When Pt2 described the pain and its inability to be controlled as 'part andparcel' of
his disease, it occurred to me that disappointment might be something that had
accompanied patients since being diagnosed with cancer. To get to the point of
having a terminal illness, overall failure, or consistent failure and disappointment,
must have been present along the course of the disease. If this is the case, the
emotion of further disappointment in response to a trial not producing the result that
a patient had hoped for may be measurable within the context of previous
disappointment. It may be that this familiar emotion of disappointment makes
dealing with the failure of the trial a little easier to tolerate. Taking other positives
from the trial might be a technique that patients had developed in the past in other
situations during their cancer journey.
9.1.2. Patient anxieties
A small group of patients expressed a view about the suitability of their place in the
trial. I was alerted to this when PtlO stated that 7 wasn't a very good candidate'.
PtlO thought this because her more sedentary lifestyle (due to her pain) limited the
painful episodes that needed controlling, thus scoring her pain lower than she might
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do otherwise. Pt3 did not recall having pain at the start of the trial and so was not
sure if he needed the drug at all.
'Pt3:..but again I wasn't actually particularly looking for a benefit but I
didn 't have any great pain....
Tom: ..right...
Pt3: ....that we were trying to cure, I was just, eh, it was an additional thing
that...it didn't....it didn't bother me ifI was on a placebo or not to be honest. '
He reconciled this in his mind by stating that he was not doing the trial for himself
anyway.
What do these two descriptions say about patients in trials? I think that they suggest
a potential for some patients to feel anxious; that they should not be in the trial. The
feelings may be those of being found out as a fraud or that their poor response to pain
may twist the results of the study. I think in PtlO's case there was an underlying
anxiety while Pt3 held a slightly more detached view that he was in the trial for
different reasons to what the researchers thought he was in it for. He gave me the
impression that he felt he knew better than the researchers but was still doing them a
favour.
9.1.3. Would patients take part again?
9.1.3.1. A willingness to take part again
My findings from this study indicated that patients showed a willingness to
participate in the same trial again or in another trial if they were offered to take part
in one in the future. This view was expressed by patients whether they had had a
reduction in their pain or not. Pt4, who did not have a reduction in her pain, stated:
'Yeah, Iwould do it again. Aye. Because maybe next time I would get it.'
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She was referring to her view that she had received the placebo and so was hoping
that in the next trial she may receive the active drug. Being on a trial and not getting
the pain reduction that they had hoped for had not put patients off trying a different
trial. Patients put the failure to achieve analgesia down to not receiving the active
drug. There is also the possibility that the active drug did not have an effect on their
pain. Other patients said that they would do another trial again because of the need
to try all available options.
9.1.3.2. A reluctance to take part again
Some patients did describe a reluctance to repeat their trial. In their opinion the trial
had not worked so they did not see the benefit in taking part again. Pt3 did not want
to take part in another trial, and had indeed rejected another trial because he felt that
his body was telling him that it had had enough. He did also describe that this had
been the opinion of his oncologist which may have played a significant contributing
factor in his decision:
'Pt3: I possibly might not on the grounds that I think we 're beginning to
feel, um, that I've been interfered with enough. And I don't mean that I've
been over interfered with but I've just had so much.... stuffput into me and
things you know....
Tom: mmm-hmm
Pt3: ...so when you're taking an additional eight tablets a day, you were
thinking 'Gosh, your putting a lot of.....
Tom.mmmm
Pt3: .... ' other stuffinto your body.'
Tom: yeah
Pt3: Andperhaps it's time you gave your body a rest.'
He gave a firm example, the only one during the study, where he stated he had been
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offered to do another trial and he had refused. The other patients held speculative
thoughts. Some others thought that they had then 'done their hit' (Ptl 6) so therefore
did not need to contribute more. Ptl6 was interesting in the fact that he brought up
the topic of doing another trial spontaneously. At the start of this quote he is clear
that he does not want to do another trial but only a few sentences later he reflects on
the need of someone else and could not rule out the possibility of doing another one.
'Ptl6have, I have no axe to grind about it, I wouldn 't necessarily go and
do another one instantly, hut um I certainly have no regrets whatsoever.
Tom: Right, why would you not do another one? Why would you not do
another one?
Ptl 6: (sigh) I suppose the commitment and, I again it's more up here than to
do wi' ma body, because you know, ma body's....knackered anyway so it
doesn't really matter. But 1, I dunno. Could be ma selfishness, maybe 1 say
'I've done one, I've done one and that's enough, to hell wi' it I'm not doing
any more'.
Tom: Uhm.
Ptl 6: But, I, I don't know. If somebody came along and there was a good
enough reason, a good enough excuse, and there was a better, or another
possible ongoing benefit for some other poor blighter, then I may very well do
it, but out of, straight off the top of ma head is that I've done one, that's
enough.'
This highlights the fact that even if patients think that they may or may not take part
in another trial, when they are given the option to take part, their entry into another
trial cannot be predicted with any certainty. It also shows the value of interviewing
patients who have actually participated in trials rather than asking patients about
theoretical trials. Patients have the potential to say one thing and do something
different when the actual opportunity arises, such as taking part in a trial.
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9.1.4. The trial as a burden
I was interested in whether patients found being on a trial a burden. Patients did not
feel that being on their trial was a burden and some could not understand why other
patients might think it was a burden.
'Tom: So you didn'tfind it a burden at all being on the trial?
PtlO: No Ifound it great fun.'
Is it genuinely the case that there was no element of burden to taking part in a clinical
trial? Burden is quite a strong word. If I were to think of another word to describe
things that might be less emotive, it might be 'down-sides', or 'difficulties'. To my
mind, 'burden' means having a serious impact in your life which I do not think has
been described by the patients studied. Even Ptl 9, who had to be withdrawn from
the study, did not see the trial as a burden.
'Ptl 9: Um, well apart from the tiredness it didn't really affect me in any
other way so, and, you know, I'd agreed to go on the trial so, I couldn't
really, ifI'd expected to come out of it, with nothing changed, it's not much of
a trial is it, ifyou know what I mean. You expect something to, to happen, you
know, obviously it wasn't going to be anything serious (coughs), but um,
expect changes to be made.'
Patients did describe difficulties however which I have gone into in more detail in
chapter 6.2. These included the size and quantity of pills to be taken, struggling with
the questions asked and the possibility of speaking to someone new.
9.1.5. After the trial finished
After some patients had spoken so positively about the benefits of being in a trial, I
wanted to know what happened after a trial finished. Some patients were still under
the care of the trial staff and receiving the active drug. Others had not seen the staff
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for some time and were happy dealing with the community palliative care team who
had looked after them before the trial started.
'Tom: You mentioned that um, during the trial, um, you could ring up
[Research Nurse 2], on a Sunday, and things like that...
Spouse: Yep
Tom: ...to answer questions ...do you have someone like that now, who you
can still ring up?
Spouse: I can ring [Community Nurse 1] ...
Ptl7: [Community Nurse 1] ...
Spouse:... [Community Nurse 1] ....Marie Curie lady...
Tom : yeah, yeah....
Spouse : [Community Nurse 1 ]...can ring her...
Tom: yeah, you can ring her any time...
Spouse: Yes...
Ptl7: mmm
Tom: she can, sort of, she can fill that role that....
Ptl7: mmm
Tom: she, was she doing that before the trial started as well?
Ptl 7: mmm, mmm'
There were some patients who did seem to miss the trial staff. Ptl 1, who had been
pleased with the added structure of care the trial offered, felt that this structure had
fallen away since the trial finished. Another patient, who had not had a good pain
response during the trial, was still in pain when I interviewed him. He did not seem
to be sure when his pain would be reviewed except for an oncology appointment a
few months away. This particular patient posed a difficulty for me as I felt that his
pain control could have been improved. After the interview we discussed options
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that might be available to him. I suggested that I could ask his local community
palliative care team to visit him but he was reluctant for me to do this.
Having heard of the potential positive impact the trial staff could make, I felt that
there could be a negative side to this after the patient was no longer in contact with
them. Would there be a void in the place where the trial staff had been? Some
patients were still in contact with the trial staff, with the contact variably maintained
by either the patient or the trial staff. This suggests a more complex situation of the
relationship between trial staff and patients after the trial had finished.
9.2. Patient views toward trials in general
In chapter seven and eight I have described the benefits of the trials to patients
regarding a reduction in their pain and the interaction with the research staff.
Concerning patients' overall opinions of clinical trials, Pt6 summed up one of the
firmly held beliefs:
'You've got to have trials.'
These patients realized the treatment they had received during their illness was at
least partly attributable to trials that had taken place in the past. Some felt that they
had a debt to pay back to all the people who had taken part in trials in the past which
had benefited them.
'Pt6: At the end of the day, ifyou didn 7 have people to try trials, you didn 7
get this guy who had cancer, I wouldn 7 he at this stage with my pain, so
you've gottae, there've gottae be guinea pigs along the line somewhere.
Tom: So you 're happy to be one?
Pt6: I'm quite, I was quite happy to be one on that case study, yeah.'
Ptl 6 described his view of the importance of clinical trials.
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'Ptl6: I just think that these sort o' things, I do appreciate that these sort o'
things are important. I really do. And I only wish to God that more people
probably saw the importance ofthis sort ofthing. I really do.
Tom: What do you mean by that?
Ptl6: Well, there's so many areas, especially involved in cancers that are
such a bloody total mystery still and they can only be sorted out through trial
and error, through people trying different things, that's the only way it's
gonnae work. Because no-one going to, well, maybe they will come up with
some huge bloody brainstorming things or genes they can stick up everybody
and blooming 'Whack', away it goes. I don't see it happening, not in my
lifetime, that's for bloody sure.
Tom: Mm.
Ptl6: But I don't see it in yours either for that matter. No, I believe the only
way we 're gonnae get on top ofthis whole thing is through research, through
checking, through trying, through drugs that've been slightly modified or, or
cross-used or what the hell.
Tom: Great.
Ptl6: No I think it's a great, I'm in favour of it, hence the, it's one o' the
reasons I did it, you know.'
This belief crossed the boundary of the analgesic effect of the trial. Some of the
strongest opinions in favour of clinical trials came from patients who had had no
reduction in their pain during the trial. When asked, patients were also of the opinion
that they would recommend taking part in a clinical trial to others. Pt5 would tell
them 'Go for it, it will work for you. It workedfor me.' The created node 'Tell the
world about trials' came as a response to Ptl's comment, 'just put me in a room' so
enthusiastic was he to encourage others to take part. Patients' reasons for feeling
strongly about trials were either due to the benefit they had received themselves or
because of their overall opinion of the necessity of trials.
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9.3. Conclusions
Patients expressed positive views towards the trial that they had taken part in and
towards trials in general. Those who were positive about their trial came from both
groups of patients, those with good and those poor pain response. Patients seemed to
favour the possibility of taking part in another trial in the future and would happily
recommend taking part in a trial to other people. This was also independent of their
response to pain. Other patients describe a fatigue towards trials or a reluctance to
go through another one.
There were still aspects of trials that patients did not like or which caused them some
levels of anxiety. Individual patients expressed views of both a positive and negative
nature rather than having a fixed opinion on the trial as a whole.
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SECTION 4 - DISCUSSION
146
Chapter 10. DISCUSSION
In this discussion chapter I will look at the central theory of the study, contextualize
the findings with the current published literature, critique the study and suggest areas
for future research before drawing my final conclusions.
10.1. The central theory of wellbeing
10.1.1. Summary of themes
There were two main reasons why patients took part in one of the clinical trials
studied: to reduce their pain and to benefit someone else. Patients described
altruistic feelings towards patients in the same trial, patients in the future, including
themselves, and towards the trial staff. Patients were also attracted by the lack of
invasive measures and the apparent simplicities of the trials.
The trial process was found to be straightforward at least, if not even enjoyable.
There were aspects that were difficult, such as taking a large number of tablets, but
patients indicated that they had not found being on the trial a burden.
Some patients had severe pain before the trial started. There were many ways in
which the pain impacted on their lives. Those patients who did have a positive
analgesic response to the trial were very pleased with the outcome. Those who did
not get a pain response still tried to take a positive outcome from the trial, such as in
the solace of an altruistic act. Patients were aware that while on the trial, failure of
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pain reduction was a possibility. Some patients could be stoical about the lack of
response while others showed an underlying disappointment.
Some patients took a great amount of pleasure and benefit from their relationship
with the trial staff. These patients were made up of both those who had a good pain
response and those who had a poor pain response during the trial. My opinion is that
this relationship was independent of a patient's pain response. Some patients
described the interaction as similar to the one they would have with family or friends.
They described the fun of taking part in the trial and of the beneficial structure that
the trial offered. It seems that patients developed feelings of trust towards the trial
staff and felt a sense of security from their presence and availability. However, some
patients were less effusive about the trial staff and again this was independent of
their response to pain. It was not clear to me why some patients would be so positive
about the trial and its staff while others were almost complimentary just to be polite
and did not describe the trial having any significant impact on their life. Some
patients would also talk of other relationships with either relatives or other health
professionals that they valued highly.
Patients were happy to have taken part in the trial. Some were happy to consider
taking part in another trial again while others thought that their body had had enough.
Patients did not tend to see the trial as a burden overall. They felt that trials were
important and needed to take place.
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10.1.2. The central theory of wellbeing explained
Over the course of the interviews, I found that that many things could have a positive
impact on a patient. The patients spoke of the relief of having their pain reduced, of
the compassion that had been shown by a trial nurse or of the security that being in a
trial could offer. Yet nothing was universal. A trial nurse could make a tremendous
impression on one patient and be described in measured terms by another. Patients
who did not have a reduction in their severe pain still described the experience as a
positive one and would take part again. I felt there was something that linked these
differences together; something that each participant shared which I had not
considered.
It struck me that the experiences of taking part in a clinical trial made an impression
on a patient's wellbeing. It was this wellbeing that was central to everything else.
I think of a patient's wellbeing as something that is unique to them. As the word
describes, it is a 'wellness' of their whole being. It is an equilibrium that is sensitive
to internal and external influences. The internal factors could be physical, emotional
or spiritual. The external factors could be the interaction with others or the loss of an
activity, such as driving. Like pain, to compare two patients' states of wellbeing
would be meaningless.
I will describe positive and negative impacts on a patient's wellbeing (see Table 3),
the impact of the trials on a patient's wellbeing as well as discussing the individuality
ofwellbeing.
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A positive impact on wellbeing
A patient's wellbeing is intangible yet we can intuitively see if something has an
impact on it. When Pt5 said that a reduction in his pain was 'relief beyond relief', it
was clear that this was having a positive effect on his wellbeing. The security of the
presence of the trial staffmade patients less anxious, which had a positive impact on
their wellbeing. When Ptl6 spoke of the 'awareness' that he felt, he seemed to be
speaking of an awareness of patients' wellbeing. The staff appeared to be willing to
do things that boosted or maintained patients' wellbeing rather than diminish it.
A negative impact on wellbeing
Aspects of the trial, or care in general, could have a negative impact on a patient's
wellbeing. Being faced with eight new tablets on top of the usual thirty tablets is one
example. Patients spoke critically of previous experiences in clinics and hospitals
regarding the manner in which they were spoken to or how they were looked after.
The instances patients recalled could have been many years previously yet they were
still told with fresh hurt or anger. These episodes had such a negative impact on
patients' wellbeing that they still recalled the incidents with clarity.
The overall impact of the trial on wellbeing
What was not clear initially was the juxtaposition between patients describing parts
of the trial which might have had a negative impact on their wellbeing and yet still
being positive about the trial in general? As I described in chapter 9.1.1.2, a patient's
pain may not have improved during the trial yet they were still positive about taking
part in the trial. In these cases there were other reasons for the patient to be positive
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about the trial. An example was Ptl 9 who felt that being on the trial may have a
potential benefit to her five daughters in the future. Despite having to withdraw from
the trial before her pain improved, by taking part in the trial and so potentially
helping her daughters in the future, she was able to take an overall positive view of
the trial and subsequently feel an increase in her wellbeing. Table 3 lists some of the
potential influences of the trial on a patient's wellbeing.
Table 3 - Examples of positive and negative influences from a trial on a patient's





Taking too many pills
Failure of the trial to reduce pain
Difficult questions to answer
Side effects
Becoming annoyed by the trial
The individuality ofwellbeing
Influences from different aspects of the trial had different significance for different
individuals. For example, the fluctuation in a patient's pain state could increase or
decrease patients' wellbeing by different amounts. Similarly, the benefit received
from the input of the trial staffmay be greater in some patients than in others. When
all of the variable factors of the trial are taken into account, the overall outcome of
the trial, whether positive or negative, is likely to vary between individuals. This
might suggest why some patients found the trial to be a very positive experience,
while for others it was something that fitted into their daily routine without having
much impact.
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The fluctuation of a patient's wellbeing is dynamic. I do not think of it as directly
proportional to factors such as disease state, or physical condition. Instead I think
that these factors play a contributory role in the state of a patient's wellbeing. If the
positive influences on a patient's wellbeing, perhaps emotional or spiritual, have a
greater effect than the negative influences, potentially physical, it may explain why a
patient, who had no reduction in their pain, was willing to continue to take part in a
clinical trial.
10.1.3. Conclusion - central theory of wellbeing
I have described the concept of a patient's wellbeing which I believe is the central
theory of advanced cancer patients' experiences of clinical trials. I have described
how positive and negative features of a trial can influence a patient's wellbeing and
how one can have a greater bearing than another towards the overall wellbeing.
However, the total influence from the clinical trial on a patient's wellbeing is finite.
Everything that goes on in a patient's life can increase or decrease their wellbeing.
The influencing factors from a clinical trial could have a very small or very large
impact on a person's overall wellbeing. The context of the trial in relation to a
person's overall wellbeing is beyond the scope of this thesis. What has been
considered is the impact that being on a trial has on a person's wellbeing.
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10.2. Considering the study findings in relation to the current
literature
10.2.1. The literature describing wellbeing
The concept of wellbeing in terminally ill patients is extensively discussed in the
literature. Some authors describe psychological wellbeing while others describe
psycho-spiritual wellbeing. I think that the overall concept is the same. I have
chosen two main papers to discuss in the context of this study.
Lin and Bauer-Wu have written a comprehensive and integrative review of the
literature on psycho-spiritual wellbeing in terminally ill patients. Their aim was to
'synthesize the literature and develop generalizations about substantive issues that
contribute to psycho-spiritual wellbeing in patients with advanced cancer' (Lin and
Bauer-Wu, 2003). The proposed themes that they presented were: self-awareness,
coping with and adjusting effectively to stress, having satisfying relationships with
and connectedness to others, sense of faith, sense of empowerment and confidence,
and living with meaning and hope. Some of their findings resonate with the findings
of my own study. An example of this was discussing patients' interactions with
health care staff. Yeung's paper found that 'health care professionals who used
empathy, understanding and reassurance contributed to positive psychological
outcomes for patients' (Yeung et al., 1999, Lin and Bauer-Wu, 2003). The authors'
concluding comments are also pertinent to this study:
'The studies suggest that psycho-spiritual wellbeing is a concept that can be
enhanced or diminished in patients with advanced cancer, and that those who
have an enhanced sense ofpsycho-spiritual wellbeing are able to cope more
effectively with the process of terminal illness and find meaning in the
experience. Open communication andpositive relationships with health care
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professionals have been shown to be important in enhancing psycho-spiritual
wellbeing. However, there is a paucity of research on specific interventions
in this area....qualitative studies are also needed to understand more fully
psycho-spiritual wellbeing among these patients' (Lin and Bauer-Wu, 2003).
It was after I had written my conceptual description of patients' wellbeing that I read
this paper. To read such similarities to what I had observed and described was
heartening and confirmatory of my findings. Although the clear primary aim of the
clinical trials studied was to reduce pain, it could be argued that for some patients, a
side benefit and therefore a specific intervention, was an improvement in patient
wellbeing. I would also argue that this study has gone some way to describing
elements of a trial that can have an impact on patients' wellbeing.
Folkman and Greer describe a theoretical framework for psychological wellbeing
during a serious illness and the variables that contribute to the psychological
wellbeing (Folkman and Greer, 2000). In my findings, I speculate that patients who
did not find an analgesic benefit from the trial tried to find a benefit from other
sources, such as performing an altruistic act or benefiting from the interaction with
the trial staff. This may have been consciously or unconsciously. Folkman and
Greer describe 'meaning based coping.' This 'generates positive affect, which
provides a psychological 'time out' from the distress and motivates further coping.
An important feature of this positive affect is that it can co-occur with negative
affect, perhaps not at the very same moment, but certainly close in time.' I think that
patients in this study were showing examples of meaning based coping when they
spoke of other parts of the trial that held benefit for them beyond just the pain
response.
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As shown above, current literature has already described components of patients'
experiences that have an influence on their wellbeing. Given the degree of
complementary elements that I have described in this thesis compared to the
described elements in the literature, I feel that within this studied group, the clinical
trials had the potential to influence the patients' sense of wellbeing. As the concept
of patients' wellbeing is something that emerged from the data as the study
progressed, I was not able to measure or assess patients' wellbeing over the course of
their trials. However there are scoring methods such as the Positive and Negative
Affect Scale that have been designed for this function (Watson et al., 1988).
Including this scoring scale in future trials may show the evolution of a patient's
wellbeing as a trial progresses.
10.2.2. The literature describing research in the advanced cancer trial
population
To my knowledge this is the first study that has explored the experiences of
advanced cancer patients who have taken part in symptom control trials, therefore I
am unable to compare this study directly with anything of a similar nature. However
there is merit in comparing the findings with advanced cancer patients' opinions on
palliative care research and their experiences in early phase chemotherapy trials.
10.2.2.1. Comparison with previous studies involving advanced cancer
patients' opinions on research
There are some similarities with the published studies that interviewed patients to
explore their opinions on research in palliative care. The theme of altruism is similar
to that described in the systematic reviews discussed in chapter two (Todd et al.,
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2009, White et al., 2008). It is interesting that one of the main negative features
described by Todd, that of anxiety relating to placebo medication, has not been borne
out in this study. Terry had found that information about trials should focus more on
discussion than on written information which was corroborated by some patients that
I interviewed (Terry et al., 2006). When I asked patients about the manner in which
they had received information regarding their trial, their responses were varied.
Some patients had a good idea of what the trial entailed and others seemed to have
largely misunderstood the main aims of the trial. Patients also showed poor
recollection the information that they had received and some held a preference for
spoken over written information.
10.2.2.2. Comparison with phase I and II clinical trials of
chemotherapeutic agents
During the literature search for this thesis, papers were excluded that had studied
life-prolonging treatments such as chemotherapy. However, as the study progressed,
I become more aware of similarities between these trials and my own area of interest.
The clearest similarity is in the studied patient population. Generally, phase I clinical
trials involve patients with advanced incurable cancer; the same population that I
have studied. Therefore there is merit in studying papers that have involved patient
experiences of chemotherapy trials, particularly phase I trials, to compare these
findings with my own.
There are four main authors who have contributed to exploring patient experiences in
oncology clinical trials (Cohen et al., 2007, Cox, 2000, Madsen et al., 2007a, Madsen
et al., 2007b, Wootten et al.). Their work comes from North American, Europe and
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Australasia. The authors have all explored patients' experiences around the time of a
clinical trial. I was aware of Madsen's work before starting my data collection due
to the similarity of the grounded theory approach that he adopted (Madsen et al.,
2007a, Madsen et ah, 2007b). His work is also discussed in chapter 2. However, I
was not aware of the other three. I will discuss the differences and similarities
between the oncology trials and the trials that I studied separately.
Differences between Phase I and II trials and my studied trials
The fundamental difference between these trials is the complex issue of offering life-
prolonging treatment. Patient motivation in taking part in the chemotherapy trials is
especially complex. Cox describes patients taking a more positive attitude to the life
prolonging nature of the trial than may have been presented to them by the trial staff
(Cox, 2000). The patients in the KPS and PBT were fully aware that the trials being
offered to them would not prolong their life.
Another difference is the physical change that patients may feel while on the two
types of trial. Often within phase I trials, the outcome may be measured by tumour
reduction rather than any subjective feeling of the patient. This makes a tangible
positive outcome from phase I trials less apparent to patients. With a clinical trial
aimed at pain reduction, patients are much more able to 'feel' that the trial is having
a positive impact. For the phase I clinical trials, patients are more likely to
experience the negative aspects of trials in the form of side effects than any positive
outcome (Cox, 2000).
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The end point of chemotherapy phase I trials seemed to be very different to the KPS
and PBT. In the phase I trials described, the most likely endpoint was when patients
were withdrawn from the trial due to side effects or deterioration (Cohen et al., 2007,
Cox, 2000, Wootten et al.). This differs from the KPS and PBT where the majority
of patients studied completed the trial with little difficulty. Being withdrawn from
the trial had a negative impact on patients who were then forced to face difficult
questions regarding future treatment options and the status of their disease (Cox,
2000, Wootten et al.). This issue did not seem to arise in the population that I
studied.
Patients did not feel that they had a choice whether to go in to the trial or not and
they also felt that they were 'living their life on hold' while being involved in the
trial (Cox, 2000). From these papers, the experience of taking part in a phase I or II
trial appeared to be very onerous. Patients were very graphic about the severity of
side effects that they had to put up with or the demands of the trial participation
(Cohen et al., 2007, Cox, 2000, Wootten et al.). Quality of life issues were discussed
and described in a negative context (Cohen et al., 2007). This also differed from
KPS/PBT findings which suggested that patients felt that they were able to reject trial
participation and did not feel that their lives were negatively impacted while on the
trial.
Similarities between phase I and II trials and my studied trials
During my reading I discovered, patients gained a lot from chemotherapy trials other
than the response to the medication. They described the positive benefit of
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performing an altruistic act, enjoying the relationship with the research staff and the
amount of attention that they received (Cohen et al., 2007, Cox, 2000, Madsen et ah,
2007b, Wootten et al.). Madsen describes the differences in patient satisfaction
between two trials where the number of doctors and the continuity of patient contact
is very different (Madsen et al., 2007b). The patients who were cared for by the
same small trial staff gave a much more favourable description of their interactions
with the trial staff than those trial participants who were cared for a large and
variable group of researchers.
I had speculated that throughout the time frame of the trial, patients might change
their opinion as to the reasons why they were taking part in the trial and the relative
importance of each reason. This was corroborated with one of the studies:
'When hope of symptom relief and cure were not met participants re¬
evaluated the benefits oftheir participation and attached a stronger meaning
to altruistic aspects ofparticipation.' (Wootten et al.)
Some patients in the phase I and II trials had difficulty with the information that they
were given (Cox, 2000, Madsen et al., 2007b). Some had either misunderstood the
point of the trial or had put an incorrect amount of hope in the possibility of a cure
for their disease. I described misunderstanding of the aim of the trials also and
particularly on the use of placebo medication. In similar comments, patients
described the various merits of written information and spoken information with trial
staff (Cox, 2000, Madsen et al., 2007b).
Patients did seem happy to have taken part in phase I and II trials and would do again
in the future (Cox, 2000). Although this opinion was similar to my findings, what
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was interesting was that the patients who felt this had also had a very difficult trial
experience with a large number of side effects and significant impact on their
lifestyle. I think that this highlights the power and significance of the undercurrent
of life-prolonging treatment in phase I and II trials. Despite going through very
challenging trial periods, patients appear willing to take part because of the overall
potential life-prolonging benefit.
Another similarity is the issue of what happens after a trial finishes. Patients in these
papers give vivid descriptions of distress and abandonment after they finish the trial,
having either completed the course of treatment or been withdrawn from the trial
(Cohen et al., 2007, Cox, 2000, Wootten et al.). This was an area that I was only
able to touch on and speculate about but the descriptions in these trials add a greater
weight to this topic.
Conclusions
I have found several differences and similarities with my own findings when
studying the experiences of advanced cancer patients who have taken part in phase I
and II trials. I am pleased that I conducted this search of the literature after I had
completed my own data collection and analysis so that I was less aware of others'
findings before I was able to engage in the topic myself. I believe that the
similarities carry greater weight and resonance due to my lack of awareness of them
before starting my own data collection.
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10.3. How is this study useful beyond the scope of the
studied participants?
The population studied was a broad section of patients with advanced cancer.
Attempts were made to sample a wide range of patients with different experiences.
Although all patients studied had metastatic cancer, for the most part they would not
be classified as in the end of life phase of their illness. At the end of the research
period, only 9 of the 21 patients interviewed had died. A lot of the patients were still
mobile outside of their houses and were still carrying out activities of daily living.
Only four patients had an ECOG score (Eastern Cooperative Oncology Group) of
three at the time of interview. Some patients were limited in their mobility within
the house although this may have been related to pain rather than overall progression
of their illness. At the start of the study, I thought that a lot of the patients would be
in a similar position to those that I encountered in hospices, spending over 50% of
their days in chairs or bed for example. However, this was not the case. The patients
studied were community based palliative care patients rather than in-patient based,
end of life palliative care patients. The group of patients studied was similar to the
types of patients that are frequently encountered within the palliative care
community. Therefore I think that the findings from this thesis hold interest for all
practitioners of palliative care. As well as holding interest for the palliative care
community, several findings of the thesis hold interest for any clinical trial
practitioner and those who interact with patients in general.
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In this section I will discuss the findings that I think are useful beyond the scope of
the studied participants. These are the concept of wellbeing, information given to
patients, recruitment of patients and transition of care.
10.3.1. The concept of wellbeing
When a patient's wellbeing is kept in mind during trial design, this may increase the
potential for the patient to find the trial a positive experience. In turn this is likely to
result in a reduced attrition rate. There is a potential benefit that lies in the
relationship between patient and trial staff. In these trials, by providing an
atmosphere of trust, security and familiarity for patients, the trial staff created an
environment that had the potential to increase their patients' wellbeing. Following
this model may be of benefit to others designing clinical trials in the future.
The concept of patients' wellbeing is not limited to clinical trials. Ptl 6 described
the environment of the regional oncology centre when someone met him and offered
him a cup of coffee.
'Tom: Can you tell me why that's so important to you?
Ptl 6: Och it is important to people who are feeling sorry for themselves and
don't know what direction they 're going in. You 're looking for, you 're no'
looking necessarily for reassurance, but you 're looking for (sighs) a bit o'
light-heartedness, I dunno. I've not really considered that aspect of it but
that's what it's about, it's just the general demeanor of the chap who's
always...always seems to be there in the, the arrival lounge area at the
[Hospital 1], so nice and chatty 'Can I help you get you a coffee, or can you
manage to get one yourself? ' and it makes a difference.'
This is an example of a positive influence on a patient's wellbeing. Whether these
actions are conscious or unconscious, patients have shown the potential value that
they can hold.
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10.3.2. Information given to patients and patient understanding of the
trial
Patients described a variable knowledge of the trials in which they participated.
Some patients were not aware of the process by which placebo medication was
administered; some had a poor understanding of the risks of side effects; others had a
complete grasp of the trial and its implications. Patients also had variable
recollection of the information that they were given. There was a group of patients
who had little inclination to read or comprehend the information sheet. They
expressed a preference for information being explained to them verbally and held a
belief that anything particularly serious would have been explained in this manner.
This calls into question the way in which information was given to patients and the
checking of patients' understanding of the trials they were undertaking. This was
similar to the findings studies involving phase I chemotherapy trials (Cox et al.,
2005, Madsen et al., 2007a). Putting greater emphasis on explanation rather than
information sheets may be considered in the design of future studies.
A pertinent question is why some patients appear to have a poor understanding of the
trial process. Certainly, by the time of interviewing a patient, it may have been a few
weeks to a few months since the trial finished and the finer details may not be as
clear in their mind. Patients did admit that they were sometimes confused about the
different information sheets that they had been given for various trials and
procedures. Looking at the situation in another way, the patients may have happily
ceded responsibility of being in a trial to the research team. If you have trust in the
research team, your knowledge requirements may be reduced.
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10.3.3. Recruitment of patients
There are many factors that have been described in the literature regarding barriers to
taking part in a clinical trial (Mills et al., 2006a). As all patients interviewed took
part in the trial, my comments describe some of the factors that patients discussed
around the time of patient recruitment, rather than barriers to taking part.
Some patients described being 'hijacked' or 'accosted' when first encountering trial
staff. Although it is difficult to know the actual situation and whether these patients
were distressed by these incidents, their choice of words suggests that there was the
potential for this first meeting to be stressful for patients, whether they agreed to take
part in the trial or not. The patients who reported these feelings of anxiety at the time
of recruitment all took part in the PBT rather than the KPS. A difference in design of
these trials is that the PBT generally started on the same day as the radiotherapy
treatment. If patients did not start their medication on this day they were unable to
take part in the trial. A standard requirement of an ethics committee is for patients
have 24 hours between initial contact and recruitment onto a trial to consider the
information they have received. As this was not always possible in the PBT, an
exception to this requirement was approved, so that patients could be recruited and
started on the trial medication on the same day. Some patients may have been
responding to this lack of time that is usually afforded to them. This suggests that
the standard requirement is beneficial for patients; to have the time to consider what
is being offered.
It may be that these episodes of stress during the first encounter are less significant
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than I have stated. Pt3 gave contradictory reports of his pain status during his
interview but he did maintain at times that he had no pain. As a result he felt that the
benefit of taking part in the trial was not for himself but for the researcher. In his
words, he was 'persuaded' to take part, even with no pain. To be entered into the
trial a patient has to have a significant degree of pain. Although Pt3's memory may
be different to what he reported at the time, his perception at the time of interview is
valid. Trial staff have to recruit patients for their trials to be a success. It may be
that some perceptive patients feel this pressure being transferred on to them.
10.3.4. Transition of care.
Patients highlighted the benefit that they can derive from the interaction with the trial
staff during the trial. However they also mentioned the difficulties that may arise
when this short yet intense relationship comes to an end. At the end of the trial some
of the aspects of the trial that the patients found so beneficial, such as the security of
presence and regular contact with the trial staff came to an end. Some patients
described restarting or increasing their contact with their community palliative care
team. Other patients appeared to be less clear where they were able to obtain a
similar style of support. Perhaps there is a greater detriment to the patient by the loss
of these benefits, than receiving them in the first place. Perhaps trial staff should be
aware of this potential during the trial and make greater efforts to prevent the
occurrence of this sense of loss. This is beyond the scope of this study but is worth
highlighting for future work (as discussed in chapter 10.5.2) .Work on this transition
has already been conducted in early phase cancer trial population (Cox et ah, 2005).
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10.4. Reflection on the whole study
Throughout the study, I have conducted reflexive practice to be aware ofmy position
within the research process. While examples of this are described throughout the
thesis, I will collate the most salient points here. I will also look at aspects of the
study that may have had an impact on the findings that have been presented.
10.4.1. Personal impact
As I have described in chapter 4.2.1, I am a 32 year old, middle-class, Caucasian
male doctor with an English accent. I think that these characteristics have played an
influential role in the outcome of the study. As a palliative care doctor, I assumed a
role of authority when patients were questioning an aspect of their care. Patients
would ask me technical questions which I was able to answer. Whilst I was able to
help patients with their questions, and so hopefully gain their trust, I was also putting
myself above them in the power dynamic. Although I tried to distance myself from
the trial staff, thus ensuring the confidentiality of the patients' views, 1 was still often
viewed as part of the trial staff. I think that this may have made patients slightly
reluctant to discuss negative aspects of their experiences as I was not a completely
independent body. Being part of the health care profession immediately puts me on
that side of the balance and 1 think that my findings are swayed towards viewing the
patients' experiences from this angle. Had the research been conducted by someone
who was not related to the health profession, their view may have been quite
different.
Although I made efforts to create an equal power dynamic, in reality this was not
possible while I presented myself as a doctor. I would not have felt comfortable
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concealing this information from patients so I acknowledged and accepted this
imbalance for what it was and the impact that it had.
Anxieties of novice researchers are to be expected and I was no different. Although I
made efforts throughout the interview process to develop my interviewing technique,
I still look back at interview transcripts critically with views of how the process
could have been better. Similarly with data analysis, had the study been conducted
by a more experienced qualitative researcher, the findings may have been different.
However it is accepted within the literature that there may be limitations of novice
researchers. Glaser described grounded theory as a learning process.
'It is okay when the future is the continuing skill development in doing
grounded theory.' (Glaser, 1999)
Similarly, Heath and Cowley offered advice which I followed throughout the
process:
'The novice researcher should set aside "doing it right" anxiety, adhere to
the principle of constant comparison, theoretical sampling and emergence
and discover which approach helps them best achieve the balance between
interpretation and data that produces a grounded theory It is wise to
remember too that the aim is not to discover the theory but a theory that aids
understanding and action in the area under investigation.' (Heath and
Cowley, 2004)
I believe that I adhered to this advice and am able to be satisfied with the results that
have been generated.
10.4.2. Areas in the study that could be improved
10.4.2.1. Patient recruitment
Patient recruitment in palliative care research can be challenging for reasons such as
gatekeeping, attrition rates and ethical limitations (Dean and McClement, 2002).
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The difficulties in this study were: gatekeeping, the manner in which patients were
approached and recontacting patients after they had been given the information sheet.
Gatekeeping
One of the exclusion criteria for the study was if patients were 'in the dying phase of
their illness.' This was decided by discussion between me and the trial staff. As
described in chapter 4.1.2, the description 'in the dying phase' of their illness is
deliberately ambiguous. Indeed it is not possible to quantify. However, by deciding
a patient was too unwell to be approached, the trial staff and I were making an
assumption on the patient's behalf that we could not be sure was their wish. On one
hand, there is a risk of offending them and their family by requesting that they give
up more of their time when they are at the end of their life. However, by assuming
that they were too unwell, we may have been preventing patients from making a
contribution that they would have liked to make. I can see the double-standard of
being aware of the hindrances of gatekeeping in palliative care research and still
acting in the same manner myself. I think that this highlights the delicate balance of
this area. As a researcher, either you take part in gatekeeping to whatever degree you
feel is appropriate, or you run the risk of offending or upsetting a percentage of
patients by asking them to take part in research. Clearly this level is different for
different researchers. Out of 22 patients that Terry interviewed for his study, 14 died
within 48 hours of the interview (Terry et al., 2006). In the same situation, I might
have excluded these patients as being in the dying phase of their illness.
The manner in which patients were approached
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There were several ways in which patients were approached to consider taking part
in this study. Some patients were telephoned by me with no prior mention of the
study by the trial staff. Others were given the information sheet or had the study
discussed with them by the trial staff before I contacted them. Certainly for the latter
approach, and even sometimes for the former, I felt that in the eyes of the patients,
this positioned me strongly alongside the trial staff. Although I made efforts to
distance myself from the trial staff, I felt that this was a significant factor. However,
during interviews, some patients had described their displeasure at being 'cold-
called' by other trials or studies. These patients may not have taken part in this study
if they had not been contacted, or at least been made aware of the study, by the trial
staff.
I have already discussed the limitation of not being able to interview a patient who
the trial staff felt had not been happy during the participation in the trial. These
patients seemed to be rare. On one occasion when a patient of this nature was
approached, it was by the trial staffwho it was felt he was not happy with. This may
have been a contributing factor to him rejecting the offer to take part in the study.
Had 1 called him, he may have been more amenable to agreeing as he may not have
seen me as part of the same team. More effort needs to be spent considering how
these patients can be included in studies like this one. It is very important that the
patients who have a poor experience of clinical trials are able to share these
experiences. The manner in which they are approached could be vital in succeeding
in recruiting them and learning from the aspects of a trial that they did not enjoy.
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Re-contacting patients after they had been given the information sheet
The ethics committee were very clear that patients were to be contacted only once to
discuss recruitment. Although I agreed with the sentiment of not pursuing patient
recruitment when it was uninvited, this did pose difficulties. There were times when
patients stated they had a chest infection or were not feeling well that day but asked
me to call back another time. I was unsure whether this was genuinely the case or
they did not want to take part in the study without actually saying so. I was in a
similar dilemma when leaving a message on patients' telephone. Throughout the
process I tended to err on the side of not recontacting patients. I felt that I would
rather be in the position of not recontacting a patient who had wanted to take part
than pursuing patients excessively who did not want to take part but did not want to
say so explicitly. I felt that if a patient was very keen to take part, they would
contact either me or the research team.
10.4.2.2. The trials being studied
The studied trials contained a small number of patients over two sites that were being
run by the same medical team. This introduces several limitations. Although the
trial nurses were different between Edinburgh and Glasgow, they had been trained
and nurtured by the same two doctors. It may be that this team is exceptional at their
delivery of patient care and the medical influence has rubbed off on the trial nurses.
If patients were recruited from different parts of the country which had entirely
different research teams there may have been a wider range of experiences,
particularly regarding the interaction with the trial staff.
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The trials are also relatively undemanding for patients and use medication that is well
established and is largely known to have a low side effect profile. These facts may
put a distortion on the findings of the patients that may not be reflected in other
symptom control clinical trials.
10.4.2.3. Data Analysis
Supervising staff
The main point of supervision was Dr Laird who was also heavily involved in the
running of the trials. He is described by the patients and is the initial medical link for
the trial nurses from Edinburgh and Glasgow. He would read the interview
transcripts and we would discuss themes that I was developing. Within this
relationship there is a conflict of interest between the running of the trial and the
development of this study. By reading the early interview transcripts, his approach
to later patients could have changed which might in turn influence their experiences
of trials. However, during the data analysis, the work was my own and the themes
that I developed were done independently. It is a limitation that he participated in
this study while being so involved in the trials. However I feel that it is a relatively
small one due to his limited contribution to the data analysis process of the study.
Methods for data analysis
During the theoretical sampling of patients, the change in patients' pain, measured by
the Brief Pain Inventory and McGill Pain Questionnaire, was used to select suitable
patients. As well as completing these pain scoring tools, patients also completed a
depression screen and a quality of life tool (the Hospital Anxiety and Depression
Scale (HADS) and the Euroqol quality of life thermometer). These could have been
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implemented during the data analysis as a point of triangulation for patient responses
and descriptions of the trial. Once the concept of wellbeing during the trials was
forming, it would have been possible to have gone back and looked at patient HADS
scores and Euroqol ratings at the start and end of the trial. This may have added
weight or challenged the views that patients held.
The decision was made close to the start of the study not to conduct focus groups. If
patients had had the opportunity to meet collectively and discuss their own and each
others' experiences of being in a clinical trial it may be that new light could have
been shed on the topic.
10.4.2.4. The interview process
The style offormat ofthe interview
I have described the flexible nature of the interview process. Patients were allowed
to bring up topics which were important to them. However, the frame of the
interview was predetermined by me and I led patients along this frame rather than
allowing them to initially lead the interview. I think that this decision restricted the
opportunity for patients to describe what they had remembered about the trial and
directed their responses towards my agenda. This may have diminished the potential
for new discovery from patients.
The choice ofhaving only one interview
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Another point of discussion was the choice to have only one interview session with
each patient. The advantage of this is that it is less time consuming for patients.
Again this was something that was important for the ethical approval of the study.
By interviewing a patient once at the end of the study, I received a snap-shot of their
opinion at that time. While these opinions remain valid, had I interviewed patients at
different points of the trial their responses may have been very different in three
main ways. Firstly, I have speculated that their opinions on hope for the trial and
their reaction to a failure to reduce pain may have changed as the trial proceeded.
Secondly, I think that as patients got to know me better, we may have been able to
have more in-depth conversations on topics that they did not feel comfortable talking
about during a first meeting. Finally, there were times when I would have liked to
have discussed issues with patients that they brought up in interviews once I had a
chance to analyse their views in the context of themselves and other patients. By
being limited to only one interview, this option was not available to me.
As patients' experiences of trials and studies were not known, on reflection, I think
that the approach of one interview per patient was appropriate for this study.
Flowever, with this studied group suggesting that taking part in research was not a
burden, a more longitudinal approach might be more appropriate for a future study.
10.5. Further studies to be developed
The findings and process of this study has suggested other studies that could be
conducted in the future, either by me or by others who could use my findings as
guidance for their own work.
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10.5.1. Changes to this study if it was repeated
With the knowledge that I have gained from conducting this study, if I were to repeat
it, there are several aspects that I would do differently.
Single interview ofpatients
Patients have described their experiences of taking part in a clinical trial. However
their opinions were sought at the end of the trial, once their participation had
finished. My speculation is that their opinions may change as the trial proceeds.
This speculation has been borne out in other studies (Wootten et ah). An example of
this is what patients were hoping to get out of the trial. The results generated suggest
that patients wanted an improved level of pain control but they were also motivated
to a certain degree by the altruistic nature of the trial. It may be that at the start of the
trial the patient's main focus was on pain control with altruism playing a small or
negligible part. As the trial progresses, and potentially their pain does not diminish,
the altruistic nature of the trial starts to play a greater role in their mind. Multiple
interviews along the course of an illness, common in the wider spectrum of social
science, can give a better picture of a patient's experience (Murray et al., 2009).
However, this approach is thought to be underused in medicine (Lewington et ah,
2007, Murray et al., 2009).
The decision to interview patients only once was made when it was unclear what
patient experiences of clinical trials were like. Having found these trials to be of
relatively little burden to patients, I think that it would be reasonable to interview
patients at different stages of a trial. At the least, it would be beneficial to interview
patients before they started the trial, while they were taking part in the trial and after
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they had completed the trial. In this manner, any change in opinion could be
monitored.
The disadvantage of this approach would lie in the selection of patients. It would be
harder to sample patients who might offer differing experiences if they were
recruited before the trial started. Because of this, it might be appropriate to have a
combination of patients who were recruited at different parts of the trial, depending
on their response and involvement in the trial.
Use ofconcurrent tools
As described in chapter 10.4.2.3,1 would take a greater benefit from the scoring tools
that patients completed. In particular these would be the HADS and Euroqol
thermometer. This data could be compared with the views that patients were giving
to stimulate further discussion.
Running of the trial
As I have described in chapter 10.4.2.1 there were several limitations to the way in
which patients were recruited and how I as the researcher was seen by the patients. I
think that it would be important to try and have a greater distance between myself
and the trial staff. They would not be involved in discussing this study with
prospective patients and would not be involved in the selection of patients who were
to be approached. This would run the risk of contacting patients who may be in the
'dying phase' of their illness but it may be that these patients would welcome the
opportunity to discuss their experience of the trial.
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I would also have supervision from someone who was not related to the trials. This
would allow a more independent view on the data that was being generated without
the risk of influencing, either consciously or sub-consciously, future patients who
were taking part in the trials.
As discussed above in chapter 10.4.2.2, there would be benefit in studying patients
from different trial sites which were being run by different trial staff. This would
allow for a wider range of patient experiences.
10.5.2. Future studies of a different nature
There are several areas of interest that have been generated from this study that I
would like to explore further.
Relating to wellbeing
The concept of wellbeing has been developed over many years. Its role in relation
towards patients with advanced cancer specifically is also well documented (Lin and
Bauer-Wu, 2003). What I think would be interesting would be to try to measure how
this wellbeing may change over the course of a clinical trial. There are several
scoring tools to measure wellbeing. The Warwick-Edinburgh Mental Well-being
Scale and the Positive and Negative Affect Schedule are just two (Tennant et al.,
2007, Watson et al., 1988). These could be incorporated into clinical trials in the
manner in which other scoring tools such as the HADS frequently are. This would
allow the change in patient's wellbeing to be assessed as a trial progressed. This
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would inform researchers in the design of future studies as to what may have the
maximum positive impact on a patient's wellbeing while taking part in a trial.
A study to investigate patient experiences after trial completion
In my findings, I commented that patients may have difficulty coming to terms with
the loss of the regular medical or nursing contact once a trial comes to an end. Cox
also discusses this sense of abandonment at the end of a phase I trial (Cox, 2000).
Cox has subsequently looked at the implementation of nurse-managed phase I trial
conclusion with positive findings (Cox et ah, 2005). There is scope to investigate
this period further for advanced cancer patients who have complete symptom control
trials. At this time in their illness trajectory, several patients will benefit from
specialist palliative care input beyond the capacity of the trial staff. Patients
described instances of this service being implemented but other patients described
still being in pain and uncertain who might be able to assist in their management.
Are trial patients being hindered from accessing palliative care services because of
their participation in a symptom control trial? The input that patients receive during
a clinical trial from trial staff is greater than can be expected for all patients in the
final period of their illness. Does the fact that patients experience this for a period of
time before returning to a more routine amount of input have a negative impact on
the patient? It would be interesting to conduct a longitudinal study of patients who
have completed a trial to see how they experienced their healthcare after the high
intensity contact offered during a trial.
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A study to investigate the attitudes of healthcare professionals towards symptom
control trialsfor advanced cancer patients
One of the most striking findings of the study was the potential benefit that patients
could receive from the relationship with the trial staff. I am interested in what it is
about these staff member that make such a difference to patients. Do they differ
from other members of the palliative care community? What are their similarities
and differences of the trial staff to each other? Does the attitude of the senior
clinicians have an impact on the staff below them? One variable that should also be
taken into account when studying the attitudes of research staff is the amount of time
they spend with patients. This simple act may be more significant than the manner
and attitudes of the research staff.
The other interesting factor is how do these trial staff members differ to other health
care professionals who may not be involved in clinical trials or palliative care? The
success of clinical trials can often depend on the willingness of other professionals to
refer patients towards the trials. Excluding palliative care physicians, those referring
patients could be oncologists, general practitioners or district nurses. What are their
opinions towards clinical trials in palliative care and what are the barriers that might
prevent them from referring patients towards trials? Where would these findings fit
in the context of the findings of this study which suggests the potential benefit to
patients from taking part in such a clinical trial? A qualitative, interview based study
of a wide range of health professionals may shed some light on this subject and
inform the knowledge of barriers towards patients taking part in clinical trials.
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10.6. Conclusion
In this thesis, I have set out to explore the experiences of advanced cancer patients
who have taken part in clinical trials. As this has not been done before, there are no
findings which I can compare my own with. I adopted a constructivist grounded
theory approach with the aim of discovering theory within the data.
Patients were motivated to take part in the clinical trials for several reasons including
a desire to reduce pain, altruism and for greater organisation or structure of their
care. Patients found the trial to have positive benefits. I have shown that the
experience of being in a clinical trial involves many different factors, of which pain
reduction is just one. Altruistic reasons for trial participation and interaction with
staff during the trial have been among the themes that have held most discussion.
I have described a model of patient wellbeing that is influenced by all aspects of the
trial. A reduction in a patient's pain may increase their wellbeing. The interaction
with the trial staffmay increase a patient's wellbeing. A failure to reduce a patient's
pain may have a negative impact on a patient's wellbeing but this may be countered
by the interaction with the trial staff to create an overall increase in a patient's
wellbeing. The influence of the trial on a patient's overall wellbeing may be large or
small, depending on other inputs in their life.
I believe that this model meets the description of a completed theory that'.. .provides
the best comprehensive, coherent and simplest model for linking diverse and
unrelated facts in a useful andpragmatic way.' (Morse, 1994)
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This study has given light to the experiences of advanced cancer patients on clinical
trials, has shown direction for future research and gives examples of well received
patient centred care.
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APPENDIX A: DATA ANALYSIS
It would not be possible or beneficial to outline the entire analytic process that took
place during this study. Instead I will describe the active process that took place,
rather than the theoretical ideal and illustrate this with extracts from the analysis.
The aim is to show the reader the process that brought me to the results described.
A.l Coding
The software package NVIVO (version 8) was used to facilitate data analysis. As
well as being able to annotate transcripts and organize memos, the central benefit of
NVIVO was to structure my coding. A code as described below is assigned to a
'node' in the package. Nodes that are, or at least initially appear to be independent
entities are referred to as 'free nodes'. Once it is clear that several free nodes are
related to each other these can be collected under the title of a 'tree node'. An




Being wrong about side effect risk
Discussing the risks of a trial
Experiencing side effects
Failing to remember potential side-effects
Remember being assured of no side effects
Showing a relaxed attitude to side effects
Trials are safe
Was it a side effect or something else
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Tree nodes can then be built up further into categories and from categories,
developing concepts and an overall theory takes place. I will outline examples of
how the stages ofmy coding developed.
A.1.1 Initial coding
Initial coding was adhered to for the first 12 interviews. This involved remaining
close to the data and where possible using gerunds to describe the data (Charmaz,
2006). By using words that reflect action I attempted to avoid making premature
conceptual conclusions before sufficient data collection and analysis had taken place.
In an example from interview 5,1 show the initial codes:
Codes Transcript
Pain was the only reason, Pt5: If it's gonnae get that pain away.
Describing pain which required trial And when you're in agony, the
meds agony I was in, I was waking up
during the night an', just wanting
somebody to do away with me....
TM: Really...
Pt5:...that how much pain I was in.
Describing initial contact made, Now, I went in there an', that day at
the Beatsons and we
met.... [research doctor 1] and
[research nurse 3]. He says well,
'We got a drug here, a trial drug'.
I says, 'Well, I'm your man. I'll do
Coming to decide to go on the trial it. I'm...I'll take this.' In a week,
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Positive outcomes from the trial ohh, so much relief.
TM: Yeah
Pt5: You know.
TM: You don't think, you didn't have to
Coming to decide to go on the trial think too hard about going ....
Pt5:...no..
TM- into it. OK.
Pt5: I never thought twice, somebody
says.... Me an' [research nurse 3]
spoke about it, and me an' my wife
Taking advice from relatives before spoke about it, and I says look,
agreeing to enrolling, 'gonnae help me, I'm taking this.'
Coming to decide to go on the trial TM: Sure
Pt5: Nobody's going to change my mind.
Stating happiness to take part TM: Sure, sure. Why might they have
changed your mind?
Pt5: They wouldnae a'! Oh they
Stating happiness to take part wouldnae 'a changed my mind.
As with the originators of grounded theory, Charmaz advocates for line-by-line
coding in the initial stages. Implicit concerns as well as explicit assumptions can be
identified. An example of an implicit concern was with Pt9. He said, 'You never get
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to hear of the people who go into the hospital, like me, and went to see the
orthopaedic surgeon ' The crucial phrase of his sentence was 'like meAlthough
innocuous on paper, the feeling with which he said these words, full of vulnerability
yet appreciation, spoke volumes for his opinions of the hospital staff that he was
describing. This could only be elicited from the recording, rather than the bare
transcription.
At the same time as the initial coding and familiarising myself with each interview, 1
annotated the transcriptions with thoughts that struck me while going through then to
refer back to at a later date.
A.1.2 Focused Coding
As the interviews progressed, I had started to develop tree nodes under which the
free nodes were placed. The advantage of focused coding is being able to move
quicker through the data compared to the time consuming line-by-line coding. If I
came across data that had been covered by another patient I did not code this in a
line-by-line manner. If the patient was saying something new I would code that
piece of data. Alternatively if I felt that a patient was making a common point but in
a particularly eloquent manner, I would code this to be able to use the quote in the
future. Below is an example ofmy focused coding.
Codes Transcript
All HCPs are great, all of them Ptl 7: A' cannae say, a' cannae honestly
say, I can criticise the treatment I've had.
Tom: You can't?
Ptl7: No really, no really.
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Criticising non-research HCPs gently
Complementing non-research HCPs
Tom: Happy customer....
Ptl 7: Aye, well, it's just unfortunate that
I've got this but I mean, I can honestly
say, [clinical doctor 5], and also see that
eh, a [clinical doctor 6], on the team, a
[clinical doctor 6]....
Tom: I don't know
Ptl7: ....She's a urologist...
Tom: ....right....
Ptl7: ...and she's, she's very good. You
know. She does have, says, 'How you
feeling?' and that, 'Not too bad', 'Any
problems with the waterworks?', 'No',
'That's fine.' Then shakes your hand and
you're out the door! (laughing)
Tom: quick!
Ptl 7: Quick! Very quick. Very
quick....[clinical doctor 5], he's very
nice and he just explains it to you, you
know, he says, 'Oh no, that's what it is.'
He'd had a look at me, see this bone
scan, and he says 'No it's coming from
there, that's what does. That's what an
electric shock is' he says, 'That's exactly
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right'. So then, that, that was more or
less it. Then when I was sitting outside,
that's when the sisters came....
A.2 Development of Categories
Once I had coded the first few interviews, several codes began to group together, for
example, the interaction with the trial staff. The responses by patients were
overwhelmingly positive both in those who had a reduction in pain and those who
had not had a reduction in their pain. As the interviews progressed, I tried to get a
fuller picture of what it was about the interactions that patients enjoyed. From here,
the issues of trust and security started to become apparent.
This is an informal memo that I wrote at the time, trying to pull together some of the
issues that were arising around research staff members:
'Going through Ptl2, trust is a big issue, and it also was with Pt9 too. Their
credibility etc. Also Pt2 likes to think about [research doctor 1] as a good
man with cars etc, Other people have said it is like talking to a member of
family or a pal. Surely you would trust them. So perhaps trust is a really big
deal that could link a lot of the other themes together. Esp the therapeutic
relationship with the nurses, maybe they are working towards winning their
trust. Has this been lost along the way, or have patients been let down.
Remember Pt5 saying that people had said that they would do things and
never did, thus diminishing the trust or the weight that you might have with
others in the future. '
Another dimension was those patients who were quite measured in their description
of their interaction with the trial staff. They were not critical but were also not as
enthusiastic as early respondents. This was interesting because I had initially thought
that all patients would be this enthusiastic. This more measured description gave a
more even balance to the category. I was interested in patients who might have felt
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that trial staff were not satisfactory in their performance. As discussed elsewhere,
recruiting patients who may have been able to shed light on this aspect of patient's
relationships with the trial staffwas to prove difficult.
By the time the interviewing and data analysis was complete, I had developed 14
categories as shown below. Some of these categories also had sub-categories. The
category 'Being on a trial', which I abbreviated to BOAT, was further split into
BOAT positive, BOAT negative and BOAT stride. BOAT stride referred to those




Being on a trial
Dealing with the placebo issue
Drugs (not trial)
Emotions regarding the trials
How you were when
Interaction with all HCPs
Interaction with lay others
Pain
Pre consent factors




Withdrawing from a trial
A.3 Theoretical Coding and Theory Generation
' Thus, I suggest renewed emphasis on actions and processes, not on individuals, as a
strategy in constructing theory and moving beyond categorizing types of individuals'
(Charmaz, 2006).
With this quote as my guide, I wanted to develop theoretical codes and an overall
theory regarding the studied phenomenon. The clear initial process was the path
through the trial period. Before interviewing started, the process of being recruited,
taking part in the trial and then having views on the experience of the trial was one
that could be seen.
In October 2010,1 wrote the following extract in a memo:
7 am thinking about the flow of the story. I can see a timeline with
pre/during/reflections. At each step along the way there are bits sprouting off
which you can then delve into in greater detail. This could be my big
picture... '
However in February 2011 my views had changed:
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'So you've got the linear pattern of the trial. Pre-trial & reasons for taking
part, then BOAT, then reflections.
But through that you have the more subtle things like trust, research nurses,
being aware, riding shotgun, the structure.
The problem with the linear pattern is that you could have worked that out
before. The subtle things really have come directly from the data. But can
you put these as one ofthe central themes? They might not apply to all of it.
I am trying to find the central category that links it all together. Within that
you have to have the subcategories. If you took trust for example as the
central category, then you could have underneath it, the trust from those who
had a pain response and those who didn't.'
On a train journey to London I was still wrestling with the concept of the central
theme. I started writing my thoughts in a memo and was struck by a moment that I
have read about in other researchers' texts but had not necessarily expected for
myself.
'What is the overriding category that can develop into the theory??
The current options are trust, the relationship with the researchers, pain. But
I can't think how to put all that together. Orfor everything to link under it.
But!! What about a person's concept of their own wellbeing? And how this is
adjusted both up and down. What causes it to rise? What causes it to fall? It
is dynamic. People who don't feel that impressed by the research team,
perhaps it is because their wellbeing is being maintained in some other way.
What examples can I think of? '
As I continued to write the memo I felt that I had made the major breakthrough in
developing my central theory and from this point worked the other categories around
this. I decided also however that it was important to outline the linear process of
taking part in a trial. The detail provided by this outline could then be latterly
applied to the central theory of the person's 'wellbeing'.
A.4 Data Saturation
The issue of data saturation is always contentious. After 21 interviews I felt that I
had achieved a satisfactory degree of saturation whereby further interviewing of
patients with a similar background to what I had already studied would generate
limited new data. I was aware that I had not been able to interview certain groups of
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patients and this is discussed elsewhere. For those patients that I was able to
interview, I feel that an acceptable level of data saturation was achieved.
A.5 Conclusion
This appendix outlines the analytic process that took place in generating the results
from the data.
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APPENDIX B: KETAMINE PAIN STUDY
Introduction
Neuropathic pain is difficult to manage and occurs in about 40% of cancer suffers.
N-methyl-D-aspartate (NMDA) receptors within the spinal cord are known to play a
role in neuropathic pain. Ketamine is a non-competitive NMDA antagonist.
Ketamine blocks the NMDA receptor which subsequently acts by 'winding down'
and minimising pain transmission. This is particularly beneficial when a hyper-
excitability state exists, as is commonly present in neuropathic pain.
Although ketamine has been shown to be effective in neuropathic pain and pain
secondary to critical limb ischaemia, its effectiveness in neuropathic pain of
malignant origin has yet to be established.
Objectives and Design
The primary objective of the trial is to determine whether the use of ketamine with
best standard pain management improves pain control more than best standard pain
management alone. The secondary objectives include comparing the two trial arms
in regard to specific neuropathic pain scoring, distress and depression scoring and to
measure the side effect profile of ketamine.
The trial is a randomized double blind with an incorporated placebo arm.
The three main components to the trial are the run-in period, the study titration
period and the assessment period.
Stage 1 Run-in period: The run-in period allows time for optimisation of opioid
analgesia using a defined schedule. To progress further in the trial, by the end of the
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run-in period patients are on a stable opioid dose and are still scoring pain at a
significantly high enough level.
Stage 2 Titration period: The patient is randomized and then given their trial
medication. During this period the patient does not receive any other analgesic but is
allowed to take breakthrough opioids at any point. The dose titration of ketamine or
placebo follows a set schedule and increases until analgesia is achieved or the side
effect profile is deemed too great to continue. The patient is monitored daily during
this stage by research staff.
Stage 3 Assessment period: Once the patient is established on a stable dose of
medication, there is a 16 day assessment period where the patient is assessed every 4
days.
Patients can optionally consent to have ten milllitres of venous blood taken at two
points in the trial for future genetic investigation to response to ketamine.
Inclusion/Exclusion criteria: The main inclusion criteria is that patients have to
have a confirmed neuropathic pain against a validated scoring criteria and that a
traditional neuropathic agent has failed to treat this effectively. Patients are excluded
for criteria that include having received chemotherapy or radiotherapy that may
affect their neuropathic pain, having a change in their tumoricidal treatment that may
affect their pain during the course of the trial or have a life expectancy of less than 2
months.




In the doses that are used in the trial period, the side effects that may be encountered
are those of hallucinations, nightmares and other transient psychotic effects.
Dose reduction
If the patient experiences side effects that are likely to be attributable to the trial,
titration should go no further. If the side effects are intolerable to the patient, the
dose should either be reduced to the previous level or maintained at the current level.
At the end of the trial, the dose of medication is reduced over a period of up to 7
days.
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APPENDIX C: PREGABALIN BONE TRIAL
Background
Cancer induced bone pain (CIBP) is a unique state that is different to that of
inflammatory pain and neuropathic pain. Its management can have unique
challenges to achieve satisfactory analgesia without unsatisfactory levels of side
effects. Radiotherapy can be effective, or partially effective for some but not all
episodes of CIBP.
At the level of the spinal cord there is a process of central sensitisation. Glutamate is
one of the key neurotransmitter involved. While there is good evidence for the
glutamate receptor blockade, inhibition of presynaptic release of glutamate is less
well studied. Animal models have suggested that the anti-convulsant gabapentin
may reduce cancer induced bone pain.
Aims
The principle aim of the study is to asses whether pregabalin and radiotherapy are
more effective at managing CIBP than radiotherapy alone. Secondary aims look at
quality of life indicators, tolerability of pregabalin and assessments of neuropathic
pain.
Trial Design
The trial is double-blind randomized controlled trial of pregabalin. Patients who




This phase optimises patients' opioid doses before randomisation. This period lasts
until the patient starts radiotherapy. If there is a sufficient degree of bone pain after
this period, they are able to process to the second stage of the trial.
2. Assessment
On the first day of the assessment phase, patients are randomized to receive
pregabalin or placebo. The number of tablets taken is increased on a weekly basis
from one tablet twice a day up to a maximum number of four tablets twice a day
(equivalent to 300mg pregabalin BD). The assessment phase lasts four weeks. If a
patient has to withdraw from the assessment phase, the drug is gradually reduced
over a period of a week.
Patients are able to take their regular opioid escape/breakthrough medication during
the period of the trial as required.
Inclusion Criteria
The significant inclusion criteria are
Age s: 18 years
Life expectancy > 2 months
Due to receive palliative radiotherapy for bone pain




Change in any tumoricidal therapy before entering the study which may be expected
to have an analgesic benefit during the study period
Patients receiving bisphosphonates purely as an analgesic regimen which may be
expected to have effects during the study period
Bed bound patients
Patients receiving wide-field irradiation
Trial Measures
At the start and end of the trial patients complete a battery of questionnaires and
assessments. They also give a blood sample for assessment. These assessments
usually take place in the hospital setting
During the assessment period patients are called at least weekly for assessment of
their pain levels and description of any side effects. This is usually conducted by
telephone.
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PATIENT INFORMATION SHEET - interview
A qualitative study using semi-structured interviews to explore patients' attitudes
towards research in palliative care.
Invitation
We would like to invite you to take part in a research study. Before you decide you
need to understand why the research is being done and what it would involve for
you. Please take time to read the following information carefully. Talk to others
about the study if you wish.
Part 1 tells you the purpose of this study and what will happen to you if you take
part.
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Part 2 gives you more detailed information about the conduct of the study.
Ask us if there is anything that is not clear or if you would like more
information. Take time to decide whether or not you wish to take part.
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Part 1
What is the purpose of the study?
The purpose of the study is to explore patients' experience of a large clinical trial to
demonstrate patient attitudes and recommendations for future research.
Why have I been chosen?
You are being invited to take part in this study because you have been identified by
your doctor or nurse as someone who has taken part in one of 3 large clinical trials
called either the Pregabalin Bone Trial, the Ketamine in Pain Study or the Menthol in
Neuropathic Type Pain study. These trials/studies are taking place in Edinburgh and
Glasgow.
Do I have to take part?
No, you do not need to take part if you don't want to. It is up to you whether or not
you take part in the study. If you do decide to take part you are still free to withdraw
at any time without giving a reason. A decision not to take part or withdraw at any
time during the study will not affect the care you receive in any way nor will it affect
your participation in the original trial.
How long will the study last?
For you the study will last approximately one hour of your time.
What will being in the study involve?
Your involvement in the study will be an informal interview. This session would last
approximately one hour. The interview would be in a place and time of your
choosing (usually your home). The topic of discussion will be your thoughts and
experiences of research, in particular the trial or study that you have just taken part
in. This interview will be with a research doctor who is trained in palliative care.
The interview will be discretely recorded by digital recorder to allow the researcher
to further examine the material at a later date.
Will I need to stay in hospital?
No- you will not need to stay in hospital.
How often will I need to visit the hospital?
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The interview can be conducted at your home, in which case you would not have to
visit the hospital. If you would prefer to conduct the interview in the hospital, you
would have to visit the hospital once, for the actual interview itself.
What happens if I decide to take part?
If you are interested in taking part you will be approached near the end of your trial
by one of the research nurses or doctors. At this time you will be able to ask any
further questions on the study that you might have. If you would like to take part in
the study we will arrange a time to meet to conduct the study. Before you take part
in the study you will be asked to sign a consent form to confirm that you agree to
take part in the study and that you understand what the study entails.
What if there is a problem?
Any complaint about the way you have been dealt with during the study or any
possible harm you might suffer will be addressed.
Might I be removed from the study?
Yes, there are two instances where you may be removed from the study. Firstly, if
the researcher feels that you are confused for whatever reason (ofwhich there may
be many) during the interview he will ask you not to continue with the interview.
Secondly, if the researcher feels that you are too unwell to take part in the interview
then again he will terminate the interview. You will also be able to remove yourself
from the study at any time without explanation required.
Will my taking part in this study be kept confidential?
Yes, it is totally confidential. You will be allocated a study number to ensure you
remain anonymous. We will only collect details of your age, sex, postcode and the
name of your condition.
Part 2
What if there is a problem?
If you have a concern about any aspect of this study, you should speak to the
researchers who will do their best to answer your questions (contact number 0131
777 3529 (Edinburgh Cancer Centre) or 0141 211 3418 (Beatson Oncology Centre).
If you remain unhappy and wish to complain formally, you can do this through the
NHS Complaints Procedure. Details can be obtained from the hospital.
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In the event that something goes wrong and you are harmed during the research and
this is due to someone's negligence then you may have grounds for a legal action for
compensation against Lothian Health Board but you may have to pay your legal
costs. The normal National Health Service complaints mechanisms will still be
available to you (if appropriate).
Are there any risks or inconveniences involved in taking part in the study?
If you agree to take part in study we will arrange a time and place to meet for the
interview. Fixing a time in your diary may be an inconvenience for you. Patient's
energy levels vary from day to day and you may not feel strong enough to commit to
the arrangement. You will be freely able to cancel or rearrange the interview at
anytime.
There will be no physical risk involved in taking part in the study. While sharing
your experiences you may have feelings or memories that are upsetting. These may
be brought back to light when discussing previous treatment. However the research
doctor is trained in palliative care and will be able to discuss these feelings
sensitively and appropriately.
What will happen to the information that I give in the study?
All information will be stored securely and confidentially. If you join the study, some
parts of your medical records and the data collected will be looked at by authorized
persons involved in the study. They may also be looked at by authorized people to
check that the study is being carried out correctly. All will have a duty of
confidentiality to you as a research participant and we will do our best to meet this
duty.
Will my GP be informed?
We will inform your GP by letter if you decide to take part with your consent.
Will my oncologist (cancer doctor) be informed?
We will inform your oncologist by letter if you decide to take part with your consent.
What will happen to the results of the study?
The results of this study will allow us to find out what patients think about research
and also how it can be improved in the future to help patients. The results will be
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published in a scientific journal. Some anonymous quotes may be used in published
material to illustrate a point.
How many people will take part?
We are planning to interview approximately 24 patients individually and a further 12
patients will make up 2 focus groups.
Who designed the study?
A group of research doctors and nurses from hospitals within Glasgow and
Edinburgh designed the study.
Who is organising and funding the study?
The study is being organized by the University of Edinburgh and jointly funded by
the University of Edinburgh and NHS Lothian.
Who has reviewed the study?
This study was reviewed by a number ofmedical specialists during its development.
The West of Scotland (1) REC has reviewed and approved this study.
Who can I contact for further information?
You will now be given time to make your decision about whether to enter this study.
If you would like to discuss any aspect of this study with a doctor not directly
involved, please contact Prof John Welsh, Tel: 0141 301 7041. If you have any
queries you can contact the researchers in your area responsible for the study.
Glasgow: Anne Todd (Research Nurse) or Dr Barry Laird (Research Fellow)
Contact: 0141 211 3418 or radio page 07654 380244
Edinburgh: Dorothy Boyle (Research Nurse)
Contact: 0131 777 3529 or radio page 07654380245
Thank you for taking the time to read this information
201
APPENDIX E: PATIENT CONSENT FORM
CONSENT FORM
Centre Number:
Patient Identification Number for this study:
Title of Project: Patients' Experience of Palliative care research: A qualitative study
using semi-structured interviews and focus groups to explore patients' experiences of
research in advanced cancer.
Name of Researcher:
Please initial box
1.1 confirm that I have read and understand the information sheet dated
for the above study. I have had the opportunity to consider the information, ask
questions and have had these answered satisfactorily.
2.1 understand that my participation is voluntary and that I am free to withdraw at
any time
without giving any reason, without my medical care or legal rights being affected.
3.1 understand that relevant sections ofmy medical notes and data collected during
the study may be looked at by individuals from regulatory authorities or from the
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NHS Trust, where it is relevant to my taking part in this research. I give permission
for these individuals to have access to my records.
4.1 note that my GP will be informed ofmy participation in the study
5.1 agree to take part in the above study.
Name of Patient Date Signature
Name of Person Date Signature
taking consent
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in
medical notes
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APPENDIX F: FIRST INTERVIEW SCHEDULE (AUG
2009)
REASONS FOR PARTICIPATING
• Can you tell me how you came to hear about the trial.
• What was your initial reaction to the trial and how did you come to be
involved?
• What were your reasons for agreeing to take part in the trial?
Areas that could be explored
Do you remember what your frame of mind was at the time of starting the
trial (including mood and emotion)?
How were you coping with your acceptance of your disease at the time?
Was there any motivation to help others in taking part?
Did you feel that taking part would help improve your symptoms?
Could you tell me if taking part in the study affected your levels of hope?
EXPERIENCE OF THE TRIAL
• What were your experiences of the trial?
• How well did you understand what you were participating in?
• Do you feel you were fully informed of the requirements of the trial?
• Had you been involved in previous research/trials?
• Did you have any negative experiences during the trial?
Areas that could be explored
What were your experiences with the research staff (i.e. doctors and nurses)?
What impact did the trial have on your life?
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How did you manage the assessment sessions? (hospital visits, frequency,
duration)
Did you feel supported by the research staff during the trial?
IMPROVEMENTS OF FUTURE TRIALS
• What area of the clinical trial could be better for patients like you? (for
example trial design, duration of trial, after care, publication of results)
• Would you recommend participation in similar studies to other patients in
your situation?
• Do you think when you look back on the trial that you would participate
in it again?
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APPENDIX G: LAST INTERVIEW SCHEDULE (March
2011)
What do you remember about the trial?
Did being on the trial change how you see yourself as a person?
How do you look back on the period of time when you were on the trial?
What happened after the trial finished?
How did you find the change after the contact with the trial staff ceased?
If not benefit, has the trial been a waste of your time?
Can you remember anything that occurred that you were not expecting during the
trial.
What area of the clinical trial could be better for patients like you?
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Tel No. 0141 211 6238
Fax: 0141 211 1847
03 December 2009
Professor Marie T Fallon
St Columba's Flospice Chair of Palliative Medicine
University of Edinburgh
Edinburgh Cancer Centre
Western General Hospital, Crewe Road
Edinburgh EH4 2XU
Dear Professor Fallon
Study Title: Patients' Experience of Palliative Care Research: A
phenomological study examining the attitudes and
experiences of patients who have participated in
research during the advanced stages of their cancer
REC reference number: 09/S0703/104
Protocol number: 1.0
The Research Ethics Committee reviewed the above amendments contained within your
letter dated 9th November 2009.
Ethical opinion
The members of the Committee present gave a favourable ethical opinion of the above
research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Ethical review of research sites
The favourable opinion applies to all NHS sites taking part in the study, subject to
management permission being obtained from the NHS/HSC R&D office prior to the start of
the study (see "Conditions of the favourable opinion" below).
Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the start of
the study.
Management permission or approval must be obtained from each host organisation prior to




For NHS research sites only, management permission for research ("R&D approval") should
be obtained from the relevant care organisation(s) in accordance with NHS research
governance arrangements. Guidance on applying for NHS permission for research is
available in the Integrated Research Application System or at http://www.rdforum.nhs.uk.
Where the only involvement of the NHS organisation is as a Participant Identification
Centre, management permission for research is not required but the R&D office should be
notified of the study Guidance should be sought from the R&D office where necessary.
Sponsors are not required to notify the Committee of approvals from host organisations.
It is responsibility of the sponsor to ensure that all the conditions are complied with
before the start of the study or its initiation at a particular site (as applicable).
Approved documents
The documents reviewed and approved at the meeting were:
Document Version Date
Covering Letter 09 November 2009
REC application amended 09 November 2009
Participant Information Sheet: Focus Group 2.0 09 November 2009
Participant Consent Form 2 0 09 November 2009
Response to Request for Further Information 09 November 2009
Participant Information Sheet: Interview 2.0 09 November 2009
Evidence of insurance or indemnity 27 July 2009
Membership of the Committee
The members of the Ethics Committee who were present at the meeting are listed on the
attached sheet.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for
Research Ethics Committees (July 2001) and complies fully with the Standard Operating
Procedures for Research Ethics Committees in the UK.
After ethical review
Now that you have completed the application process please visit the National Research
Ethics Service website > After Review
You are invited to give your view of the service that you have received from the National
Research Ethics Service and the application procedure. If you wish to make your views
known please use the feedback form available on the website.
The attached document "After ethical review - guidance for researchers" gives detailed
guidance on reporting requirements for studies with a favourable opinion, including:
• Notifying substantial amendments
• Adding new sites and investigators
• Progress and safety reports
• Notifying the end of the study
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The NRES website also provides guidance on these topics, which is updated in the light of
changes in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve our
service. If you would like to join our Reference Group please email
referencearouo@nres.nosa.nhs.uk.
09/S0703/104 Please quote this number ori all correspondence





Enclosures: List of names and professions ofmembers who were present at the
meeting and those who submitted written comments
"After ethical review - guidance for researchers" SL-AR2
Site approval form (SF1)






ANNELLS (1996) Grounded theory method: Philosophical perspectives, paradigm
of inquiry and postmodernism. Qualitative Health Research, 6, 379-393.
BARBOUR, R. S. (2001) Checklists for improving rigour in qualitative research: a
case of the tail wagging the dog? BMJ, 322, 1115-7.
BARBOUR, R. S. (2005) Making sense of focus groups. Med Educ, 39, 742-50.
BERRY, S. R. (2004) For purposes of research, palliative care patients should not be
considered a vulnerable population. Clin Oncol (R Coll Radiol), 16, 223-4.
BLUFF, R. (Ed.) (2005) Grounded Theory: The methodology, Berkshire, Open
University Press.
BORGSTEEDE, S. D., DELIENS, L., FRANCKE, A. L., STALMAN, W. A.,
WILLEMS, D. L., VAN EIJK, J. T. & VAN DER WAL, G. (2006) Defining
the patient population: one of the problems for palliative care research.
Palliat Med, 20, 63-8.
BRITTEN, N. (1995) Qualitative interviews in medical research. BMJ, 311, 251-3.
CASARETT, D. J. (2003) Assessing decision-making capacity in the setting of
palliative care research. J Pain Symptom Manage, 25, S6-13.
CHARMAZ, K. (Ed.) (2006) Constructing grounded theory: A practical guide
through qualitative analysis., London, Sage Publications Inc.
CHOCHINOV, H. M. (2009) The culture of research in palliative care: you probably
think this song is about you. JPalliat Med, 12, 215-7.
COHEN, M. Z., SLOMKA, J., PENTZ, R. D., FLAMM, A. L., GOLD, D.,
HERBST, R. S. & ABBRUZZESE, J. L. (2007) Phase I participants' views of
quality of life and trial participation burdens. Support Care Cancer, 15, 885-
90.
COX, K. (2000) Enhancing cancer clinical trial management: recommendations from
a qualitative study of trial participants' experiences. Psychooncology, 9, 314-
22.
210
COX, K., WILSON, E., ARTHUR, A., ELKAN, R. & ARMSTRONG, S. (2005) A
randomised controlled trial of nurse-managed trial conclusion following early
phase cancer trial participation. Br J Cancer, 93, 41-5.
COYNE, I. T. (1997) Sampling in qualitative research. Purposeful and theoretical
sampling; merging or clear boundaries? JAdv Nurs, 26, 623-30.
CROTTY, M. (Ed.) (1998) The foundations ofsocial research: meaning and
perspectives in the research process., Thousand Oaks, CA., Sage
Publications Inc.
DAVIS, M. P. & WALSH, D. (2004) Epidemiology of cancer pain and factors
influencing poor pain control. Am JHosp Palliat Care, 21, 137-42.
DE RAEVE, L. (1994) Ethical issues in palliative care research. Palliat Med, 8, 298-
305.
DEAN, R. A. & MCCLEMENT, S. E. (2002) Palliative care research:
methodological and ethical challenges. Int JPalliat Nurs, 8, 376-80.
DENZIN, N. K. & LINCOLN, Y. S. (Eds.) (1994) Handbook ofqualitative research,
Thousand Oaks, CA., Sage Publications Inc.
DEY, I. (Ed.) (1999) Grounding grounded theory: Guidelines for qualitative
inquiry., Edinburgh, Academic Press.
DOBRATZ, M. C. (2003) Issues and dilemmas in conducting research with
vulnerable home hospice participants. JNurs Scholarsh, 35, 371-6.
FLEMMING, K„ ADAMSON, J. & ATKIN, K. (2008) Improving the effectiveness
of interventions in palliative care: the potential role of qualitative research in
enhancing evidence from randomized controlled trials. Palliat Med, 22, 123-
31.
FOLKMAN, S. & GREER, S. (2000) Promoting psychological well-being in the face
of serious illness: when theory, research and practice inform each other.
Psychooncology, 9, 11-9.
FONTANA, A. & FREY, J. (Eds.) (1994) Interviewing: The art ofscience.,
Thousand Oaks, CA., Sage Publications Inc.
GLASER, B. G. (Ed.) (1978) Theoretical Sensitivity, Mill Valley, CA., Sociology
Press.
211
GLASER, B. G. (Ed.) (1992) Basics ofgrounded theory analysis: Emergence vs.
forcing., Mill Valley, CA., Sociology Press.
GLASER, B. G. (1999) The future of grounded theory. Qualitative Health Research,
9, 836-845.
GLASER, B. G. (Ed.) (2001) The grounded theory perspective I: Conceptualisation
contrasted with description, Mill Valley, CA., Sociology Press.
GLASER, B. G. (2002) Constructivist Grounded Theory? Forum: qualitative social
research, 3, Art. 12.
GLASER, B. G. & STRAUSS, A. L. (Eds.) (1967) The discovery ofgrounded
theory: Strategiesfor qualitative research, Chigago, Aldine Publishing Co.
GUBA, E. G. & LINCOLN, Y. S. (Eds.) (1989) Fourth Generation Evaluation,
Newbury Park CA., Sage Publications Inc.
GYSELS, M., SHIPMAN, C. & HIGGINSON, I. J. (2008) Is the qualitative research
interview an acceptable medium for research with palliative care patients and
carers? BMCMed Ethics, 9, 7.
HAWRYLUCK, L. (2004) People at the end of life are a vulnerable research
population. Clin Oncol (R Coll Radiol), 16, 225-6.
HEATH, H. & COWLEY, S. (2004) Developing a grounded theory approach: a
comparison of Glaser and Strauss. Int JNurs Stud, 41, 141-50.
HSIEH, H. F. & SHANNON, S. E. (2005) Three approaches to qualitative content
analysis. Qual Health Res, 15, 1277-88.
KELLE, U. (2005) "Emergence" vs. "forcing" of empirical data? A crucial problem
of "grounded theory" reconsidered. Forum: qualitative social research, 6, art.
27.
KUPER, A., LINGARD, L. & LEVINSON, W. (2008) Critically appraising
qualitative research. BMJ, 337, al035.
KVALE, S. (Ed.) (2009) Interviews: learning the craft ofqualitative research
interviewing, Los Angeles, CA., Sage Publications Inc.
LEWINGTON, S., WHITLOCK, G., CLARKE, R„ SHERLIKER, P., EMBERSON,
J., HALSEY, J., QIZILBASH, N„ PETO, R. & COLLINS, R. (2007) Blood
cholesterol and vascular mortality by age, sex, and blood pressure: a meta-
212
analysis of individual data from 61 prospective studies with 55,000 vascular
deaths. Lancet, 370, 1829-39.
LIN, H. R. & BAUER-WU, S. M. (2003) Psycho-spiritual well-being in patients
with advanced cancer: an integrative review of the literature. JAdv Nurs, 44,
69-80.
LINCOLN, Y. S. & GUBA, E. (Eds.) (1985) Naturalistic Enquiry, Beverly Hills,
CA., Sage Publications Inc.
LING, J., REES, E. & HARDY, J. (2000) What influences participation in clinical
trials in palliative care in a cancer centre? Eur J Cancer, 36, 621-6.
MADSEN, S. M., HOLM, S. & RIIS, P. (2007a) Attitudes towards clinical research
among cancer trial participants and non-participants: an interview study using
a Grounded Theory approach. JMed Ethics, 33, 234-40.
MADSEN, S. M., HOLM, S. & RIIS, P. (2007b) Participating in a cancer clinical
trial? The balancing of options in the loneliness of autonomy: a grounded
theory interview study. Acta Oncol, 46, 49-59.
MAYS, N. & POPE, C. (2000) Qualitative research in health care. Assessing quality
in qualitative research. BMJ, 320, 50-2.
MELVIN, C. S. (2009) When to Refer Patients to Palliative Care: Triggers, Traps,
and Timely Referrals. Journal ofHospice and Palliative Nursing, 11, 291-
301.
MILES, M. B. A. H., A.M. (1994) Qualitative Data Analysis, Thousand Oaks, CA.,
Sage Publications Inc.
MILLS, E. J., SEELY, D., RACHLIS, B„ GRIFFITH, L„ WU, P., WILSON, K„
ELLIS, P. & WRIGHT, J. R. (2006a) Barriers to participation in clinical trials
of cancer: a meta-analysis and systematic review of patient-reported factors.
Lancet Oncol, 7, 141-8.
MILLS, J., BONNER, A. & FRANCIS, K. (2006b) Adopting a constructivist
grounded theory: Implications for research design. Interational Journal of
Nursing Practice, 12,8-13.
MILLS, J., BONNER, A. & FRANCIS, K. (2006c) The development of
constructivist grounded theory. Interational Journal ofQualitative Methods,
5, 1-10.
213
MORSE, J. M. (Ed.) (1994) Emergingfrom the data: The cognitive process of
analysis in qualiative enquiry, Thousand Oaks, CA, Sage Publishing Inc.
MURRAY, S. A., KENDALL, M., CARDUFF, E., WORTH, A., HARRIS, F. M.,
LLOYD, A., CAVERS, D„ GRANT, L. & SHEIKH, A. (2009) Use of serial
qualitative interviews to understand patients' evolving experiences and needs.
BMJ, 339, b3702.
POLKINGHORNE, D. (2005) Language and Meaning: Data Collection in
Qualitative Research. Journal ofCounseling Psychology, 52, 137-145.
PUNCH, K. F. (1998) Introduction to Social Research: Quantitative and Qualitative
Approaches, Thousand Oaks, Sage Publications Inc.
ROSS, C. & CORNBLEET, M. (2003) Attitudes of patients and staff to research in a
specialist palliative care unit. Palliat Med, 17, 491-7.
SANDELOWSKI, M. (1995) Sample size in qualitative research. Res Nurs Health,
18, 179-83.
SEALE, C. (Ed.) (1999) The quality ofqualitative research, London, Sage
Publications Inc.
SEALE, C. (2002) Quality Issues in Qualitative Inquiry. Qualitative Social Work, 1,
97-110.
SEIBOLD, C. (Ed.) (1992) New York, Oxford University Press.
SEYMOUR, J. & CLARK, D. (1998) Phenomenological approaches to palliative
care research. Palliat Med, 12, 127-31.
STRAUSS, A. L. & CORBIN, J. (Eds.) (1990) Basics ofqualitative research:
Grounded theory procedures and techniques., Newbury Park CA., Sage
Publications Inc.
STRAUSS, A. L. & CORBIN, J. (Eds.) (1994) Grounded theory methodology: An
overview, London, Sage Publications Inc.
STRAUSS, A. L. & CORBIN, J. (Eds.) (1998) Basics ofqualitative research:
Techniques andprocedures for developing grounded theory, Thousand Oaks,
CA., Sage Publications Inc.
SUN, V. C., BORNEMAN, T., FERRELL, B„ PIPER, B., KOCZYWAS, M. &
CHOI, K. (2007) Overcoming barriers to cancer pain management: an
institutional change model. J Pain Symptom Manage, 34, 359-69.
214
TENNANT, R„ HILLER, L., FISHWICK, R., PLATT, S., JOSEPH, S., WEICH, S.,
PARKINSON, J., SECKER, J. & STEWART-BROWN, S. (2007) The
Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development
and UK validation. Health Qual Life Outcomes, 5, 63.
TERRY, W., OLSON, L. G., RAVENSCROFT, P., WILSS, L. & BOULTON-
LEWIS, G. (2006) Hospice patients' views on research in palliative care.
Intern Med J, 36, 406-13.
TODD, A. M., LAIRD, B. J., BOYLE, D„ BOYD, A. C., COLVIN, L. A. &
FALLON, M. T. (2009) A systematic review examining the literature on
attitudes of patients with advanced cancer toward research. J Pain Symptom
Manage, 37, 1078-85.
WALSHE, C. E., CARESS, A. L„ CHEW-GRAHAM, C. & TODD, C. J. (2004)
Case studies: a research strategy appropriate for palliative care? Palliat Med,
18,677-84.
WATSON, D., CLARK, L. A. & TELLEGEN, A. (1988) Development and
validation of briefmeasures of positive and negative affect: the PANAS
scales. JPers Soc Psychol, 54, 1063-70.
WHITE, C. & HARDY, J. What do palliative care patients and their relatives think
about research in palliative care?-a systematic review. Support Care Cancer,
18,905-11.
WHITE, C. D„ HARDY, J. R„ GILSHENAN, K. S„ CHARLES, M. A. &
PINKERTON, C. R. (2008) Randomised controlled trials of palliative care - a
survey of the views of advanced cancer patients and their relatives. Eur J
Cancer, 44, 1820-8.
WILLIAMS, A. M„ CROOKS, V. A., WHITFIELD, K„ KELLEY, M. L„
RICHARDS, J. L„ DEMIGLIO, L. & DYKEMAN, S. Tracking the evolution
of hospice palliative care in Canada: a comparative case study analysis of
seven provinces. BMC Health Serv Res, 10, 147.
WOOTTEN, A. C., ABBOTT, J. M., SIDDONS, H. M„ ROSENTHAL, M. A. &
COSTELLO, A. J. A qualitative assessment of the experience of participating
in a cancer-related clinical trial. Support Care Cancer, 19, 49-55.
215
YEUNG, E. W„ FRENCH, P. & LEUNG, A. O. (1999) The impact of hospice
inpatient care on the quality of life ofpatients terminally ill with cancer.
Cancer Nurs, 22, 350-7.
216
